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Abstract 
There is a growing recognition of the involvement of the gut microbiota in drug 
metabolism and vice versa the impact of drug intake on the microbiome. In this thesis, 
we focus our attention on psychotropic medications (from the Greek root psychè = 
mind and tropòs = turning). With few isolated studies showing that brain-targeting 
medications can have antimicrobial activity in vitro, we sought to investigate the 
impact of psychotropics on the microbiome and intestinal physiology in vivo. Across 
a range of psychotropic medications, lithium, valproate, aripiprazole and fluoxetine 
significantly impacted the microbiome composition and diversity. These effects were 
not directly linked to changes in intestinal permeability or short-chain fatty acids levels 
(Chapter 2).  
The mood stabilisers lithium and valproate significantly impacted bile acid 
metabolism and targeted a set of bile-metabolising bacteria. Two mechanisms 
hypothesised as possible players in the bile-targeted effects of lithium and valproate, 
hepatic inflammation and intestinal permeability, did not seem to play any overt role 
in the disruption of bile pathways (Chapter 3). 
We next investigated whether perturbations of the microbiome, through administration 
of probiotics or antibiotics, could alter the pharmacokinetics of olanzapine and 
risperidone, two antipsychotic medications. Antibiotics increased the blood levels of 
olanzapine (AUC, area under the curve) but did not influence the absorption of 
risperidone. The antibiotics did not have a direct effect on the expression of CYPs 
involved in the metabolism of antipsychotics. Among the bacterial genera detected by 
16S sequencing, the relative abundance of Alistipes significantly correlated with the 
AUC of olanzapine but not risperidone, suggesting that this bacterium might play a 
role in the pharamacokinetic alterations observed in olanzapine-treated rats (Chapter 
4).   
Lastly, intrigued by the findings of Chapter 2, we moved on to look at the microbiome-
targeting effects of psychotropic drugs in a human population, the Dutch LifeLines 
DEEP cohort. Although the small sample size and certain limitations which should be 
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addressed in future population-based studies, minor effects of drug consumption on 
the human gut microbiota were detected (Chapter 5).  
Overall, these results provide novel insight on the role exerted by psychotropic 
medications on the microbiota-gut-liver-brain axis. Possible implications of this work 
include optimisation of drug efficacy or toxicity, use of the microbiome as a tool to 
distinguish responders from non-responders and improvement of personalised 
medicine.  
  1  
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1.1 Gut Microbiota 
Our gut houses a staggering amount of microorganisms that estimates consider 
contains 150 times as many genes as our genome (Qin et al., 2010). This population is 
mainly composed of bacteria belonging to 500-1000 different species (Qin et al., 
2010). Fungi, archaea, and viruses are also present in the gut but less is known about 
their underlying functions. The intestinal microbiota does not remain stable throughout 
lifespan, in fact the microbiota of newborn infants, acquired at delivery, is 
characterised by low diversity and a relative dominance of the phyla Proteobacteria 
and Actinobacteria (Kurokawa et al., 2007). The microbial composition of the 
neonatal gut is influenced by a number of factors including antibiotic use, diet, mode 
of delivery, environmental factors and the maternal microbiota (Dominguez-Bello et 
al., 2010; Faa et al., 2013; Koenig et al., 2011; Marques et al., 2010). Interestingly, the 
microbiota of formula-fed infants is significantly different from the microbiota of 
breastfed infants (Bezirtzoglou et al., 2011; Lee et al., 2015; Wang et al., 2015). 
Moreover, vaginally delivered infants acquire the vaginal microbiota of the mother, 
whereas infants delivered by caesarean section are colonised by other environmental 
sources (Dominguez-Bello et al., 2010). In the first months of life, the number of strict 
anaerobes such as Clostridium, Bacteroides and bifidobacteria increases gradually and 
after 1 year of age a complex adult-like microbiota is established. The adult microbiota 
is more stable over time and more complex than the neonate microbiota (Hamady and 
Knight, 2009). The gut microbiota is involved in basic human biological processes, 
including modulating the metabolic phenotype, epithelial development, and innate 
immunity (Nicholson et al., 2012b; Sommer and Bäckhed, 2013; Willson et al., 2018). 
Chronic diseases such as obesity, inflammatory bowel disease (IBD), diabetes 
mellitus, metabolic syndrome, atherosclerosis, alcoholic liver disease (ALD), 
nonalcoholic fatty liver disease (NAFLD), cirrhosis, and hepatocellular carcinoma 
have been associated with the human microbiota (Haghikia et al., 2018; Lavelle and 
Sokol, 2018; Ponziani et al., 2019; Sircana et al., 2018; Soderborg et al., 2018). 
Taxonomic levels used to classify the microbiome include: phylum (i.e. Firmicutes), 
class (i.e. Bacilli), order (i.e. Lactobacillales), family (i.e. Lactobacillaceae), genus 
(i.e. Lactobacillus) and species (i.e. Lactobacillus gasseri). 
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1.2 Microbiota-Gut-Brain Axis 
The microbiota-gut-brain axis is a bidirectional pathway through which the brain 
regulates the activity of the gut and vice versa. This bidirectional axis functions 
through a series of different routes (Bercik et al., 2012; Dinan et al., 2015; Rhee et al., 
2009) and comprises an afferent and an efferent pathway (Figure 1.1). 
 
Figure 1.1 The gut microbiota communicates to the brain through several routes that 
characterise the microbiota-gut-brain axis. These routes include the vagus nerve, production 
of SCFAs, immune activation with production of immune mediators, production of 
neurotransmitters and tryptophan. The gut microbiota is also able to convert primary bile 
acids into secondary bile acids, which activate receptors on EECs and stimulate the secretion 
of gut peptides. Neuroactive compounds produced by gut microbiota enter the circulation and 
reach the brain, subsequently affecting neuroendocrine function. Abbreviations: 5-HT (5-
hydroxytryptamine) serotonin, CCK cholecystokinin, DC dendritic cell, EEC enteroendocrine 
cell, ENS enteric nervous system, GABA ɣ-aminobutyric acid, GLP-1 glucagon-like peptide-
1, IL interleukin, LPS lipopolysaccharide, NTS nucleus tractus solitarii, PYY peptide YY, 
SCFAs short chain fatty acids. Figure adapted from (Cussotto et al., 2018). 
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1.2.1 Afferent Signalling  
The vagus nerve, the tenth cranial nerve that has both efferent and afferent divisions, 
is a major modulatory constitutive communication pathway between the bacteria 
exposed to the gut and the brain (Bercik et al., 2011; Bravo et al., 2011). The immune 
system provides a further route of communication between gut microbes and the brain, 
in fact microbiota and probiotics have a direct effect on the immune system (Duerkop 
et al., 2009; Forsythe and Bienenstock, 2010). Symbiotic bacteria are crucial for the 
maturation of the immune system in fact, they provide signals for the development of 
key lymphocyte subsets (Edelman and Kasper, 2008). Moreover, gut bacteria 
contribute to intestinal epithelial cell maturation and can induce alterations in the 
circulating levels of pro- and anti-inflammatory cytokines that directly affect brain 
function, especially areas such as the hypothalamus, where IL-1 and IL-6 provide a 
potent release of CRF (Duerkop et al., 2009). Gut bacteria contribute to the host 
metabolism by production of metabolites such as bile acids, choline and short chain 
fatty acids (SCFAs, namely acetic propionic and butyric acid) that are able to influence 
a range of physiological and metabolic functions (De Vadder et al., 2014). The free 
SCFAs are also able to cross the blood-brain barrier (BBB) through monocarboxylate 
transporters and act in several brain regions (Vijay and Morris, 2014). Although it 
remains to be established whether the microbiota can produce neuropeptide-like 
compounds, it is capable of generating a number of neurotransmitters and 
neuromodulators (Cryan and Dinan, 2012; Nicholson et al., 2012a). Members of the 
genera Candida, Streptococcus, Escherichia and Enterococcus synthesise 5-
hydroxytryptamine (5-HT); members of the genera Escherichia, Bacillus and 
Saccharomyces generate dopamine and/or noradrenaline; members of the genus 
Lactobacillus produce acetylcholine; and members of the genera Lactobacillus and 
Bifidobacterium produce gamma-aminobutyric acid (GABA) (Barrett et al., 2012; 
Cryan and Dinan, 2012; Lyte, 2014; Nicholson et al., 2012a). An example of the 
connection of the gut microbiome with the host neurophysiological systems is a study 
showing that the excitability of gut sensory neurons located within the myenteric 
plexus of the ENS relies on the presence of the normal commensal microbiota for 
proper functioning (Neufeld et al., 2011). Several studies have suggested that another 
mechanism involved in the gut-brain communication is tryptophan metabolism. 
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Tryptophan is an essential amino acid and is a precursor to many biologically active 
agents, such as serotonin (Ruddick et al., 2006). Most of the tryptophan is metabolised 
to kynurenine and the disruption of this metabolic pathway has been linked to both 
gastrointestinal and brain disorders (Fitzgerald et al., 2008). The first rate-limiting step 
in the kynurenine metabolic cascade is catalysed by some enzymes (specifically 
indoleamine-2,3-dioxygenase and tryptophan 2,3-dioxygenase) whose activity can be 
induced by inflammatory mediators and by corticosteroids, respectively (Ruddick et 
al., 2006). Evidence suggests that a probiotic bacterium, Bifidobacterium infantis, can 
alter concentrations of kynurenine through modulation of the gut microbiota 
(Desbonnet et al., 2008). Another class of molecules, gut-derived peptides, can reach 
the systemic circulation and bind receptors on immune cells and vagus nerve terminals 
thereby enabling indirect gut-brain communication (Lach et al., 2017). 
 
1.2.2 Efferent Signalling  
The HPA axis represents the main efferent route from the brain to the gut. When 
activated, the resulting secretion of cortisol (in humans) or corticosterone (in rodents) 
affects immune cell activity; both locally in the gut and systemically (Del Rey, 2008). 
Neuronal efferent activation includes also the efferent branch of the vagus nerve that, 
when activated induces a release of acetylcholine which, in turn, affect the levels of 
cytokines (Paton et al., 1971). 
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1.3 Microbiota-Gut-Liver Axis 
The crosstalk between the intestine and liver is increasingly recognised, strengthened 
by the parallel rise in incidence of liver diseases and gastrointestinal and immune 
disorders (Hartmann et al., 2015; Schnabl and Brenner, 2014). The gut and the liver 
communicate via tight bidirectional links through the biliary tract, portal vein and 
systemic circulation. The liver communicates with the intestine by releasing bile acids 
and many bioactive mediators into the biliary tract and the systemic circulation. In the 
intestine, host and microorganisms metabolise endogenous (bile acids and amino 
acids) as well as exogenous (from diet and environmental exposure) substances, the 
products of which translocate to the liver through the portal vein thus influencing liver 
function (Starkel and Schnabl, 2016) (Figure 1.2). Drugs and xenobiotics, which are 
commonly metabolised in the liver, can also translocate from the gut to the liver and 
vice versa, being exposed to the gut microbiota (Zimmermann et al., 2019b). Some 
key communication routes between the gut and the liver are discussed in this section.  
Figure 1.2 Bidirectional communication between gut and liver. The liver releases primary 
bile acids and antimicrobial molecules (IgA and angiogenin 1) into the intestinal lumen 
through the biliary tract. Conversely, gut products such as microbial metabolites and MAMPs 
translocate to the liver via the portal vein. The systemic circulation also allows the exchange 
of substances between the gut and the liver. Liver metabolites from dietary, endogenous or 
xenobiotic substances (e.g. free fatty acids, choline metabolites, ethanol metabolites) are 
transported to the intestine through the capillary system. Abbreviations: MAMPs microbial-
associated molecular patterns; SCFAs short-chain fatty acids; TMA trimethylamine; TMAO 
trimethylamine N-oxide. Figure adapted from (Tripathi et al., 2018). 
  7  
 
1.3.1 Enterohepatic circulation of bile acids 
Bile acids (BAs) are amphipathic molecules synthesised from cholesterol in the liver. 
Following conjugation to either glycine or taurine, BAs are released in the biliary tract 
and, together with other biliary components, enable emulsification and absorption of 
dietary fats, cholesterol, and fat-soluble vitamins (Chiang, 2013). About 95% of the 
BAs are actively reabsorbed in the distal ileum and carried back to the liver (Chiang, 
2013; Wahlstrom et al., 2016). The remaining 5% are deconjugated, dehydrogenated 
and dehydroxylated by the intestinal microbiota to form secondary bile acids, which 
reach the liver via passive absorption into the portal circulation. The liver recycles 
BAs and secretes them back to the biliary tract completing the “enterohepatic 
circulation” i.e. a system of exchange between the gut and the liver. A carrier-mediated 
process transports hydrophilic primary bile acids across cell membranes for uptake 
into intestinal epithelial cells. Regulatory effects of BAs have been mostly studied in 
regard to farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5 
(TGR5). BAs bind to FXR in the enterocytes and induce transcription of an enterokine, 
fibroblast growth factor 19 (FGF19; FGF15 in mouse). FGF19 reaches the liver 
through the portal vein and down-regulates the de novo synthesis of BAs by inhibiting 
key enzymes involved in the synthesis of new BAs (Zarrinpar and Loomba, 2012). 
Additionally, BAs bind to TGR5 on the plasma membrane and act on tissues beyond 
the liver. This binding mediates host energy expenditure (Broeders et al., 2015; Pols 
et al., 2011) glucose homeostasis (Thomas et al., 2009) and anti-inflammatory immune 
responses (Perino and Schoonjans, 2015; Schaap et al., 2014). BAs and the gut 
microbiota closely interact and modulate each other. BAs exert direct control on the 
intestinal microbiota. By binding to FXR, they induce production of antimicrobial 
peptides such as angiogenin (ANG1) and RNase A family member 4 (RNASE4), 
which are directly involved in inhibiting gut microbial overgrowth and, subsequently, 
gut barrier dysfunction (Inagaki et al., 2006; Parseus et al., 2017). An alteration in the 
gut microbiota composition can shift the balance between primary and secondary bile 
acids and their subsequent enterohepatic cycling, the metabolic effects of which are 
not comprehensively understood. However, because of differences in the affinity of 
these two classes of BAs for the FXR, these shifts have been associated with increased 
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hepatic bile acid synthesis and metabolic stress (Arab et al., 2017; Jiang et al., 2015a; 
Mouzaki et al., 2016; Ridlon et al., 2014). 
 
1.3.2 Intestinal permeability in the microbiota-gut-liver axis 
The main components of the intestinal barrier, enterocytes, are tightly attached to 
adjacent cells by apical junctional proteins that include claudins, occludins, E-
cadherins and junctional adhesion molecules (JAMs) (Turner, 2009). This barrier 
confines the passage of microbes and molecules from the gut lumen, while allowing 
active transport of nutrients across the junctions. The intestinal barrier is strengthened 
by several additional lines of defence: Mucins (heavily glycosylated protein 
aggregates) form a physical barrier between luminal bacteria and the underlying 
epithelial layer (Turner, 2009); antibacterial lectins, such as regenerating islet-derived 
protein IIIɣ (REG3G), which are produced by intestinal Paneth cells, target bacteria 
associated with mucosal lining (Abreu, 2010; Gallo and Hooper, 2012). As additional 
line of defence, immunoglobulins (specifically secretory immunoglobulin A) 
produced by plasma cells and transported into the intestinal lumen, can neutralise 
microbial pathogens by blocking epithelial receptors (Mantis et al., 2011). Finally, 
commensal bacteria are closely associated with the gut mucosa, and strengthen barrier 
integrity by stimulating cell-mediated immunity via toll-like receptor mediated 
signalling (Abreu, 2010; Rakoff-Nahoum et al., 2004) or by producing metabolites 
that directly strengthen tight junctions (short chain fatty acids) (Wachtershauser and 
Stein, 2000; Yaku et al., 2012; Ziegler et al., 2016) and inhibit other microbes (Graham 
et al., 2017; Lobos et al., 2017; Walsh et al., 2017). An important association between 
the gut microbiota, inflammation and gut barrier integrity is provided by Akkermansia 
muciniphila, a Gram-negative anaerobe that colonises the intestinal mucus layer. 
Reduced levels of A. muciniphila have been associated with thinning of mucus layer 
(compromising gut barrier integrity) and increased inflammation, which promote both 
alcoholic and non-alcoholic liver damage (Everard et al., 2013; Grander et al., 2018). 
A. muciniphila has also been shown to induce beneficial effects on metabolism and 
weight control in diet-induced obesity (Dao et al., 2019; Depommier et al., 2019). 
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When the gut barrier is compromised, microbes and microbe-derived molecules can 
translocate to the liver through the portal system, causing inflammation and hepatic 
injury. Some translocated intestinal products may also directly interact with host 
factors and contribute to exacerbation of liver disease (Filliol et al., 2017; Lopez-
Lazaro, 2016; Scott et al., 2017a; Wu et al., 2017b; Zhu et al., 2013). 
 
1.3.3 Systemic circulation in the microbiota-gut-liver axis 
Bacteria and MAMPs  
Intestinal dysbiosis (e.g. small intestinal bacterial overgrowth, SIBO) and increased 
intestinal permeability can lead to translocation of microbial-associated molecular 
patterns (MAMPs) in the portal circulation. On reaching the liver, MAMPs induce 
localised inflammation through pattern recognition receptors (PRRs) on Kupffer cells 
(Seki et al., 2007) and hepatic stellate cells (Gabele et al., 2008; Isayama et al., 2006). 
Endotoxin-mediated activation of Toll-like Receptor 4 (TLR4) (Gabele et al., 2008; 
Isayama et al., 2006) along with TLR9 (Hartmann et al., 2012), are the primary drivers 
of immune response in liver disease. TLR signalling in Kupffer cells activates a 
downstream proinflammatory cascade, leading to MYD88-mediated activation of NF-
kB (Seki and Schnabl, 2012). 
 
Choline metabolites  
Choline is a macronutrient important for liver function, brain development, nerve 
function, muscle movement and metabolism (Zeisel and da Costa, 2009; Zeisel et al., 
1991). Importantly, rodents fed a choline-deficient diet have been used to model 
human non-alcoholic steatohepatitis (Han et al., 2017; Muraki et al., 2017; Rutenburg 
et al., 1957). Choline is processed by the host into phosphatidylcholine, which assists 
in excretion of very-low density lipoproteins (VLDL) particles from the liver. This 
prevents hepatic accumulation of triglycerides and subsequent liver steatosis. 
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Additionally, intestinal bacteria play a key role in the conversion of choline to 
trimethylamine (TMA) (Craciun and Balskus, 2012; Rath et al., 2017; Romano et al., 
2015). TMA, in turn, can translocate to the liver through the portal circulation where 
it is converted to trimethylamine N-oxide (TMAO) (Canyelles et al., 2018). The 
importance of methylamines is increasingly being recognised with respect to liver, 
cardiometabolic and even neurological disorders. Increased systemic circulation of 
TMAO is concomitant with reduced levels of host-produced phosphatidylcholine, an 
imbalance characteristically seen in those with intestinal dysbiosis (Tang et al., 2013; 
Wang et al., 2011b; Yin et al., 2015). Increased TMAO in circulation can also augment 
the incidence of abdominal aortic aneurysm in mice and lower hippocampal blood 
flow (Beilfuss et al., 2018; Conrad et al., 2018). 
 
Free fatty acids  
Free fatty acids include short-chain fatty acids (SCFAs) and long-chain fatty acids 
(LCFAs). Butyrate, propionate (produced by bacterial fermentation) and acetate 
(produced by both host and bacteria) are the dominant SCFAs in the large intestine. 
Butyrate is an energy source for the enterocytes and facilitates maintenance of 
intestinal barrier (Wachtershauser and Stein, 2000; Yaku et al., 2012; Ziegler et al., 
2016). Alcohol-induced liver injury is characterised by reduced butyrate and 
propionate (Chen et al., 2015c; Cresci et al., 2017) and increased acetate (possibly 
produced by ethanol metabolism in the lumen, but predominantly derived from ethanol 
metabolism in the liver). A reduction in butyrate is linked to weakening of intestinal 
tight junctions and hence an increase in permeability (Peng et al., 2009; Yan and 
Ajuwon, 2017). Butyrate supplementation in the form of tributyrin reduced ethanol-
induced intestinal permeability and subsequent liver injury in mice on a short-term 
alcohol diet (Cresci et al., 2017). However, how tributyrin mechanistically protects 
intestinal barrier function still needs to be clarified. Luminal species of LCFAs include 
pentadecanoic acid (C15:0), palmitic acid (C16:0), heptadecanoic acid (C17:0) and 
stearic acid (C18:0). In mice fed alcohol chronically, pentadecanoic acid and 
heptadecanoic acid, which are only produced by bacterial fermentation, were 
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significantly reduced when compared to control mice on isocaloric diet (Chen et al., 
2015c). In the same study, there was also an overall reduction in total LCFAs which 
was associated with decreased luminal lactobacilli (known metabolisers of saturated 
LCFAs). Even though it has not yet been demonstrated that LCFA supplementation 
can restore Lactobacillus spp., dietary supplementation of Lactobacillus rhamnosus 
increased luminal LCFAs (Shi et al., 2015), suggesting that Lactobacillus-induced 
increase in intestinal free fatty acids contribute to its probiotic effects. 
 
Ethanol and acetaldehyde  
The mucosa of the GI tract absorbs ethanol by simple diffusion. Gut microbiota and 
enterocytes express alcohol-metabolizing enzymes such as alcohol dehydrogenase, 
which co-metabolises ethanol into acetaldehyde and acetate. In germ-free mice, the 
absence of microbiota was associated with increased hepatic expression of ethanol-
metabolizing enzymes, which led to faster ethanol elimination from the blood (Chen 
et al., 2015a). Acetaldehyde, a metabolite of ethanol, has been implicated in 
weakening the intestinal tight junctions compromising the gut barrier and allowing 
translocation of microbial products (Chaudhry et al., 2016; Chen et al., 2015b; Mir et 
al., 2016; Yan and Schnabl, 2012). Acetaldehyde has also been associated with 
downregulating the expression of antimicrobial peptides (AMPs) in the intestine 
(Hartmann et al., 2013; Yan et al., 2011) and eliciting inflammatory and adaptive host 
immune responses (Mottaran et al., 2002; Park et al., 2016; Wang et al., 2011a). 
 
1.4 Bile Acid Synthesis, Metabolism and Microbiota 
Bile acids are the major functional components of bile. They are synthesised from 
cholesterol in the liver, stored in the gall bladder and subsequently released into the 
small intestine (Chiang, 2013). The host enzymes and feedback pathways involved in 
bile acid synthesis are well characterised. A crucial mediator in bile acid metabolism 
is the gut microbiota, with its unique enzymatic machinery capable of deconjugating 
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bile acids in the intestine and therefore playing an essential role in bile acid 
homeostasis (Ramirez-Perez et al., 2017).  
 
1.4.1 Bile acids synthesis  
Bile acids are a product of the steroid cholesterol and are generated through either the 
classical or alternative pathway in hepatocytes. The host enzymes responsible for bile 
acid synthesis are cytochrome P450 family enzymes, mainly CYP7A1, CYP8B1 and 
CYP27A1 (Chiang, 2013). Following synthesis of new bile acids, these are conjugated 
to either glycine or taurine, a process that increases their solubility for secretion into 
biliary fluid. The process is carried out by bile acid cholyl-CoA synthetase (BAC) 
activity and amidation at C24 to either glycine or taurine by the enzyme bile acid-
CoA:amino acid N-acyltransferase (BAT). As a result, the majority of bile acids 
excreted from the liver are conjugated (Figure 1.3). Bile is secreted into the duodenum 
via the common bile duct and its main physiological roles in the small intestine are the 
emulsification of fats, the release of fat-soluble vitamins and the regulation of 
cholesterol metabolism (Begley et al., 2005a). Feedback regulation of specific 
enzymes results in alterations to the ratio of individual bile acids in the bile acid pool. 
Overall regulation of bile acid synthesis is through feedback inhibition of CYP7A1. 
Direct interaction between bile acids and the farnesoid X receptor FXR downregulates 
CYP7A1 gene expression (Chiang, 2013). Alternatively, FXR is activated locally in 
the enterocytes by bile acids and promotes the expression of the mediator Fgf19, which 
enters circulation and represses CYP7A1 in hepatocytes through interaction with a 
specific cellular receptor (Fgfr4). The enterohepatic circulation of bile acids is very 
efficient, with 95% of bile acids actively reabsorbed in the terminal ileum and 
transported back to the liver via the portal circulation. Approximately 5% of bile salts 
are lost through the faeces (Chiang, 2013). 
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Figure 1.3 Transporters and enzymes involved in the synthesis and enterohepatic 
circulation of bile acids. Abbreviations: ASBT apical sodium-bile acid transporter, BSEP bile 
salt export pump, BSH bile salt hydrolase, CYP cytochrome P450, FGF19 fibroblast growth 
factor 19, FGFR4 fibroblast growth factor receptor 4, FXR farnesoid X receptor, G/T-CA 
glyco/tauro-cholic acid, G/T-CDCA glyco/tauro-chenodeoxycholic acid, HMGCR 3-hydroxy-
3-methylglutaryl-CoA reductase, ILBP ileal lipid binding protein, MRP multidrug resistance 
protein, NTCP Na+-taurocholate cotransporting polypeptide, Ost α/β organic solute 
transporter α/β, SHP small heterodimer partner, SREBF1 sterol regulatory element binding 
transcription factor 1, TGs triglycerides. 
 
1.4.2 Bile acids metabolism: gut microbiota as a key player 
The chemical composition of bile acids is strongly influenced by the gut microbes, 
which have bile-related enzymatic activity (Ridlon et al., 2014) (Figure 1.4). Bile salt 
hydrolases (BSH; EC 3.5.1.24) are microbial enzymes that belong to the Ntn-
hydrolase superfamily of proteins. These enzymes cleave the amide bond between the 
glycine and taurine moiety conjugated to the steroid nucleus of bile salts. This cleavage 
liberates bile acids and is the crucial first step for further bile acid alterations by the 
gut microbiota (Begley et al., 2006). BSH activity has been reported in the commensal 
genera Lactobacillus (Chae et al., 2013; Corzo and Gilliland, 1999; Elkins et al., 2001; 
Jayashree et al., 2014), Bifidobacterium (Grill et al., 1995; Kim et al., 2004a; Tanaka 
et al., 2000), Enterococcus (Franz et al., 2001; Wijaya et al., 2004), Clostridium spp 
(Coleman and Hudson, 1995; Gopal-Srivastava and Hylemon, 1988; Rossocha et al., 
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2005) and Bacteroides spp (Kawamoto et al., 1989; Stellwag and Hylemon, 1976). 
Interestingly BSH activity is not only confined to gut bacteria, but it has been found 
in Xanthomonas maltophilia isolated from soil (Dean et al., 2002; Pedrini et al., 2006) 
and thermophilic Brevibacillus sp isolated from hot springs (Sridevi and Prabhune, 
2009; Sridevi et al., 2009). This indicates that BSH activity might be a widespread 
feature of bacteria adapted to different environments. There is evidence of horizontal 
transmission of BSH amongst gut bacteria, suggestive of strong evolutionary selection 
for this activity (Jones et al., 2008). BSH coding sequences are widely distributed in 
both Bacteria and Archaea, suggesting a strong host-driven selection (Jones et al., 
2008). Moreover, the BSH alleles detected in human microbiota were markedly 
different in other environments such as the murine gut. The host species-specific 
selection of microbial BSH activity may indicate host species-specific functional 
differences in BSH activity (Jones et al., 2008). Interestingly, conjugated bile acids 
are toxic to bacteria, particularly at low pH, and are proposed to influence the growth 
of bacteria in different regions of the GI tract (Islam et al., 2011). The presence of 
BSH can thus confer a protective effect for some bacterial species through bile acid 
deconjugation. Several studies have also shown that BSH is advantageous for bacterial 
colonisation (Bateup et al., 1995; Begley et al., 2005b; De Smet et al., 1995; Delpino 
et al., 2007).   
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Figure 1.4 The gut microbiota is a key metaboliser of bile acids. Bacteria with bile salt 
hydrolase (BSH) and 7α-dehydroxylase activity play a key role in the metabolism of bile acids 
from conjugated bile acids to primary, secondary and tertiary unconjugated bile acids. The 
majority of bile acids are then recycled through the portal circulation.  
 
 
Once BSH enzymes have liberated bile salts from the taurine or glycine amide they 
are now accessible to microbial enzymes for further metabolism (Figure 1.4). The 
subsequent bile acid modifications are performed mainly by anaerobes in the lower 
intestine and they include re-amidation (Ridlon and Hylemon, 2012), oxidation-
reduction reactions (Ridlon et al., 2006), esterification and desulfatation reactions. 7α-
dehydroxylation, or removal of and hydroxyl (OH) group at the C7 position, is critical 
for secondary and tertiary bile acid formation and leads to the generation of 
deoxycholic acid (DCA) from cholic acid (CA), while chenodeoxycholic acid (CDCA) 
is converted to lithocholic acid (LCA) (Ridlon et al., 2006). In the hepatocyte, 
secondary bile acids may have different fates; DCA and LCA may be conjugated to 
glycine or taurine and allowed to circulate with other conjugated primary bile acids, 
otherwise LCA can be altered by CYP3A4 to generate hyodeoxycholic acid (HDCA) 
(Xie et al., 2001). Alternatively, LCA may also be converted by Clostridium species 
to the beneficial hydrophilic bile acid ursodeoxycholic acid (UDCA) (Béguet et al., 
2004; Hofmann and Hagey, 2008). CA can also be converted to UDCA in a two-step 
process involving C7α to β epimerization and 12αHSDH oxidation. These activities 
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are distinct to some members of the Clostridia, Bacteroides and E. coli (Braun et al., 
2011).  
 
1.4.3 Bile acids shape the structure of the gut microbiota 
Studies on germ-free rodents have demonstrated that microbiota-free animals have 
more bile acids than conventionally colonised animals (Gustafsson et al., 1957; Sayin 
et al., 2013; Swann et al., 2011; Wostmann, 1973), suggesting a dynamic interplay 
between host bile acid composition and gut microbiota. Indeed, the level of bile acids 
in the intestine can influence the profile of the gut microbiota. Cholic acid (CA) 
administration in mice promoted the synthesis of antimicrobial bile acids that altered 
the microbial composition and increased the levels of the more tolerant phylum 
Firmicutes (Islam et al., 2011). Within this phylum, Clostridia and Erysipelotrichia 
were significantly increased along with increased conversion of cholic acid to 
deoxycholic acid (Islam et al., 2011). This study suggests a potential for bile acids to 
select bacterial populations with subsequent impact on bile acids signatures (Yokota 
et al., 2012). Feeding on a diet enriched in saturated milk-derived fats to Il-10 knock-
out mice led to enhanced synthesis of tauro-conjugated bile acids which promoted the 
outgrowth of Bilophila wadsworthia, a potential pathobiont associated with gut 
inflammation. The inflammatory effect was not seen in mice fed a diet rich in 
vegetable-derived fats (Devkota et al., 2012). Intriguingly, we have recently shown 
that alterations in the microbial composition in a mouse model of autism were 
accompanied by reduced bile acid metabolism in the intestine (Golubeva et al., 2017). 
 
1.5 Intestinal Barrier Integrity and the Gut Microbiota 
The intestinal tract represents the body’s largest interface with the external 
environment and it has two main functions: as an absorption site, it allows movement 
of nutrients from the lumen into circulation; as a barrier, it prevents the translocation 
of harmful entities including microorganisms. Barrier defences include both 
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immunogenic mechanisms such as immunoglobulins and mucosal lymphocytes as 
well as non-immunogenic mechanisms such as selective intestinal permeability. Tight 
junctions, also known as occluding junctions, are multiprotein junctional complexes 
which prevent the leakage of molecules, transported solutes and water through the 
intestinal wall. The opening of tight junctions can cause an increase in intestinal 
permeability which, in turn, acts as a trigger for detrimental effects on distal organs in 
the host (Figure 1.5) (Fasano, 2011; Leonard et al., 2017; Suzuki, 2013). The passage 
of microbes, microbial products, and antigens into the mucosa can result in activation 
of the immune system and secretion of inflammatory mediators (Márquez et al., 2016). 
Increased intestinal permeability has been reported in several diseases including 
Crohn's disease (Teshima et al., 2012), celiac disease (Heyman et al., 2012), diabetes 
(Cox et al., 2017), rheumatoid arthritis (Bjarnason et al., 1984) and schizophrenia 
(Severance et al., 2015),  among others.  
Figure 1.5 Intestinal barrier function. In physiological conditions, the gastrointestinal 
epithelium is tightly impermeable. A malfunction in tight junction functionality might increase 
the leakiness of the barrier. In this condition, bacteria and their products can translocate from 
the mucosal side to the serosal side, with detrimental consequences for the host. The Ussing 
chamber apparatus allows to detect changes in intestinal permeability.  
  18  
 
1.5.1 Regulators of intestinal permeability 
Intestinal permeability is a highly regulated dynamic process and the main regulators 
of permeability are: 
 Mast cells: substances released from mast cells during degranulation can mediate 
epithelial and endothelial permeability (Berin et al., 1998; Wershil, 2000). 
Mediators of mast cells activation include allergens, physical injury, microbial 
pathogens and various compounds through their associated G-protein coupled 
receptors (e.g., morphine through opioid receptors) or ligand-gated ion channels 
(da Silva et al., 2014; Moon et al., 2014).  
 Intracellular pathways: nitric oxide (NO) appears to be an important intracellular 
mediator for regulating the normal physiology of the GI tract. Several in vivo and 
in vitro studies have indicated that a low level of NO is important for maintenance 
of normal mucosal barrier function. Overproduction of NO has been associated to 
abnormal barrier function (Alican and Kubes, 1996; Salzman et al., 1995). 
 Heredity: many hereditary immunological defects might affect intestinal barrier 
function. Disrupted intestinal permeability was reported in 18% of first-degree 
relatives and 23% of the spouses of patients with Chron’s disease as compared to 
3% in controls (Soderholm et al., 1999). The authors of this study suggested that 
baseline permeability was determined by environmental factors, whereas 
permeability provoked by acetylsalicylic acid was a function of the genetically-
determined state of the mucosal barrier. 
 Diet, psychological stress, oxidative stress, exercise, aging and the use of 
medications: all of these factors have been shown to mediate changes in baseline 
intestinal permeability (Barau and Dupont, 1990; Deitch et al., 1995; Keshavarzian 
et al., 1992; Ma et al., 1992; Pals et al., 1997; Saunders et al., 1994; Sigthorsson et 
al., 1998; Wilson and Baldwin, 1999). 
 Gut microbiota: interactions between the gut microbiota and the intestinal barrier 
might involve changes in permeability. I will discuss this point in the following 
section.  
A growing body of evidence supports the notion that commensal microbes can, 
directly or indirectly, modulate intestinal permeability. Rats with a stable mixed 
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aerobic and anaerobic microbiota showed higher intestinal permeability than rats on 
antibiotics (Garcia-Lafuente et al., 1998) and this was confirmed in a subsequent study 
in rats where colonisation with Escherichia coli, Klebsiella pneumoniae and 
Streptococcus viridans significantly increased the lumen to blood clearance of 
mannitol. On the contrary, colonisation with Lactobacillus brevis had the opposite 
effect and reduced permeability (Garcia-Lafuente et al., 2001). It is still unclear 
whether these changes in intestinal permeability are the result of direct bacterial action 
or are mediated by immune mechanisms. In a study using in vitro ileal mucosa, the 
bacterial endotoxin lipopolysaccharide (LPS) caused increased intestinal permeability 
and bacterial translocation (Go et al., 1995). This effect appeared to be mediated by 
up‐regulation of inducible nitric oxide synthase activity (iNOS) as it was inhibited by 
iNOS inhibitors (Mishima et al., 1999). As mentioned earlier, immune system 
activation by luminal bacteria or their products might be a major player in modulating 
permeability. Release of inflammatory mediators and cytokines can modify intestinal 
permeability directly or indirectly. For example, in an intestinal monolayer model, 
interferon directly increased permeability by affecting tight junctions (Madara and 
Stafford, 1989). Furthermore, neutrophil transmigration induced by the bacterial 
peptide N-formylmethionyl-leucyl-phenylalanine (FMLP) resulted in a reversible 
increase in the permeability of an intestinal epithelial monolayer (Nash et al., 1987). 
More and more evidence supports a role for the microbiota in regulating intestinal 
permeability.  
 
1.5.2 Measuring intestinal permeability ex-vivo 
The Ussing chamber technique is a simple and reliable method for investigating 
intestinal permeability to both macromolecules and ions (Ussing and Zerahn, 1951).  
For the assessment of macromolecular diffusion across the intestinal epithelium, a 
fluorescent tracer flux measurement is performed. This allows measurement of the 
steady-state rate of transfer of the tracer (e.g. 4 kDa FITC-dextran) across the 
epithelium from the luminal bath to the basolateral bath. The intestinal section is 
opened and oriented as a flat sheet to separate the two halves of the chamber. The 
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intestinal preparation is situated vertically such that the mucosal membrane is facing 
one chamber half, whereas the serosal membrane the other half-chamber, thus 
separating the solutions that independently bath each chamber half. The reservoirs 
above each chamber are water jacketed to enable warming to 37 °C. At each timepoint, 
samples are collected from the basolateral bath and the amount of FITC-dextran is 
measured in a spectrophotometer at 485nm excitation / 535nm emission wavelengths. 
The baseline level of FITC (timepoint zero) is ultimately subtracted from each of the 
following timepoints (Figure 1.5, Figure 1.6).  
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Figure 1.6 Schematic drawing of the Ussing chamber apparatus. Permeability to 
macromolecules: A piece of intestine is mounted in the Ussing chamber and FITC-dextran is 
added to the mucosal compartment. Quantification of FITC in samples collected from the 
serosal chamber, at different timepoints, provides a readout of permeability to 
macromolecules. High levels of FITC-dextran in the serosal compartment are associated with 
loose barrier function. Permeability to ions: In the same apparatus, a 5mV voltage clamp 
allows for the detection of short-circuit current (Isc). Transepithelial electrical resistance 
(TEER) is calculated from ΔIsc and voltage, according to Ohm’s law. An increase in TEER is 
associated with tighter barrier function.  
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For the assessment of permeability to ions, transepithelial electrical resistance (TEER) 
is calculated through Ohm’s law. In a “leaky” epithelium, the ionic conductance 
through the paracellular pathway, in contrast to the transcellular pathway, accounts for 
> 90% of the total transepithelial ionic conductance (Frizzell and Schultz, 1972). 
Hence, changes in transepithelial ionic conductance can signal untoward effects on the 
tissue integrity. Changes in the transcellular conductance are usually difficult to detect 
with the Ussing chambers. Ion conductance through the paracellular pathway of the 
epithelium is limited by both the tight junctional complex and the relative apposition 
of the basolateral membranes of adjacent epithelial cells, which determines the volume 
of the surrounding aqueous column. A constant 5mV voltage is applied and the 
resulting change in current is measured, an approach that is generally called “voltage 
clamping”. The short-circuit current (Isc) is defined as the charge flow per time when 
the tissue is short-circuited (Figure 1.6).  
 
For the measurement of permeability to both macromolecules and ions, seromuscular 
stripping of the intestinal preparation might be performed for two main reasons: 
1) the seromuscular layers represent a significant diffusion barrier to experimental 
drugs/isotopes and to nutrients/oxygen, which reduces the viability of the intestinal 
preparation 
2) whole-thickness intestinal preparations undergo rhythmical neuromuscular 
contractions that produce corresponding changes in the transepithelial voltage 
potential and thus Isc by physiological means. 
 
The Ussing chamber technique provides a short-term organ culture method that allows 
precise measurement of electrical and transport parameters of intact, polarised 
intestinal epithelium. The principal weakness of the Ussing chamber technique lies in 
the interpretation of a relatively small number of measurements to describe the 
complex physiological system of the intestinal mucosa. The intestinal mucosa contains 
many cell types communicating through a variety of systems, which may not be 
differentiated utilising Ussing chamber measurements. Another minor concern with 
the Ussing chamber method relates to the limited viability and optimal function of an 
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ex vivo intestinal preparation, considering that the tissue can be examined for 
maximum a maximum of three hours, following which it starts degrading. 
 
1.6 Drugs and the Gut Microbiota  
The role of the microbiota in health and disease has stretched to all disciplines of 
medicine and this now includes pharmacology and therapeutics (Walsh et al., 2018). 
The field of pharmacomicrobiomics has emerged over the past decade (ElRakaiby et 
al., 2014; Saad et al., 2012) and has predominantly focused on the impact that the gut 
microbiota exerts on drug metabolism. A recent investigation in vitro assessed the 
ability of 76 different human gut bacteria to metabolize 271 oral drugs and found that 
two thirds of the drugs tested were significantly reduced by at least one bacterial strain 
and that each strain metabolized 11-95 different drugs (Zimmermann et al., 2019a). 
Also, a growing body of research has demonstrated that several pharmaceutical 
compounds including paracetamol, digoxin, metformin and cancer drugs among 
others, influence the human gut microbiota and/or microbial isolated strains. As 
bacteria can, in turn, modulate drug efficacy and toxicity (Alexander et al., 2017; 
Currò, 2018; Kelly et al., 2016), the emerging drug-microbe bidirectional interaction 
might be crucial for future drug development and clinical practice. Moreover, this 
suggests that drug-related confounding effects should be taken into consideration in 
future microbiome association studies (Figure 1.7). 
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Figure 1.7 The bidirectional link between xenobiotics and gut microbiota. The gut 
microbiota alters the chemical structures or the absorption rate of ingested compounds, 
including dietary components, industrial chemicals, and drugs. These changes affect 
xenobiotic toxicity, efficacy, bioavailability and disease risk. The microbial enzymes 
responsible for such transformations are poorly understood. Several xenobiotics alter the 
composition and function of gut microbiota although the precise mechanisms remain poorly 
understood. In some instances, xenobiotics display direct antimicrobial activity themselves. 
 
 
1.7 Drugs Affect the Gut Microbiota 
Antibiotics represent the most direct and effective way of targeting intestinal 
microbes. Evidence gathered from in vitro and in vivo studies suggests that a course 
of short-term antibiotics can substantially change the gut microbiota composition 
(Jakobsson et al., 2010; Maurice et al., 2013). Several host-targeting non-antibiotic 
drugs have also been shown to influence the gut microbiota. In a population-based 
cohort, deep sequencing of gut microbiomes of 1,135 participants showed relations 
between the microbiota and 19 drug groups (Zhernakova et al., 2016). Other studies 
have pointed out an association between drug consumption and the microbiome. 
Analysis of two independent population-level cohorts revealed that, among different 
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factors, the use of medications was responsible for the largest total variance and 
interacted with other covariate-microbiota associations (Falony et al., 2016). The 
composition of the gut microbiota can change in relation to the number and type of 
medications consumed. Differences in the relative abundance of specific bacteria were 
detected in individuals taking a single drug, a combination or none. In particular, there 
were differences in the gut microbiota of individuals taking NSAIDs (nonsteroidal 
anti-inflammatory drugs) with PPIs (proton-pump inhibitors) versus those taking 
NSAIDs without PPIs (Rogers and Aronoff, 2016). Regarding polypharmacy, in 
elderly hospitalised patients there was a significant negative correlation between the 
number of drugs and microbial alpha-diversity (Chao1 index). Moreover, the number 
of drugs was associated with the average relative abundance of 15 different taxa, with 
PPIs, antidepressants and antipsychotics exhibiting the strongest association with 
single bacteria abundance (Ticinesi et al., 2017).  
 
1.8 The Gut Microbiota Affects the Pharmacokinetics of 
Drugs 
Pharmacokinetics (from the Greek root pharmakon = drug and kinetikos = moving, 
“putting in motion") is a branch of pharmacology dedicated to determining the fate of 
xenobiotics administered to a living organism. Absorption is one of the four 
compartments of the pharmacokinetics multi-compartmental model (Arundel, 1997), 
together with distribution, metabolism and excretion (ADME) (Pacey et al., 2011).  
In the next two sections, we provide some of the most compelling evidence on the 
interaction between gut microbiome and drug absorption/metabolism prior to 
discussing the relevance to psychotropic compounds.  
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1.8.1 The gut microbiota affects drug absorption 
In pharmacology, absorption is the movement of a substance from the site of 
administration to the bloodstream (Doogue and Polasek, 2013). Very little is currently 
known about the role played by the gut microbiota in drug absorption but a few reports 
on the topic exist. It is interesting to note that all the three studies mentioned in this 
section use the same experimental approach: manipulation of the gut microbiota 
through administration of probiotics.  
The action of gliclazide, a sulfonylurea used to treat diabetes, may be enhanced by 
administering probiotics. In diabetic rats, the blood levels of gliclazide are higher 
following a 3-days pre-treatment with probiotics (at the dose of 75 mg/kg) compared 
to non-treated rats, suggesting that the gut microbiota might mediate the extent of the 
drug absorption (Al-Salami et al., 2008). In a recent study, a three-day administration 
of Lactobacillus reuteri K8 reduced the absorption of orally administered 
acetaminophen in mice, whereas administration of Lactobacillus reuteri K9 did not 
have an effect (Kim et al., 2018). This effect was probably mediated by probiotic-
induced modulation of gut microbial enzyme activity given that the probiotic 
significantly increased both sulfatase and arylsulfate transferase and significantly 
decreased β-glucuronidase, which are the bacterial enzymes involved in 
acetaminophen metabolism. Finally, the antiarrhythmic drug amiodarone showed 
elevated blood levels following administration of probiotics in rats. In detail, the 
probiotic E.coli strain Nissile 1917 was administered to rats for 7 days, followed by a 
single dose of amiodarone per os. The probiotic increased amiodarone plasmatic levels 
by 43% compared to saline-treated controls, suggesting a microbiota-mediated 
increase in drug absorption (Matuskova et al., 2014).  
 
1.8.2 The gut microbiota affects drug metabolism 
The fate of xenobiotics depends not only by the host but also by the bacteria 
harbouring our gastrointestinal tract and it has become more investigated, over the past 
decades, the role of gut microbiome in xenobiotic metabolism. The whole field has 
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been termed “pharmacomicrobiomics” (Rizkallah et al., 2010). In this paragraph, we 
offer a glimpse into the known effects of the gut microbiota on drug metabolism. 
Digoxin, a cardiac glycoside that has been widely used for hundreds of years to treat 
heart failure and arrhythmias, is a striking example. This drug is inactivated in the gut 
by the Actinobacterium Eggerthella lenta (Haiser et al., 2013). Moreover, increased 
consumption of dietary protein in germ-free mice inhibited the reduction of digoxin 
by E. lenta (Haiser et al., 2013). The microbial biotransformation of orally 
administered lovastatin, a drug used for lowering cholesterol levels and reduce the 
risk of cardiovascular disease, was reduced by concomitant administration of 
antibiotics in rats (Yoo et al., 2014). This could result in altered systemic 
concentrations of either the intact drug and/or its metabolites (Yoo et al., 2014). 
Amlodipine, a medication used to treat high blood pressure and coronary artery 
disease, undergoes clearance when incubated with a faecal suspension, suggesting that 
the gut microbiota metabolises this drug (Yoo et al., 2016). As a confirmation, a two-
days treatment with the antibiotic ampicillin in rats increases the plasma levels of 
amlodipine, possibly because of the decreased microbial biotransformation in the 
gastrointestinal tract (Yoo et al., 2016). Mesalazine, also known as 5-aminosalicylic 
acid (5-ASA), is an anti-inflammatory drug used to treat inflammatory bowel disease, 
including ulcerative colitis or to maintain remission in Crohn's disease (Rachmilewitz, 
1989). The faecal microbiota plays a key role in acetylating 5-ASA, with 44% of 
anaerobic bacteria tested in incubation with the drug exhibiting this property (van 
Hogezand et al., 1992). The metabolism of sulfasalazine, a drug used for the treatment 
of rheumatoid arthritis, ulcerative colitis and Crohn's disease, is also likely to be 
mediated by intestinal bacteria. When sulfasalazine was fed to conventional rats, none 
of the drug was recovered in the urine, faeces or caecum; however if administered in 
combination with the antibiotic neomycin, the drug was recovered in faeces and 
caecum (Peppercorn and Goldman, 1972). In addition, when sulfasalazine was given 
to germ-free rats, recovery of drug in the faeces was over 50% whereas the urine 
contained an additional 1-2%. In germ-free rats infected with four specific bacteria 
normally found in the intestinal tract of rodents, sulfasalazine was metabolised as in 
conventional rats (Peppercorn and Goldman, 1972). Sulfasalazine is metabolised by 
azoreductases in the gut. The probiotic strains Lactobacillus acidophilus L10, 
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Bifidobacterium lactis B94 and Streptococcus salivarius K12 given to rats for three 
consecutive days increased azoreductase activity in ex vivo colon contents with a 
corresponding increase in sulfasalazine metabolism (Lee et al., 2012). Interestingly 
however, the same probiotic treatment in rats, followed by an oral 100 mg/kg dose of 
sulfasalazine, did not alter the pharmacokinetic parameters (Lee et al., 2012). 
Administration of diclofenac, a NSAID, induced enteropathy in mice; however, oral 
pre-treatment with a bacteria-specific β-glucuronidase inhibitor was able to protect 
against diclofenac-induced enteropathy (LoGuidice et al., 2012), suggesting that the 
gut microbiota might play a crucial role in the metabolism of this medication. The 
antithrombotic effect of aspirin seems to be affected by the gut microbiota. In rats, 
administration of the antibiotic ampicillin significantly prolongs the bleeding time in 
aspirin-dosed rats (Kim et al., 2016). Moreover, oral administration of ampicillin 
reduces the aspirin-metabolizing activity of the microbiota by 67% (Kim et al., 2016). 
Intestinal microbial azoreductases play a key role in the reduction of azo dyes (Chung 
et al., 1992). A wide variety of anaerobic bacteria isolated from caecal or faecal 
contents from experimental animals and humans have the ability to cleave the azo 
linkages to produce aromatic amines (Chung et al., 1992). Moreover, the azoreductase 
activity in a variety of intestinal preparations is affected by various dietary factors 
including antibiotics and supplementation with live cultures of lactobacilli (Chung et 
al., 1992).  
Choline and carnitine are dietary amines that have wide-ranging roles in human 
metabolism (Zeisel and da Costa, 2009) and are precursors of trimethylamine (TMA), 
a compound that can cause trimethylaminuria when not appropriately metabolised by 
the host (Mackay et al., 2011). In a recent study, the quantification and detailed 
characterization of the TMA-producing bacteria in human faecal samples have 
resulted particularly in Clostridium XIVa strains and Eubacterium sp. strain AB3007 
(Rath et al., 2017). In a different study, carnitine metabolism was mediated by Rieske-
type oxygenases present in the human microbiota (Zhu et al., 2014).  
Chemotherapeutic drugs have also been shown to be metabolised by the gut 
microbiota (Alexander et al., 2017). Of 30 chemotherapeutic drugs examined in vitro, 
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the efficacy of 10 was found to be significantly inhibited by certain bacteria, while the 
same bacteria improved the efficacy of six others (Lehouritis et al., 2015). As further 
corroboration of these findings, the chemoresistance or increased cytotoxicity 
observed in vitro with sample drugs (gemcitabine and CB1954) was replicated in in 
vivo murine subcutaneous tumour models (Lehouritis et al., 2015). The dose-limiting 
side effect of the common colon cancer chemotherapeutic irinotecan is severe 
diarrhea that arises following reactivation of the drug by symbiotic bacterial β-
glucuronidases in the gut (Ma and McLeod, 2003; Mathijssen et al., 2001). Oral 
administration of a bacterial β-glucuronidase inhibitor protected mice from irinotecan-
induced toxicity, suggesting that such inhibitors may be designed to prevent 
undesirable enzyme activities in the intestine (Wallace et al., 2010). The gut 
microbiota also plays a crucial role in the metabolism of 5-fluorouracil, another 
chemotherapeutic compound (Nakayama et al., 1997). The antineoplastic drug 
doxorubicin is effectively metabolised by Raoultella planticola in vitro, as 
demonstrated by Yan and colleagues (Yan et al., 2018). Specifically, R. planticola was 
shown to deglycosylate doxorubicin into its metabolites 7-deoxydoxorubicinol and 7-
deoxydoxorubicinolone via a reductive deglycosylation mechanism. Moreover, 
doxorubicin was degraded anaerobically by Klebsiella pneumoniae and E.coli 
BW25113 in vitro (Yan et al., 2018). In a recent study, 5-fluorouracil (5-FU) and 5-
fluoro-2'-deoxyuridine (FUDR) were found to act through bacterial ribonucleotide 
metabolism to elicit their cytotoxic effects in Caenorhabditis elegans (Garcia-
Gonzalez et al., 2017), suggesting that bacteria in the host play an important role in 
the response to chemotherapeutics. Similar findings were also obtained in a different 
study (Scott et al., 2017b). Finally, a recent study found that the anticancer immune 
effects of cyclophosphamide are modulated by the gut microbiota. Indeed, the 
changes induced by this chemotherapeutic on the gut microbiota stimulate the 
generation of a specific subset of "pathogenic" T helper 17 cells and immune responses 
typically associated to this medication (Viaud et al., 2013). 
Interestingly, two studies have also highlighted a role for the microbiome in patients 
undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy 
(Gopalakrishnan et al., 2018; Matson et al., 2018; Routy et al., 2018). The diversity 
and composition of the microbial community differed between responders and non-
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responders, accompanied by functional differences in gut bacteria in responders 
(including enrichment of anabolic pathways) (Gopalakrishnan et al., 2018). In the 
same study, immune profiling suggested enhanced systemic and antitumor immunity 
in responding patients with a favourable gut microbiome as well as in germ-free mice 
receiving faecal transplants from responding patients (Gopalakrishnan et al., 2018). 
Resistance to immunotherapy can be attributed to abnormal gut microbiome 
composition, according to a different study. Antibiotics administration inhibited the 
clinical benefit of immunotherapy in patients with cancer; moreover, faecal microbiota 
transplantation (FMT) from cancer patients into germ-free mice ameliorated the 
antitumor effect only when the donor was a responder, whereas FMT from 
nonresponding patients failed to do so (Routy et al., 2018).  
While a scarce knowledge exists on the link between the microbiome and drug 
absorption /metabolism, this topic assumes high clinical relevance, considering that 
changes in absorption and metabolism can correspond to alterations in drug efficacy 
and toxicity. There are no studies so far exploring the effects of microbial perturbations 
on psychotropic drug pharmacokinetics and more research is warranted, especially 
considered that several psychotropics have been shown to alter the gut microbiota 
composition (see following sections). Overall, the growing evidence underlies a 
fascinating interaction between intestinal bacteria and drug efficacy (Figure 1.8), 
suggesting that precision medicine strategies should include the intestinal microbiota 
as a potential treatment modifier (Jobin, 2018). 
 
  
  31  
 
 
Figure 1.8 The complex interaction between drugs and gut microbiota. Drugs influence the 
host through their mechanism of action (pharmacodynamics) and vice versa the host 
influences the fate of the drugs (pharmacokinetics). In this bidirectional interaction, the gut 
microbiota plays both a direct (red arrows) and an indirect (blue arrows) role. Drug → 
Microbiota interactions (left panel): Drugs can directly influence the microbiota through 
antimicrobial activity (i.e. SSRIs). Drugs can also alter the physiological properties of host 
organs (i.e. PPI-mediated alterations of pH), which in turn might affect the microbiota 
composition. Microbiota → Drug interactions (right panel): The microbiota can directly 
metabolise drugs through bacterial-derived enzymes. The microbiota can also alter the host 
capacity to metabolise drugs, which in turn might affect the fate of the drug. The precise 
mechanisms supporting the complex interplay between drugs and gut microbiota are not yet 
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1.9 Psychotropic Drugs and the Gut Microbiota 
In this thesis, I will focus on psychotropic compounds (from the Greek root psychè = 
mind and tropòs = turning), which modulate brain and behaviour, and I will explore 
the scientific evidence on the interaction between psychotropic compounds and the 
gut microbiome in vivo or in isolated strains (in vitro) (Figure 1.9). For each class of 
psychotropic compound taken into consideration, sub-sections will be based on the 
experimental approach used (observations in vitro, in vivo or in humans). Regarding 
in vitro experiments, some attempts have been made to try and find the best dose 
translational to the human gut setting. Maier and colleagues have deduced colon 
concentrations on the basis of drug excretion patterns from published work, and small 
intestine concentrations on the basis of daily doses of individual drugs. Based on their 
approximations, a threshold of 20 μM was below the median small intestine and colon 
concentration of the majority of human-targeted drugs (Maier et al., 2018). It is 
important to keep this in mind when considering data generated from in vitro isolated 
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Figure 1.9 Psychotropic compounds affect the gut microbiota composition. Not only 
psychotropic medications but also other psychoactive compounds can influence the 
microbiome either directly or indirectly. Figure from (Cussotto et al., 2019a). 
 
1.10 Antipsychotics and the Gut Microbiota  
Antipsychotics are drugs used for the prophylaxis and acute treatment of psychotic 
illnesses including schizophrenia and psychosis associated with depression and mania 
(Gardner et al., 2005). They also have an important role as an alternative or adjunct to 
benzodiazepines in the management of the acutely disturbed patient, for both 
tranquillisation and sedation. The common mechanism of action of all antipsychotics 
is to decrease brain dopamine function by blocking the dopamine D2 receptors 
(Laruelle et al., 2005). 
Analysis of faecal microbiota from 76 elderly hospitalised patients showed that, 
among several therapeutic classes, the use of antipsychotics had a strong association 
with gut microbiota composition (Ticinesi et al., 2017). In a recent study, differences 
in faecal microbiota between patients with first-episode psychosis and healthy 
controls, were associated with response after up to 12 months of treatment (Schwarz 
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et al., 2018), suggesting that the gut microbiota might be involved in treatment 
response. Specifically, Lactobacillaceae and Bifidobacteria were highly abundant in 
patients with first-episode psychosis and correlated positively with severity of 
psychotic symptoms and negatively with global functioning (Schwarz et al., 2018). In 
a tour de force in vitro screening study of more than 1,000 drugs against 40 
representative gut bacterial strains, it was found that 24% of human-targeting drugs 
inhibited the growth of at least one strain (Maier et al., 2018). Provocatively, nearly 
all subclasses of the chemically diverse antipsychotics targeted a significantly more 
similar pattern of species than expected from their chemical similarity, raising the 
possibility that antimicrobial action may not only manifest as side effect of 
antipsychotics, but also be part of their mechanism of action (Maier et al., 2018). This 
hypothesis should be ideally verified by assessing whether microbiome manipulations 
(i.e. antibiotic administration) have an effect on the efficacy of antipsychotics. 
Remarkably, the Maier et al. study provides an exhaustive justification for the dose 
used in the in vitro screening. The authors argue that, based on drug excretion patterns 
from published work, the chosen concentration of 20 μM is below the median colon 
concentration of the human-targeted drugs tested (Maier et al., 2018) and therefore has 
translational validity. Notably, in their experiment, human-targeted drugs that showed 
anticommensal activity had lower plasma and estimated small intestinal 
concentrations than ones with no such activity, suggesting that more human-targeted 
drugs would inhibit bacterial growth if probed at higher doses, closer to physiological 
concentrations. In a recent study in vitro, the antibacterial activity of antipsychotics 
against Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli, 
Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii was 
investigated. Phenothiazines and thioxanthenes showed differential antibacterial 
activity at concentrations ranging from 64 to 1024 μg/mL, which was independent of 
antibiotic-resistance patterns (Nehme et al., 2018). How these concentrations translate 
to those found in the colon following an oral administration of antipsychotics in 
humans is not clear and is not mentioned in the study, thus these findings might lack 
translational relevance. 
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1.10.1 Typical antipsychotics and the gut microbiota 
Typical (first-generation) antipsychotics were first developed in the 1950s and the first 
compounds to come into medical use were the phenothiazines, such as 
chlorpromazine. Typical antipsychotics are characterised by extrapyramidal adverse 
effects such as dystonia, Parkinsonian symptoms (bradykinesia, rigidity and tremor), 
akathisia, tardive dyskinesia, cardiovascular effects such as postural hypotension, 
prolactin increase and sedation (Leucht et al., 2009).  
 
Evidence from in vitro studies 
Studies on the interaction between typical antipsychotics and gut bacteria have been 
only carried out in vitro. Other approaches, such as in vivo or human observations, are 
missing from literature, and one reason for this gap might be more and more 
consideration is directed towards the new class of antipsychotics, the atypical 
(Skonieczna-Zydecka et al., 2018).  
Thioridazine, a phenothiazine antipsychotic, has been shown to possess antimicrobial 
activity in vitro against methicillin-susceptible S. aureus (Hahn and Sohnle, 2014; 
Ordway et al., 2002b), vancomycin-resistant pathogenic strains of Enterococcus 
species (Wainwright et al., 1999), Mycobacterium tuberculosis (Amaral et al., 1996; 
Bettencourt et al., 2000; Ordway et al., 2003; Viveiros and Amaral, 2001), 
Pseudomonas aeruginosa and Mycobacterium avium (Viveiros et al., 2005). 
Fluphenazine, another typical antipsychotic, possesses pronounced action against 
both Gram-positive and Gram-negative bacteria at concentrations of 20-100 μg/mL 
(Dastidar et al., 1995). Upon investigation of the antimicrobial activity of 
trifluoperazine against 293 strains (from two Gram-positive and eight Gram-negative 
genera), 46 of 55 strains of S. aureus were inhibited by doses of 10-50 μg/mL. This 
drug also inhibited strains of Shigella spp., Vibrio cholerae and V. parahaemolyticus 
at concentrations of 10–100 μg/mL (Mazumder et al., 2001). Bacillus spp. and 
Staphylococcus spp. were strongly inhibited by the antipsychotic prochlorperazine; 
while E.coli, Salmonella, Klebsiella and Pseudomonas were only moderately sensitive 
  36  
 
or resistant to the drug (Rani Basu et al., 2005). Chlorpromazine, another typical 
antipsychotic, had in vitro antimycobacterial properties (Kristiansen and Vergmann, 
1986; Molnar et al., 1977) and also exerted an inhibitory synergistic effect in 
combination with certain antibiotics (Amaral et al., 1992). Moreover, this medication 
has been shown to inhibit significantly the growth of S. aureus (Ordway et al., 2002a) 
and E.coli (Amaral and Lorian, 1991; Csiszar and Molnar, 1992). Keeping in mind 
that these data come from in vitro bacterial cultures, it is important to remark that a 
direct extrapolation and translation into the gut microbiome scenario is not always 
possible. 
 
1.10.2 Atypical antipsychotics and the gut microbiota 
Atypical antipsychotics act on numerous receptors and modulate several interacting 
transmitter systems. All atypicals (except amisulpride) exhibit greater antagonism of 
5-HT2 receptors than of D2 receptors, compared with the typical agents. Atypical drugs 
that do antagonise dopamine D2 receptors appear to have affinity for those in the 
mesolimbic system rather than the nigrostriatal system, producing side effects of lesser 
degree. Clozapine and risperidone exert substantial antagonism of α2-adrenoceptors, 
while aripiprazole is a unique drug because it is a partial dopamine D2-receptor agonist 
that acts conversely as an antagonist in regions where dopamine is overactive, such as 
the limbic system (Bennett and Brown, 2008). 
 
Evidence from in vitro studies  
The effect of olanzapine on the growth of two commensal bacterial strains, E. coli 
NC101 and Enterococcus faecalis OGIRF was assessed in vitro across a range of 
supraphysiologic concentrations (280 to 560 µg/mL). Olanzapine completely inhibited 
the growth of E.coli at concentrations above 537 µg/mL, while it did not affect the 
growth of E. faecalis (Morgan et al., 2014). 
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Evidence from in vivo studies (rodents) 
Most of the studies performed in vivo have been focusing on two atypical 
antipsychotics, olanzapine and risperidone. Administration of olanzapine for 3 weeks 
in rats was able to induce specific alterations of the microbiota profile in both males 
and females (Davey et al., 2012). Moreover, administration of olanzapine in mice 
exacerbated the weight gain induced by high-fat diet (Morgan et al., 2014). 
Interestingly, this effect was absent under germ-free conditions but emerged quickly 
upon microbial colonization of the gut, suggesting that gut microorganisms might be 
necessary for the common adverse effect of olanzapine, weight gain (Morgan et al., 
2014). As a proof of concept, the impact of antibiotics on olanzapine-induced weight 
gain was also demonstrated. Coadministration of an antibiotic cocktail in female rats 
treated with 2 mg/kg of olanzapine for 21 days, attenuated body weight gain, uterine 
fat deposition, macrophage infiltration of adipose tissue and plasma free fatty acid 
levels, all of which were increased by olanzapine alone (Davey et al., 2013). More 
recently, one last experiment has looked at microbiota changes and olanzapine 
administration. In this case, the prebiotic B-GOS (bimuno galactooligosaccharide) was 
administered to adult female Sprague-Dawley rats in coadministration with olanzapine 
(2-week, daily intraperitoneal injection at a dose of 10 mg/kg) and the intake of B-
GOS significantly attenuated olanzapine-induced weight gain (Kao et al., 2018). 
Although B-GOS alone increased Bifidobacteria spp., and reduced species within the 
Firmicutes (coprococcus, oscillibacter, c. coccoides, roseburia intestinalis cluster, 
clostridium XVIII cluster) and Proteobacteria (Escherichia/Shigella spp.) phyla, no 
effects of olanzapine were observed. This is a discrepancy with other studies, maybe 
due to the duration and dose of olanzapine administration and/or the method of 
bacterial analysis. Importantly, additional studies are required to test whether the 
bacteria affected by B-GOS would proliferate beyond control levels with a longer 
duration of olanzapine administration at a clinically relevant dose. It is important to 
note that sex differences might play a key role in response to atypical antipsychotics 
and thus many studies to date have been performed in females, however more 
investigations are warranted in male counterparts. The impact of risperidone on the 
gut microbiota has also been investigated in vivo. Female mice treated with risperidone 
at a dose of 80 μg/day over two months exhibited significant excess weight gain, due 
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to reduced energy expenditure, which correlated with an altered gut microbiota (Bahr 
et al., 2015b). Interestingly, faecal transplant from risperidone-treated mice into naïve 
recipients caused a 16% reduction in total resting metabolic rate, attributable to 
suppression of non-aerobic metabolism (Bahr et al., 2015b). Aripiprazole, an atypical 
antipsychotic with a mode of action that is distinct from most currently available 
antipsychotic drugs, was able to induce marked changes in microbiota composition in 
rats following a 4-week treatment at 20 mg/kg/day. The relative abundance of various 
taxa including Clostridium, Ruminiclostridium, Intestinibacter and Eubacterium 
coprostanoligens was increased by aripiprazole administration (Cussotto et al., 
2019b). 
 
Evidence from studies in humans 
A recent study has looked at the association between intake of atypical antipsychotics 
(AAP) and gut microbiota. In a cross-sectional design study, faecal samples of more 
than 100 bipolar patients were collected and analysed through 16S ribosomal 
sequencing. Participants were divided into two groups: one group AAP-treated and 
one group drug-free at the time of faecal sample collection. Atypical antipsychotics 
included in the AAP cohort were: clozapine, olanzapine, risperidone, quetiapine, 
asenipine, ziprasodone, lurasidone, aripiprazole, paliperidone, and iloperidone. The 
microbiota communities of AAP-treated and non-treated patients were significantly 
separated, with AAP-treated females showing decreased species diversity compared 
to non-AAP-treated females; while males did not show significant diversity. Three 
specific genera, Lachnospiraceae, Akkermansia, and Sutterella were differentially 
abundant in the two groups (Flowers et al., 2017). While this study provides critical 
insight into the AAP-mediated changes in gut microbiota, the report included no 
information regarding diet, which is an important environmental factor that drives the 
composition of gut microbiota. Moreover, the authors observed medication‐specific 
microbiota differences, but it is not known how these translate into functional 
differences. In a cross-sectional cohort study on psychiatric patients, the effect of 
AAPs on the gut microbiota was examined. Although no significant differences in 
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microbiota composition were detected at baseline between AAP users and nonusers, 
non‐AAP users showed an increase in the bacterial genus Alistipes. AAP‐treated 
females also had decreased diversity compared with non ‐treated females (Flowers et 
al., 2019). One more human study investigated the impact of risperidone on gut 
microbiota composition. In psychiatrically ill children, chronic treatment with 
risperidone was associated with an increase in body mass index (BMI) and a 
significantly lower ratio of Bacteroidetes:Firmicutes as compared with antipsychotic-
naïve psychiatric controls. Moreover, a longitudinal observation revealed a gradual 
decrease in the Bacteroidetes:Firmicutes ratio over the ensuing months of treatment 
with risperidone (Bahr et al., 2015a). Although the small sample size and the fact that 
polypharmacy was not taken into account, this study offers preliminary evidence that 
the human gut microbiome is altered in patients treated chronically with risperidone. 
  
1.11 Antidepressants and the Gut Microbiota 
Antidepressants are medications used to treat symptoms of depression, social anxiety 
disorder, seasonal affective disorder and mild chronic depression, as well as other 
conditions (Delgado, 2004). Antidepressants can be broadly divided into four main 
classes: tricyclic antidepressants (TCAs), selective serotonin-reuptake inhibitors 
(SSRIs), monoamine oxidase inhibitors (MAOIs) and novel compounds, some of 
which are related to TCAs or SSRIs (see SNRIs, serotonin-noradrenaline reuptake 
inhibitors) (Bennett and Brown, 2008). The mechanism of action is based on the 
“monoamine hypothesis”, which proposes that the main cause of depression is a 
deficiency of the neurotransmitters noradrenaline (NA) and serotonin (5-HT, 5-
hydroxytryptamine) in the brain. However, different classes present different 
mechanisms of action: SSRIs prevents 5-HT reuptake, TCAs inhibit NA reuptake but 
effects on 5-HT reuptake vary widely, MAOIs increase the availability of NA and 5-
HT by preventing their degradation in the presynaptic terminal (Fiedorowicz and 
Swartz, 2004). 
  40  
 
In a cohort of elderly subjects, intake of antidepressants was strongly associated with 
changes in gut microbiota composition (Ticinesi et al., 2017). A different population-
level analysis of gut microbiome composition found that antidepressants were 
significantly correlated to microbiome composition (Falony et al., 2016). The field of 
antidepressants and gut microbiota is in constant expansion, but there is currently not 
sufficient knowledge on the effect that these drugs exert on the ecology of the gut 
microbiota. On the other hand, a consistent amount of research has examined the 
antimicrobial activity that these compounds have against various bacterial strains in 
vitro. In the following sections, evidence related to all subclasses of antidepressant 
compounds will be taken into consideration.  
 
1.11.1 Tricyclic antidepressants (TCAs) and the gut microbiota 
Evidence from in vitro studies 
TCAs in general inhibit NA reuptake and some compounds can also block 5-HT 
reuptake to a certain extent (Horn, 1980). All studies to date looking at TCAs and 
microbiota have been performed in vitro.  
Clomipramine and imipramine have been shown to possess cytotoxic effects against 
both human protozoan parasites Leishmania donovani and Leishmania major 
(Zilberstein and Dwyer, 1984). Mandal and colleagues have analysed the 
antimicrobial activity of Amitriptyline hydrochloride against 253 bacterial strains (72 
Gram-positive and 181 Gram-negative) and 5 fungal strains in vitro. Moreover, they 
carried out a mortality experiment with or without amitriptyline in mice challenged 
with a virulent strain of Salmonella typhimurium (Mandal et al., 2010). Out of 254 
bacterial strains, 185 were inhibited at different doses of amitriptyline, with 
Staphylococcus spp., Bacillus spp. and Vibrio cholerae being the most affected 
bacteria (Mandal et al., 2010). Regarding fungal strains, amitriptyline inhibited both 
Cryptococcus spp. and Candida albicans. Finally, in the in vivo experiment, 
amitriptyline at 25 μg/g and 30 μg/g body weight significantly protected the mice from 
Salmonella typhimurium (Mandal et al., 2010). Promethazine and imipramine have 
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been demonstrated to inhibit the growth of E. coli and Yersinia enterocolitica through 
interference with plasmid replication (Csiszar and Molnar, 1992; Molnar, 1988), and 
imipramine was also able to inhibit the parasite Giardia lamblia (Weinbach et al., 
1992). Desipramine has been shown to be effective against Plasmodium falciparum 
(Basco and Le Bras, 1990; Salama and Facer, 1990). 
 
1.11.2 Selective serotonin-reuptake inhibitors (SSRIs) and the gut 
microbiota 
Evidence from in vitro studies 
SSRIs, as their name indicates, act predominantly by preventing 5-HT reuptake, with 
little or no effect on NA reuptake (Stahl, 1998).  
SSRIs have excellent activity against Brucellae (Muñoz-Criado et al., 1996) and they 
have been shown to be synergistic in combination with antibiotics against some 
microorganisms such as Corynebacterium urealyticum (Garcia-Rodriguez et al., 1991; 
Munoz-Bellido et al., 1996). Interestingly, SSRIs also affect the normal physiology of 
some bacteria, for example they inhibit slime production in coagulase-negative 
staphylococci (Munoz Criado et al., 1997) and inhibit swarming in swarming species 
in Proteus (Muñoz-Criado et al., 1998). Upon analysis of the antimicrobial activity of 
four SSRIs against E.coli, sertraline was the most potent antimicrobial compound 
(Bohnert et al., 2011). Since the discovery of sertraline as a strong antimicrobial, the 
research has been focused mainly on this compound. Sertraline inhibits the growth of 
S. aureus, E.coli and P. aeruginosa, and it also has synergy in combination with 
antibiotics (Ayaz et al., 2015). Moreover, sertraline has potent antifungal activity 
against Cryptococcus neoformans (Rossato et al., 2016; Trevino-Rangel Rde et al., 
2016; Zhai et al., 2012), Coccidioides immitis (Paul et al., 2016) and Candida spp. 
(Lass-Florl et al., 2003). In a different study it was shown that sertraline was able to 
kill 97.5% of the promastigotes of Leishmania donovani at a dose of 30mg/L while, at 
the lowest concentration (3 mg/L), it induced significant loss of viability in the 
promastigotes (61%) (Palit and Ali, 2008). Fluoxetine had a strong dose-dependent 
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antimicrobial activity in vitro against L. rhamnosus and E.coli, while escitalopram 
only exerted a minor antimicrobial effect on E.coli, without affecting the growth of L. 
rhamnosus (Cussotto et al., 2019b).  
 
Evidence from in vivo studies (rodents) 
Evidence from our laboratory has recently shown that 4 weeks of fluoxetine 
administration in drinking water in rats at a translationally relevant dose of 10 
mg/kg/day completely inhibited the growth of Succinivibrio and Prevotella caecal taxa 
(Cussotto et al., 2019b). Whether the microbiome changes influence the efficacy 
and/or toxicity of fluoxetine still needs to be teased apart.  
 
1.11.3 Other antidepressants and the gut microbiota 
Evidence from in vitro studies 
Interestingly, the era of antidepressants started with isoniazid, a compound that also 
has antimicrobial activity against Mycobacterium tuberculosis and is currently used to 
treat tuberculosis (Jena et al., 2014; Lei et al., 2000). Ketamine is a non-competitive 
NMDA (N-methyl-d-aspartate) antagonist that acts at the PCP (phencyclidine) binding 
site in the NMDA receptor and possess a fast onset of action as antidepressant (Bennett 
and Brown, 2008). Ketamine showed antimicrobial activity in vitro against six 
different strains of bacteria: S. aureus, S. epidermidis, E. faecalis, S. pyogenes, P. 
aeruginosa and E. coli; with S. aureus and S. pyogenes being the most sensitive strains 
(Begec et al., 2013; Gocmen et al., 2008). There is currently little known regarding the 
effects of ketamine on gut microbiota and other classes of antidepressants, such as 
MAOIs (monoamine oxidase inhibitors) and SNRIs (serotonin-norepinephrine 
reuptake inhibitors), have not been investigated. Given the wide range of antimicrobial 
effects that most antidepressants show against different strains, it is perhaps not 
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surprising to speculate that SNRIs or MAOIs might exert a microbial effect. This 
represents a future direction for research.  
 
1.12 Antianxiety Drugs and the Gut Microbiota 
Evidence from in vitro studies 
The literature to date lacks comprehensive studies investigating the effects of 
antianxiety agents on the gut microbiome, however some studies in vitro have been 
carried out to assess whether these compounds possess antimicrobial activity. 
Propranolol is a beta-receptor blocker that is commonly used to overcome the somatic 
symptoms of anxiety such as tachycardia and palpitations (Whitlock and Price, 1974). 
In vitro this compound was able to inhibit the growth of S. aureus (Kruszewska et al., 
2004) and E.coli (Hadera et al., 2018). However, the data are divergent, as a different 
study showed that propranolol did not inhibit the growth of S. aureus (Jerwood and 
Cohen, 2008). More research in vivo and in humans is warranted to investigate the 
microbial effects of antianxiety drugs. 
 
1.13 Anticonvulsants/Mood Stabilisers and the Gut 
Microbiota 
Mood stabilisers are used to treat mood disorders, characterised by intense and 
sustained mood shifts, typically bipolar disorder, borderline personality disorder and 
schizoaffective disorder. Many agents described as mood stabilisers are also 
categorised as anticonvulsants (Rapoport et al., 2009). No population-based studies 
have been carried out to date looking at the influence of anticonvulsants on the 
microbiome, but some preclinical data exist and are examined in the following 
sections.   
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Evidence from in vitro studies 
We have recently screened the antimicrobial activity of lithium and valproate against 
E.coli and L. rhamnosus in vitro and these two medications did not inhibit the growth 
of the two bacteria (Cussotto et al., 2019b). Interestingly however, valproate has 
previously been shown to inhibit Mycobacterium smegmatis but not to affect E. coli 
(Esiobu and Hoosein, 2003). Lamotrigine showed good antibacterial activity against 
Gram-positive bacteria B. subtilis, S. aureus and S. faecalis (Qian et al., 2009) and 
inhibition of bacterial ribosome biogenesis (Stokes et al., 2014). Finally, some 
evidence also showed that gabapentin and topiramate possess differential 
antimicrobial activity in vitro (Kruszewska et al., 2004).   
 
Evidence from in vivo studies (rodents) 
A 4-weeks administration of lithium and valproate in the chow of Sprague-Dawley 
rats was able to change markedly the caecal microbiome (Cussotto et al., 2019b). 
Bacterial richness was increased in both treatments compared to vehicle-treated 
animals; moreover, at the genus level, lithium increased the relative abundance of 
Ruminococcaceae and decreased Bacteroides, while valproate decreased the relative 
abundance of S24-7 uncultbact and increased Ruminococcaceae (Cussotto et al., 
2019b). Valproate, but not lithium, also affected the levels of SCFAs in the caecum. 
How these microbial changes relate to drug efficacy is not clear. Moreover, it is also 
not clarified whether these drugs affect directly the gut microbiota (i.e. they reach the 
caecum) or indirectly (i.e. through gut-brain signalling).  
 
1.14 Opioid Analgesics and the Gut Microbiota  
Opioid analgesics act to reduce the intensity and unpleasantness of pain. They produce 
their effects by activating specific G-protein-coupled receptors in the brain, spinal cord 
and peripheral nervous system (Trang et al., 2015). Acting as agonists at opioid 
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receptors, these compounds reduce neuronal excitability and inhibit the release of pain 
neurotransmitters (Conlon and Bird, 2015).  
 
Evidence from in vitro studies 
Morphine did not possess antimicrobial activity against any of the 10 microbial 
strains studied with the agar dilution method (Rosenberg and Renkonen, 1985). 
Another opioid analgesic, tramadol, had strong bactericidal activity in vitro against 
E.coli and S. epidermidis and weak antimicrobial activity against S. aureus and P. 
aeruginosa (Tamanai-Shacoori et al., 2007). Methadone exerted antimicrobial 
activity in vitro against S. aureus, P. aeruginosa and S. marcescens (Sheagren et al., 
1977). 
 
Evidence from in vivo studies (rodents) 
In a morphine-dependent murine model, significant shifts in the gut microbiome and 
metabolome within one day following morphine treatment were detected. Morphine 
was administered through the pellet implantation method, so that plasma levels of 
morphine were maintained in the 0.6 - 2.0 µg/ml range (range observed in opioid 
abusers and patients on opioids for moderate to severe pain). Morphine-induced 
alterations in gut microbial composition were associated to a significant increase in 
pathogenic bacteria and a decrease in communities associated with stress tolerance 
(Wang et al., 2018). In a different study in mice, both intermittent and sustained 
morphine administration influenced the gut microbiome in a way that was causally 
related to behaviours associated with opioid dependence (Lee et al., 2018). 
Interestingly, subcutaneous injections of tramadol reduce the growth of S. aureus 
through enhancing phagocytes and tissue inflammation, however, it does not eliminate 
P. aeruginosa (Farzam et al., 2018). 
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Evidence from studies in humans 
One study has examined the effect that opioids might have on the gut microbiota in 
humans. In a cohort of cirrhotic patients, chronic opioid use (hydromorphone N=7, 
fentanyl N=1, methadone N=1, morphine sulphate N=1, oxycodone N=23, Percocet, 
N=3, tramadol N=23, and combinations of the drugs N=3) was associated to 
significant changes in microbiome composition, with lower relative abundance of 
Bacteroidaceae and Ruminococcaceae (Acharya et al., 2017). This analysis was 
carried out at drug class level, and it was not possible to discriminate between the 
effects induced by each single compound.  
 
1.15 Drugs of Abuse, Alcohol, Nicotine and the Gut 
Microbiota 
Considering that accumulating evidence supports the role of the gut microbiota in 
central nervous system (CNS) function, the interaction between the gut microbiome 
and drugs of abuse, as well as alcohol and nicotine, represents an expanding field.  
 
Evidence from in vitro studies 
Ketamine was antimicrobial in vitro in a dose-dependent manner against some micro-
organisms in propofol, which is a strong growth-promoting factor (Begec et al., 2013). 
The ketamine MIC (minimal inhibitory concentration) was 19.5 µg/mL for S. aureus 
and 312.5 µg/mL for E. coli and P. aeruginosa. As ketamine has antidepressant 
potential, some of its microbial effects have already been described in Section 5.3.  
Cannabis is obtained from the annual plant Cannabis sativa and its varieties Cannabis 
indica and Cannabis americana. Psychological reactions to cannabis vary widely, 
depending on the predisposition of the individual and can include euphoria, memory 
impairments and time-spatial sense impairments. In vitro assays have shown that 
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cannabis exerts a strong antimicrobial activity against a wide range of micro-
organisms (Appendino et al., 2008; M M Ali et al., 2018; Nissen et al., 2010).  
Nicotine, one of the main components of tobacco, possesses all the characteristics of 
a drug of dependence. It modulates dopamine activity in the midbrain, particularly in 
the mesolimbic system, which promotes the development and maintenance of reward 
behaviour (Rice and Cragg, 2004). Two studies in vitro have evaluated the 
antimicrobial activity of nicotine. The psychotropic compound was active against 
E.coli, P. aeruginosa and S. faecalis at a dose of 2 µg/µl (Idrees Zaidi et al., 2012) and 
against Listeria monocytogenes and Viridans streptococci at a dose of 10 µg/mL 
(Pavia et al., 2000).  
 
Evidence from in vivo studies (rodents) 
The gut microbiota of rats undergoing methamphetamine-induced conditioned place 
preference is different from that of control animals. Moreover, the fecal microbial 
diversity is slightly higher in metamphetamine-treated rats. The propionate-producing 
genus Phascolarctobacterium is attenuated in metamphetamine-treated rats and the 
family Ruminococcaceae is increased in the same group (Ning et al., 2017). In 
addition, the SFCA propionate was decreased in the faecal matter of rats that received 
methamphetamine (Ning et al., 2017). The microbiome might play a role also in 
cocaine addiction: administration of antibiotics in mice induced an enhanced 
sensitivity to cocaine reward and an enhanced sensitivity to the locomotor-sensitizing 
effects of repeated cocaine administration (Kiraly et al., 2016). Regarding cannabis, 
recent evidence has shown that modifications in the gut microbiota consequential to 
diet-induced obesity are prevented in mice treated chronically with Δ9 
tetrahydrocannabinol (THC), the major psychoactive constituent of cannabis (Cluny 
et al., 2015). 
Alcohol generally exerts on cells in the CNS a depressant effect that is probably 
mediated by particular membrane ion channels and receptors (Whitlock and Price, 
1974). Alcohol enhances inhibitory GABAA-stimulated flux of chloride through 
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receptor-gated membrane ion channels, a receptor subtype effect that might be 
involved in the motor impairment caused by alcohol (Abrahao et al., 2017). Exposure 
to 4 weeks of chronic intermittent vaporised ethanol in mice markedly altered the gut 
microbiota, increasing the levels of Alistipes and decreasing Clostridium IV, Dorea 
and Coprococcus (Peterson et al., 2017). In a mouse model of alcoholic liver disease, 
Bacteroidetes and Verrucomicrobia were increased in mice fed alcohol compared with 
a relative predominance of Firmicutes in control mice (Yan et al., 2011). Several other 
studies in rodents have highlighted a correlation between chronic alcohol 
consumption, leading to liver disease, and microbiome composition (Fouts et al., 2012; 
Guarner et al., 1997; Yan and Schnabl, 2012). Interestingly, corroborating the idea that 
the gut microbiome might play a role in alcohol consumption, two dietary means have 
been used as modulators of the gut microbiome during alcohol consumption. Saturated 
and unsaturated dietary fats (Kirpich et al., 2016), for example, as well as rhubarb 
extract (Neyrinck et al., 2017), have been shown to modulate the changes in gut 
microbiota induced by alcohol intake. 
Finally, the psychotropic nicotine administered in drinking water influenced the gut 
microbiota composition in a sex-specific manner in mice. In treated females, 
Christensenellaceae, Anaeroplasmataceae and unassigned families in the orders 
Bacillales were significantly reduced. Families such as Turicibacteraceae and 
Peptococcaceae were largely increased in male counterparts (Chi et al., 2017).  
 
Evidence from studies in humans 
In a human cohort, cocaine users displayed a higher relative abundance of 
Bacteroidetes than non-users (Volpe et al., 2014). The composition and diversity of 
intestinal microbiota in a cohort of 50 patients with substance use disorders (SUD; of 
which 52% on heroin and 30% on methamphetamine) was significantly different 
from those of healthy controls. The relative abundance of Thauera, Paracoccus, and 
Prevotella was significantly higher in SUD patients compared to healthy participants 
(Xu et al., 2017). The intestinal microbiota of SUD people would change 
independently of the type of substance abused, suggesting that the global switch of 
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lifestyle due to SUD in general could be responsible for the changes in microbiome. 
Importantly, almost all patients with SUDs are involved in alcohol and tobacco 
addiction, which may also account for the microbiome effects (Xu et al., 2017). The 
microbiome of chronic marijuana users displayed a Prevotella:Bacteroides ratio that 
was 13-fold lower than the one of non-users (Panee et al., 2018). A combination of 
THC and cannabidiol (CBD) has been shown to mitigate experimental autoimmune 
encephalomyelitis (EAE) by altering the gut microbiome (Al-Ghezi et al., 2017).  
Regarding alcohol, the mucosa-associated colonic microbiome was altered in 
alcoholics compared to control participants. Specifically, the alcoholics with dysbiosis 
had lower median abundances of Bacteroidetes and higher ones of Proteobacteria. 
Moreover, these alterations were correlated with high levels of serum endotoxin in a 
subset of the samples (Mutlu et al., 2012). Two similar studies have demonstrated that 
alcohol-dependent subjects have an increased intestinal permeability which is linked 
to significant microbiome alterations (de Timary et al., 2015; Keshavarzian et al., 
2009; Leclercq et al., 2014). Bacterial overgrowth was found in the jejunum of patients 
with chronic alcohol abuse (Bode et al., 1984). In cirrhotic patients, the proportion of 
phylum Bacteroidetes was significantly reduced, whereas Proteobacteria and 
Fusobacteria were highly enriched compared to healthy controls. Moreover, 
Enterobacteriaceae, Veillonellaceae and Streptococcaceae were prevalent in patients 
with cirrhosis at the family level (Chen et al., 2011).  
Nicotine consumption and also smoking cessation induced profound changes in the 
gut microbiome in humans, with an increase of Firmicutes and Actinobacteria and 
decrease of Bacteroidetes and Proteobacteria at the phylum level. In addition, smoking 
cessation induced an increase in microbial diversity (Biedermann et al., 2013). The 
effect of tobacco smoke on the oral and gut microbiome has been recently investigated 
in a human cohort, where tobacco smokers displayed a higher relative abundance of 
Prevotella, lowered Bacteroides and lower Shannon diversity in tobacco smokers 
compared to controls (Stewart et al., 2018). 
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1.16 Xanthines and the Gut Microbiota 
The three xanthines caffeine, theophylline and theobromine occur naturally in plants. 
These compounds have complex and incompletely elucidated actions, which include 
inhibition of phosphodiesterase (the enzyme that breaks down cyclic AMP), effects on 
intracellular calcium distribution and noradrenergic function (Bennett and Brown, 
2008). All xanthines stimulate mental activity to different extents and their effects vary 
according to the mental state and personality of the subject (Bennett and Brown, 2008).  
 
Evidence from in vitro studies 
Xanthines were screened against several microbial strain and all compounds displayed 
antimicrobial activity, with caffeine being the most effective compound (Raj and 
Dhala, 1965). The morphology of Aerobacter aerogenes and A. cloacae was affected 
by caffeine (Raj and Dhala, 1965). Coffee also inhibited the growth of E.coli and E. 
faecalis in vitro (Tatsuya and Kazunori, 2013). However, this is not the first study 
showing that caffeine has antimicrobial activity in vitro, as a previous experiment had 
already demonstrated this concept (Daglia et al., 2007). 
 
Evidence from in vivo studies (rodents) 
A two-weeks administration of cocoa’s theobromine to healthy adult rats was shown 
to induce marked changes in gut microbiota composition. Specifically, rats that 
received a 10% cocoa-containing diet had lower intestinal counts of E.coli, whereas 
rat that received a 0.25% theobromine-containing diet had lower counts of 
Bifidobacterium spp., Streptococcus spp. and Clostridium histolyticum-C. perfingens 
group compared to normal-fed rats (Martín-Peláez et al., 2017). Consumption of 
fermented green tea, containing theophylline, was able to restore the changes in gut 
microbiota composition associated to diet-induced obesity in mice (Seo et al., 2015). 
In a different study, consumption of 500 μL/day of coffee for three consecutive days 
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in specific-pathogen-free mice induced E.coli and Clostridium spp. counts to decrease 
significantly (Tatsuya and Kazunori, 2013). Caffeine-rich Pu-erh tea remodelled the 
intestinal dysbiosis in mice with metabolic syndrome (Gao et al., 2018). Specifically, 
Akkermansia muciniphila and Faecalibacterium prausnitzii were speculated to be the 
key gut bacterial links between the Pu-erh Tea treatment and metabolic syndrome at 
the genus and species levels (Gao et al., 2018). Chronic coffee consumption in diet-
induced obese rats was accompanied by decreased abundance of Clostridium Cluster 
XI and increased levels of Enterobacteriaceae. Moreover, SCFAs (short-chain fatty 
acids) were largely increased in the coffee-fed rats (Cowan et al., 2014). It is important 
to note that studies on the effects of caffeine on gut microbiota are not always 
consistent, for example in a different experiment on rats, 8 weeks of coffee 
consumption did not alter the gut microbiota composition (Cowan et al., 2013). A 3-
weeks regimen with oral administration of 0.7 mg/kg/day in mice decreased 
Lactobacillus ratios compared to controls, but none of the other taxa were affected 
(Kleber Silveira et al., 2018). 
 
Evidence from studies in humans  
Caffeine consumption has received much attention in recent years in relation to 
microbiome alterations often associated to metabolic disorders. Consumption of 3 
cups of coffee daily for 3 weeks in healthy volunteers did not alter faecal profiles of 
the dominant microbiota, but increased the population of Bifidobacterium spp. (Jaquet 
et al., 2009). Moreover, in some subjects, there was a specific increase in the metabolic 
activity of Bifidobacterium spp. (Jaquet et al., 2009)
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1.17 The Gut Microbiota in Psychiatric Disorders  
The drugs investigated throughout this thesis are commonly used in the treatment of 
different psychiatric disorders such as depression and schizophrenia and it is important 
to highlight that the gut microbiome has been characterised in such psychiatric 
populations. In this section, I will give a glimpse into the current evidence relating the 
gut microbiota to psychiatric disorders (Table 1.2). 
 
1.17.1 The microbiome in schizophrenia 
Schizophrenia is characterised by high rates of co-morbid gastrointestinal problems 
(Severance et al., 2015). A recent preliminary study of patients with first-episode 
psychosis identified differences in the microbiota composition, including reduced 
prevalence of Lactobacillus and Bifidobacteria species compared to healthy age-
matched controls (Schwarz et al., 2018). Interestingly, the differences in microbiota 
were correlated with severity of negative symptoms and risk for remission at 12-
months follow-up but did not correlate with duration of antipsychotic drug treatment. 
A different study has reported a link between the oropharyngeal microbiome 
composition and schizophrenia, without indicating the direction of the change (Castro-
Nallar et al., 2015). It was recently shown that, compared to healthy controls, 
schizophrenic patients have significantly lower levels of faecal Bifidobacterium, 
Escherichia coli and Lactobacillus and higher levels of Clostridium coccoides. After 
24-weeks of treatment with risperidone, a significant increase in the numbers of faecal 
Bifidobacterium and E. coli was observed (Yuan et al., 2018). The authors concluded 
that drug naïve, first episode patients with schizophrenia showed abnormalities in 
microbiota composition and that risperidone treatment caused significant changes in 
faecal bacteria. In a different study, schizophrenic patients showed higher levels of 
Proteobacteria, Succinivibrio, Megasphaera, Collinsella, Clostridium, Klebsiella and 
Methanbrevibacter and lower levels of Blautia, Coprococcus, Roseburia compared to 
healthy controls (Shen et al., 2018). In addition, 12 significant microbiota biomarkers 
  53  
 
were used as diagnostic factors for distinguishing the schizophrenic cohort from the 
healthy cohort (Shen et al., 2018). Yolken and colleagues employed metagenomic 
analysis to characterize bacteriophage genomes in the oral pharynx of 41 individuals 
with schizophrenia and 33 control individuals without a psychiatric disorder. Upon 
analysis, one bacteriophage genome, Lactobacillus phage phiadh, was found to be 
significantly increased in individuals with schizophrenia, including when  controlled 
for age, gender, race, socioeconomic status and smoking (Yolken et al., 2015). 
Intriguingly, within the group of individuals with schizophrenia, the level of 
Lactobacillus phage phiadh correlated with the prevalence of immunological disorders 
as well as with the administration of valproate (Yolken et al., 2015). Several studies 
have pointed to an association between schizophrenia and the immune response (Kelly 
et al., 2017b; Lin et al., 1998; Maes et al., 2000) and this provides additional 
foundation for investigating the microbiome in schizophrenia, given the key role the 
microbiome plays in maintaining immune function (Belkaid and Hand, 2014; Hooper 
et al., 2012). The probiotics Lactobacillus rhamnosus GG and Bifidobacterium 
animalis subsp. lactis regulated immune and intestinal epithelial cells which improved 
control of gastrointestinal leakage in patients with schizophrenia (Tomasik et al., 
2015). In a different trial, the two strains Lactobacillus rhamnosus GG and 
Bifidobacterium animalis subs. lactis failed to show any effects in attenuating the 
symptomatology of schizophrenia (Dickerson et al., 2014). The chosen probiotics, 
however, reduced the risk for severe bowel problems in a small group of outpatients 
with moderate to severe schizophrenia symptoms. Severance and colleagues 
conducted a randomized, placebo-controlled, longitudinal pilot study and explored the 
use of probiotics in the treatment of both yeast gut infection and psychiatric symptoms 
in schizophrenic patients (Severance et al., 2017). Probiotics decreased Candida 
albicans antibody levels and gastrointestinal symptoms in male subjects. Trends 
towards improvement in positive psychiatric symptoms in males treated with 
probiotics who were seronegative for C. albicans were also observed (Severance et al., 
2017). 
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1.17.2 The microbiome in depression 
A growing body of work is currently focused on the microbiome-gut-brain axis in 
depression (Dash et al., 2015; Foster and McVey Neufeld, 2013). Germ-free mice 
display reduced depressive-like behaviour compared to control mice (Zheng et al., 
2016) and both probiotic and prebiotic treatments have been shown to reduce 
depressive-like behaviour in rodent models (Bravo et al., 2011; Burokas et al., 2017; 
Desbonnet et al., 2010). Randomized trials have shown the efficacy of probiotics on 
mood (Messaoudi et al., 2011; Steenbergen et al., 2015) as well as the ability to reduce 
responses to stress (Kato-Kataoka et al., 2016). However, other studies have produced 
controversial results and more trials are needed to demonstrate efficacy and to identify 
the specific strains that are most beneficial (Bruce-Keller et al., 2018; Doron and 
Snydman, 2015). Similarly, large, controlled and well-powered studies about the 
efficacy of prebiotics are warranted (Bruce-Keller et al., 2018). Some difficulties still 
persist in translating beneficial effects of probiotics in humans (Kelly et al., 2017a). 
An altered microbial composition has been reported in patients with depression (Jiang 
et al., 2015b; Kelly et al., 2016; Naseribafrouei et al., 2014; Zheng et al., 2016), with 
two studies showing a reduction in the relative abundance of Faecalibacterium. 
Another study reported lower levels of Bifidobacterium and Lactobacillus in 
depressed patients (Aizawa et al., 2016). Finally, faecal transplantation of microbiota 
from depressed patients into rodents (microbiota-depleted rats and germ free mice, 
respectively) was able to transfer anxiety-like and depressive-like behaviours to the 
recipients (Kelly et al., 2016; Zheng et al., 2016). Interestingly, the rats receiving the 
FMT, which were treated for 12 weeks (with twice weekly ‘top-up’ doses), also 
showed an increase in plasma kynurenine and kynurenine/tryptophan ratio, a change 
reported in the depressed donor group (although total tryptophan was not significantly 
altered) as well as an increase in acetate and total short-chain fatty acids, as measured 
in their faeces (Kelly et al., 2016). In a recent population-based study, a large 
microbiome population cohort (Flemish Gut Flora Project, n=1,054) was surveyed 
with validation in independent data sets to study how microbiome features correlated 
with host quality of life and depression. Butyrate-producing Faecalibacterium and 
Coprococcus were consistently associated with higher quality of life indicators. 
Together with Dialister, Coprococcus spp. were depleted in depression, even after 
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correcting for the confounding effects of antidepressants (Valles-Colomer et al., 
2019). Gut-brain module analysis of faecal metagenomes identified the microbial 
synthesis potential of the dopamine metabolite 3,4-dihydroxyphenylacetic acid as 
correlating positively with mental quality of life and indicated a potential role of 
microbial γ-aminobutyric acid production in depression (Valles-Colomer et al., 2019).  
 
1.17.3 The microbiome in bipolar disorder 
Few studies to date have investigated the link between the microbiome and bipolar 
disorder. Yolken and colleagues have demonstrated that patients with bipolar mania 
were approximately twice as likely as other patients to have recently received 
antibiotics (Yolken et al., 2016). A recent population-based study showed that the 
microbiome of bipolar patients was different than healthy controls, at least for patients 
with more severe symptoms (Evans et al., 2017). Specifically, significant differences 
in two genera of Firmicutes, Faecalibacterium and an unclassified member of 
Ruminococcaceae, were observed (Evans et al., 2017). Among these patients, 
increased Faecalibacterium was associated with improved physical health, reduced 
depressive symptoms, and better sleep quality. Notably, Ruminococcaceae and 
Faecalibacterium have also been observed to be decreased in patients with depression, 
and levels of Faecalibacterium were negatively associated with depressive symptoms 
(Jiang et al., 2015b). Atypical antipsychotic treatment was associated with reduced gut 
biodiversity, particularly in female patients (Flowers et al., 2017). Patients on atypical 
antipsychotic treatment showed specific taxonomic shifts, with relatively increased 
levels of Lachnospiraceae, while non-treated individuals had higher levels of 
Akkermansia. Interestingly, probiotic supplementation reduced the rates of 
rehospitalization in patients recently discharged following hospitalization for mania 
(Dickerson et al., 2018). 
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Table 1.2 Human studies reporting microbiome alterations in stress-related psychiatric disorders. Note that obsessive compulsive disorder (OCD), 
attention-deficit/hyperactivity disorder (ADHD) and panic disorders are not included in the table due to lack of evidence. 
 
Condition Microbiome features References 
Anxiety disorder Chao 1 richness ↓, Bacteroidetes ↓, Ruminococcus gnavus ↓, Fusobacterium ↓  (Jiang et al., 2018) 
Autism Increased: Lactobacillus ↑, Desulfovibrio ↑, Clostridium ↑, Bacteroides/Firmicutes ratio 
↓ 
(Tomova et al., 2015) 
 Sutterella spp. ↑, Ruminococcus torques ↑ (Wang et al., 2013) 
 Clostridium ↑, Bacteroides ↑, Porphyromonas ↑, Prevotella ↑, Pseudomonas ↑, 
Aeromonas ↑, Enterobacteriaceae ↑, Enterococcus ↓, Lactobacillus ↓, Streptococcus ↓, 
Lactococcus ↓, Staphylococcus ↓, Bifidobacteria ↓ 
(De Angelis et al., 
2013) 
 Lactobacillus ↑, Prevotella ↓, Coprococcus ↓, Veillonellaceae ↓ (Kang et al., 2013) 
 Sutterella ↑, Lachnospiraceae ↑, Ruminococcaceae ↑ (Williams et al., 2011) 
 Lactobacillus ↑, Bifidobacterium ↓, Enterococcus ↓ (Adams et al., 2011) 
 Bacteroidetes ↑, Proteobacterium ↑, Actinobacterium ↓, Bifidobacterium ↓ (Finegold et al., 2010) 
 Clostridium clusters I and II ↑ (Parracho et al., 2005) 
 Collinsella ↑, Corynebacterium ↑, Dorea ↑, Lactobacillus ↑, Alistipes ↓, Bilophila ↓, 
Dialister ↓, Parabacteroides ↓, Veillonella ↓ 
(Strati et al., 2017) 
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Bipolar disorder Faecalibacterium ↓ (Evans et al., 2017) 
Depression Bifidobacterium ↓, Lactobacillus ↓ (Aizawa et al., 2016) 
 Bacteroidetes ↑, Proteobacteria ↑, Actinobacteria ↑, Firmicutes ↓ (Jiang et al., 2015b) 
 Chao 1 richness ↓, Eggerthella ↑, Holdemania ↑, Gelria ↑, Turicibacter ↑, 
Paraprevotella ↑, Anaerofilum ↑, Prevotella ↓, Dialister ↓ 
(Kelly et al., 2016) 
 Actinomycineae ↑, Coriobacterineae ↑, Lactobacillaceae ↑, Streptococcaceae ↑, 
Clostridiales incertae sedis XI ↑, Eubacteriaceae ↑, Lachnospiraceae ↑, 
Ruminococcaceae ↑, Erysipelotrichaceae incertae sedis ↑ 
(Zheng et al., 2016) 
Post-traumatic 
stress disorder 
Microbial community structure ↔, α- and β-diversity ↔, signature of vulnerability to 
developing PTSD 
(Hemmings et al., 
2017) 
Schizophrenia Firmicutes ↑, Ascomycota ↑, Bifidobacterium ↑ Lactobacilli ↑, Neisseria ↓, Haemophilus 
↓, Capnocytophaga ↓  
(Castro-Nallar et al., 
2015) 
 Lactobacillus phage phiadh ↑ (Yolken et al., 2015) 
 Lactobacillus ↑, Tropheryma ↑, Halothiobacillus ↑, Saccharophagus ↑, Ochrobactrum ↑, 
Deferribacter ↑, Halorubrum ↑ Anabaena ↓, Nitrosospira ↓, Gallionella ↓ (first episode 
psychosis) 
(Schwarz et al., 2018) 
Abbreviations: ↓ indicates a decrease, ↑ indicates an increase, ↔ indicates no changes compared to human healthy controls.  
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1.18 Aims and Objectives 
There is growing recognition of the role played by the gut-brain axis in psychiatric 
disorders. Despite efforts to characterise how psychotropic medications work at a 
central level, the influence of these drugs on the gut microbiota and other distal body 
sites are currently under-investigated. In this thesis we examine the complex 
relationship between psychotropic medications, the gut microbiome, liver function and 
intestinal physiology. The investigation of the complex drug-gut interaction carried 
out in this thesis, has a strong translational potential and could lead to new avenues for 
clinical practice and personalised medicine. Successful translation of the work here 
presented, for example, could lead to using the microbiome as a stratification tool and 
distinguish drug responders from non-responders. 
 
Aim 1: Do psychotropic medications affect the microbiome 
composition and intestinal permeability? 
In recent years it has become evident that many types of drugs can influence the gut 
microbiota composition (Maier et al., 2018). Moreover, several psychotropic drugs 
such as antidepressants have shown antimicrobial activity in vitro (see Introduction 
section 1.9 Psychotropic Drugs and the Gut Microbiota). With a focus on 
psychotropic drugs, we wanted to investigate whether these medications could 
influence microbiome composition both in vitro and in vivo. The in vivo model 
consisted of a chronic administration (4 weeks) of psychotropic drugs to healthy adult 
Sprague-Dawley rats. Moreover, we investigated the influence of these medications 
on intestinal permeability ex vivo (Chapter 2, Figure 1.10). 
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Aim 2: Do psychotropic medications affect the composition and 
biotransformation of bile acids? 
While analysing the microbiome data of the previous study we noticed that the two 
psychotropics and mood stabilisers lithium and valproate significantly altered bile 
acids levels in rats. Thus, we investigated whether the microbiome might have been 
implicated in the changes observed. We therefore examined pathways involved in the 
biosynthesis and metabolism of bile acids and hypothesised some mechanistic insights 
(Chapter 3, Figure 1.10).  
 
Aim 3: Do modifications of the gut microbiota influence the 
pharmacokinetics of psychotropic medications? 
“Pharmacomicrobiomics” is an expanding field that studies how certain intestinal 
bacteria can metabolise xenobiotics (Rizkallah et al., 2010). After showing that 
psychotropic drugs influence the gut microbiota (see Chapter 2), we wanted to look at 
the reverse scenario: would perturbations of the microbiome influence the absorption 
of the two antipsychotics olanzapine and risperidone? As modulators of microbiome 
composition, we used two common approaches: antibiotic and probiotic 
administration. This investigation was carried out in healthy adult rats (Chapter 4, 
Figure 1.10).   
 
Aim 4: Do psychotropic medications affect the composition of the 
human gut microbiota? 
Following observations in rats and intrigued by the results from Chapter 2, we 
examined the microbiome-targeted effects of psychotropic medications in a human 
cohort, the Dutch LifeLines-DEEP population (Chapter 5, Figure 1.10).  
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Figure 1.10 Diagram representing the aims of the thesis. Aim 1 (Chapter 2) investigates the 
effect of psychotropic medications on the microbiome and intestinal barrier function. Aim 2 
(Chapter 3) investigates the effects of the mood stabilisers lithium and valproate on bile acid 
metabolism and bile-associated microbial taxa. Aim 3 (Chapter 4) focuses on how 
perturbations of the gut microbiota could impact the absorption of two widely prescribed 
antipsychotics: olanzapine and risperidone. Aim 4 (Chapter 5) examines the microbiome 
composition following psychotropic intake in a human population. Aims 2 and 3 are also 
linked to the investigation of gut microbiota composition.  
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Chapter 2  
 
Differential Effects of Psychotropic Drugs on 
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Abstract 
Rationale Growing evidence supports a role for the microbiota in regulating gut-brain 
interactions and thus psychiatric disorders. Despite substantial scientific efforts to 
delineate the mechanism of action of psychotropic medications at a central nervous 
system (CNS) level, there remains a critical lack of understanding of how these drugs 
might affect the microbiota and gut physiology.  
 
Objectives We investigated the antimicrobial activity of psychotropics against two 
bacterial strains resident in the human gut, Lactobacillus rhamnosus and Escherichia 
coli. In addition, we examined the impact of chronic treatment with these drugs on 
microbiota and intestinal parameters in the rat.  
 
Results In vitro, fluoxetine and escitalopram showed differential antimicrobial effects. 
Lithium, valproate and aripiprazole administration significantly increased microbial 
species richness and diversity, while the other treatments were not significantly 
different from controls. At the genus level, several species belonging to Clostridium, 
Peptoclostridium, Intestinibacter and Christenellaceae were increased following 
treatment with lithium, valproate and aripiprazole when compared to the control 
group. Animals treated with escitalopram, venlafaxine, fluoxetine and aripiprazole 
exhibited an increased permeability in the ileum. 
 
Conclusions These data show that psychotropic medications differentially influence 
the composition of gut microbiota in vivo and that fluoxetine and escitalopram have 
specific antimicrobial activity in vitro. Interestingly, drugs that significantly altered 
gut microbial composition did not increase intestinal permeability, suggesting that the 
two factors are not causally linked. Overall, unravelling the impact of psychotropics 
on gastrointestinal and microbiota measures offers the potential to provide critical 
insight into the mechanism of action and side effects of these medications.   
 
Keywords: psychotropics, intestinal permeability, gut microbiota, diversity, richness, 
short-chain fatty acids, antimicrobial 
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Introduction 
The burden of psychiatric disorders on society continues to grow, with estimates from 
the World Health Organization (WHO) suggesting that worldwide 322 million and 60 
million people are affected by depression and bipolar disorder respectively (World 
Health Organization, 2017). Treatment options used in the management of psychiatric 
disorders are often associated with metabolic side effects (Beyazyüz et al., 2013; 
Correll et al., 2015; Olguner Eker et al., 2017; Reynolds and Kirk, 2010; Tschoner et 
al., 2007) and high non-response rates (Ackenheil and Weber, 2004; Al-Harbi, 2012; 
Hatta and Ito, 2014; Nelson, 1998). Over the last decade, a growing body of evidence 
has highlighted a significant role for the gut microbiota in interactions between the gut 
and the brain (Bercik et al., 2012; Collins et al., 2012; Cryan and Dinan, 2012; Dinan 
et al., 2013; Mayer et al., 2014; Mayer et al., 2015). Moreover, alterations in this 
microbiota-gut-brain axis are associated with several behavioural and psychiatric 
conditions (Cryan and Dinan, 2012; Foster and McVey Neufeld, 2013; Luna and 
Foster, 2015). Strikingly, individuals with depression (Jiang et al., 2015b; Kelly et al., 
2016; Naseribafrouei et al., 2014; Zheng et al., 2016), bipolar disorder (Evans et al., 
2017) and schizophrenia (Dinan et al., 2014; Schwarz et al., 2018) alterations in 
microbiota composition compared to controls. Moreover, recent data has shown that 
the transfer of microbiota from humans with depression into microbiota-depleted rats 
or mice induces a depressive-like phenotype, indicating that the gut microbiota may 
play a key role in the onset of depressive behaviour (Kelly et al., 2016; Zheng et al., 
2016). 
Despite substantial scientific efforts to unravel the effects of psychotropic medications 
on the central nervous system, the impact that these drugs have on gut physiology and 
microbiota composition is rarely considered. Some isolated studies have shown that 
antidepressants and antipsychotics possess a microbiota-targeted action. Indeed 
sertraline, fluoxetine and paroxetine are bactericidal against gram-positive bacteria 
such as Staphylococcus and Enterococcus (Ayaz et al., 2015; Coban et al., 2009), 
however, these data are mostly reliant on in vitro microbiological studies and are not 
exhaustive. Regarding antipsychotics, it has been shown that chronic administration 
of the antipsychotics olanzapine and risperidone affects the gut microbiota 
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composition in animals and humans (Bahr et al., 2015b; Davey et al., 2012; Kao et al., 
2018; Morgan et al., 2014). A recent study has demonstrated that intake of atypical 
antipsychotics is associated with significant changes in microbiota composition 
(Flowers et al., 2017), while larger cohort studies have suggested that the use of 
medications can alter the gut microbiota more generally (Falony et al., 2016; Maier et 
al., 2018). Behavioural responses to cocaine, another compound belonging to the class 
of psychotropics, have recently been shown to be affected by gut microbiota shifts in 
mice (Kiraly et al., 2016).  
Importantly, psychotropic medications are often administered orally, thus the gut 
microbiota represents a plausible target for distal action of these drugs. To this end, 
we sought to examine the effects that commonly used psychotropics have on 
microbiota composition and intestinal permeability, which is closely regulated by the 
gut microbiota (Karl et al., 2017; Ott et al., 2017; Ulluwishewa et al., 2011). 
Furthermore, we assess the antimicrobial activity of these medications against isolated 
strains resident in the human gut, L. rhamnosus and E.coli. Unravelling the 
comparative microbiome and gastrointestinal actions of different psychotropics in vivo 
will provide new insight into the mechanism of these drugs and their side effects and 
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Methods 
Bacterial growth-inhibition assay  
Lactobacillus rhamnosus 6118 was grown in anaerobiosis at 37ºC overnight in MRS 
broth (BD Difco Lactobacilli MRS Broth). Escherichia coli APC105 was grown 
shaking overnight at 37ºC in BHI broth (Oxoid™ Brain Heart Infusion Broth). 
Overnight cultures were resuspended in broth to an OD reading (optical density at 
600nm wavelength) of 0.1, which corresponded to their lag phase. Resuspended 
cultures were incubated with a range of drugs dissolved in sterile deionised water at 
different concentrations (100, 400 and 600 μg/mL). The OD of the bacteria was 
measured every hour for up to seven hours. The vehicle consisted of the dissolution 
medium only and each curve was produced in triplicates. 
 
Animals 
Adult male Sprague Dawley rats (n=8/group; 200-250g on arrival) were obtained from 
Envigo UK. They were housed 2 per cage and maintained under a 12-h light/dark 
cycle, provided with chow and water ad libitum. Rats in the same cage underwent the 
same treatment to avoid confounding factors such as coprophagy. Animals were 
acclimated to housing conditions for one week prior to experimental treatment. 
Experiments were conducted in accordance with European Directive 2010/63/EU. 
Approval by the Animal Experimentation Ethics Committee of University College 
Cork was obtained before commencement of all animal-related experiments.  
 
Drug administration 
Each drug was administered for 28 days in drinking water or in the chow and 
administration continued throughout the behavioural assessment until the animals 
were culled (Figure 2.1, Table 2.1). 
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Figure 2.1. Experimental 
timeline. Abbreviations: 
OF open field, SCFAs 






Table 2.1 List of psychotropics employed in this study and their mechanism(s) of action. 
Abbreviations: ↑ increase, SSRI selective serotonin reuptake inhibitor, SNRI serotonin and 
norepinephrine reuptake inhibitor, 5-HT serotonin, NE norepinephrine/noradrenaline, NO 
nitric oxide, GABA ɣ-aminobutyric acid, D dopamine 
 
 
Drug Class  Main medical uses Mechanism(s) of action 
Antidepressants: 
Escitalopram SSRI  Major depressive 
disorder, generalised 
anxiety disorder 
↑ synaptic levels of 5-HT by blocking the 
reuptake of the neurotransmitter into the 
presynaptic neuron 
Venlafaxine SNRI  Major depressive 
disorder, generalised 
anxiety disorder 
↑ synaptic levels of 5-HT and NE by blocking 
the reuptake of the neurotransmitters into the 
presynaptic neuron 
Fluoxetine SSRI  Major depressive 
disorder, generalised 
anxiety disorder 
↑ synaptic levels of 5-HT by blocking the 
reuptake of the neurotransmitter into the 
presynaptic neuron 
Other Psychotropics: 






↑ release of 5-HT in the brain, interacts with 
NO signalling pathway in the brain, modulates 
glutamate levels, regulates mitochondrial 
function, lowers levels of inositol triphosphate 
Valproate  Anticonvulsant  Epilepsy, bipolar 
disorder, schizophrenia 
Blocks voltage-gated sodium channels and ↑ 









It is silent antagonist of some subpopulations 
of D2 receptors but also a high-efficacy partial 
agonist of other D2-receptor subpopulations. It 
has predominantly antagonist activity on 
postsynaptic D2 receptors and partial agonist 
activity on presynaptic D2 receptors. It is also 
a partial agonist of the D3 receptor and the 5-
HT1A receptor 
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The control group received a standard diet (Ssniff, SM Teklad Global 18% Protein 
Rodent diet, item no. S9912-S710) and drinking water. A second group received 6.38 
mg/kg/day of escitalopram oxalate (5 mg/kg/day of free base) in drinking water and 
standard diet. A third group received 20mg/kg/day of venlafaxine HCl in drinking 
water and standard diet. A fourth group received 10mg/kg/day of fluoxetine HCl in 
drinking water and standard diet. A fifth group received 0.2% lithium-supplemented 
diet, corresponding to approx. 150mg/kg/day, and hypertonic saline water (1.5% 
NaCl, in order to prevent lithium-induced ionic imbalance). A sixth group received 
2% valproate-supplemented diet, corresponding to approx. 1.5g/kg/day, and drinking 
water. A seventh group received 0.027% aripiprazole-supplemented diet, 
corresponding to approx. 20mg/kg/day, and drinking water. The concentration of each 
drug in drinking water and in the chow was determined from the average daily 
water/food consumption and the average body weight per rat. These dosing regimens 
have been previously used in chronic behavioural and neurochemical studies in rats 
(Ariel et al., 2017; Kaminska and Rogoz, 2016; Lyons et al., 2012; Monti et al., 2010; 
O’Leary et al., 2012; Segnitz et al., 2009; Sogaard et al., 2005; Vidal et al., 2010; 
Watase et al., 2007). The drinking bottles were protected from light and changed every 
second day and the chow was stored at 4 ºC during the experiment. 
 
Open Field (OF) Test 
To assess possible sedative effects of treatments, the animals were placed in an open 
arena brightly lit from above and the test was carried out as previously described 
(O’Mahony et al., 2014). Briefly, 30 minutes before behavioural testing, animals were 
habituated to the room. The apparatus consisted of a white round arena with a diameter 
of 90 cm, brightly lit to 1000 lux. At the beginning of the test, animals were placed 
into the centre of the arena and allowed to explore for 10 min. After testing animals 
were returned to their home cage. The arena was cleaned with 70% ethanol between 
trials to ensure that no cue smell remained from the previous trail. Faecal output was 
manually scored. Total distance travelled was analysed using a tracking software 
system (Ethovision XT 11.5, Noldus). None of the treatments at the doses tested 
affected the locomotor activity or the faecal output of the animals (Figure S.2.1). 




Freshly isolated ileal and colonic tissues were placed in Krebs solution and cut along 
the mesenteric border. Tissues were then mounted into the Ussing chamber apparatus 
(Harvard Apparatus, Kent, UK, exposed area of 0.12cm2) as previously described 
(Golubeva et al., 2017). 4kDa FITC-dextran was added to the mucosal chamber at a 
final concentration of 2.5mg/mL; 200μL samples were collected from the serosal 
chamber after one hour and every 30 minutes for the following 3 hours. FITC was 
measured at 485nm excitation / 535nm emission wavelengths. 
 
Microbiota composition and Short Chain Fatty Acids analysis in the caecal 
content 
Caecum was harvested and immediately snap-frozen and stored at -80ºC prior to the 
analysis. DNA was extracted using the Qiagen QIAmp Fast DNA Stool Mini Kit 
coupled with an initial bead-beating step. The V3-V4 hypervariable region of the 16S 
rRNA gene was amplified and prepared for sequencing as outlined in the Illumina 16S 
Metagenomic Sequencing Library protocol. Samples were sequenced at Teagasc 
Sequencing Facility (TFRC, Moorepark) on the Illumina MiSeq platform using a 
2×250 bp kit. Reads were assembled, processed and analysed following the pipeline, 
described in Supplemental Methods. Short chain fatty acids (SCFAs) were measured 
by gas chromatography, using a Varian 3500 GC flame-ionization system fitted with 
a ZB-FFAP column. For construction of the heatmap, Log2 ratios were calculated 
from group medians of highly abundant bacteria at the genus level using R (version 
3.3.2) and R Studio (version 1.0.136). 
 
Statistical analysis  
Data are presented as mean + SEM. Intestinal permeability and in vitro data were 
analysed using mixed between-within subjects ANOVA followed by unpaired two-
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tailed t-test. Body weight and organ weights were analysed using one-way ANOVA 
followed by Dunnett’s test. 16S rRNA sequencing data was analysed using Kruskal-
Wallis non-parametric test followed by Mann-Whitney U test and corrected for 
multiple comparisons using the Benjamin-Hochberg false discovery rate (FDR) 
method. Grubbs method was employed to test for any specific outliers (Grubbs, 1950). 
Threshold for statistical significance was set at p<0.05.  
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Results  
Fluoxetine and escitalopram exert specific antimicrobial activity against two 
bacterial strains resident in the human gut 
We tested the effects of psychotropic medications on growth of Lactobacillus 
rhamnosus 6118 and E.coli APC105 in vitro. These bacterial strains belong to two of 
the four dominant phyla of the mammalian gut (Firmicutes and Proteobacteria 
respectively).  Each drug was assessed at three different concentrations (100, 400 and 
600 µg/mL). Growth curves were performed measuring the optical density (OD) at 
different time points. Growth of L. rhamnosus was completely inhibited by 400 and 
600 µg/mL fluoxetine, while growth of E.coli was inhibited by 600 µg/mL 
escitalopram and by all three doses of fluoxetine (Figure 2.2). Venlafaxine, lithium 
and valproate did not exhibit antimicrobial activity in vitro. Aripiprazole’s 
antimicrobial activity was not assessed due to its tendency to precipitate with 
components of the broth, resulting in high risk of false positive data from OD 
measurements. 
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Figure 2.2 Effect of psychotropic drugs on growth of Lactobacillus rhamnosus 6118 and 
Escherichia coli APC105 in vitro. Escitalopram and fluoxetine have differential 
antimicrobial effects. In bold are bactericidal doses. Statistics: Data are expressed as 
mean+SEM. *p<0.05, **p<0.01 and ***p<0.001 (n=3/group). Escitalopram effect on E.coli: 
F(7;56)=491.682, p<0.001 for the effect of Time, F(3;8)=82.898, p<0.001 for the effect of 
Treatment, F(21;56)=59.87, p<0.001 for the Time×Treatment interaction. Fluoxetine effect on 
L. rhamnosus: F(7;56)=42.467, p<0.001 for the effect of Time, F(3;8)=28.574, p<0.001 for 
the effect of Treatment, F(21;56)=15.439, p<0.001 for the Time×Treatment interaction. 
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Fluoxetine effect on E.coli: F(7;56)=188.805, p<0.001 for the effect of Time, F(3;8)=712.570, 
p<0.001 for the effect of Treatment, F(21;56)=176.477, p<0.001 for the Time×Treatment 
interaction. Data were analysed with a mixed between-within subjects ANOVA. F=F-statistic. 
Mean values in each time point were further compared to the vehicle with unpaired t-test. 




Administration of fluoxetine, lithium, valproate and aripiprazole significantly 
alters gut microbiota composition 
Our in vitro results demonstrated that certain psychotropic drugs differentially 
modulate the growth of resident gut bacteria. To confirm this in an in vivo setting and 
to assess if any of the treatments induced changes in intestinal microbiota composition, 
we performed 16S sequencing of bacterial rRNA of the caecum content following 
chronic administration in rats. The sequencing revealed a significant increase in the 
bacterial richness and diversity of rats treated with lithium, valproate and aripiprazole 
as compared to the vehicle-treated group (Figure 2.3A). Moreover, separation 
according to group was further illustrated through principal coordinate analysis 
(PCoA), with statistical support of the significant separation between escitalopram, 









  73  
 
 
Figure 2.3 Altered microbiota richness and diversity in psychotropic-treated animals as 
compared to vehicle-treated animals. (A) Alpha diversity. Statistics: Kruskal-Wallis test for 
Chao1 (p=0.000) and Shannon (p=0.000). Mann-Whitney U test for: Chao1 index: lithium 
U(16)=6, p=0.006; valproate U(16)=10, p=0.021; aripiprazole U(16)=12, p=0.036. Shannon index: 
lithium U(16)=0, p=0.001; valproate U(16)=2, p=0.002; aripiprazole U(16)=0, p=0.001. Data are 
expressed as median and min-to-max values. *p<0.05, **p<0.01 and ***p<0.001 (n=8/group). 
(B) Principal coordinate analysis of Bray-Curtis compiled distance matrix of all microbial 
relative abundances compared with the vehicle group (light grey ellipse). Escitalopram, 
venlafaxine, lithium, valproate and aripiprazole show significant variation from the vehicle 
(Adonis PERMANOVA p<0.05). (C) Heatmap of log2 fold change ratio of medians at the 
genus level. Red indicates an increase and blue a decrease of taxa in the different treatment 
groups as compared to vehicle-treated rats. Microbial genera that were significantly different 
in at least one of the experimental groups compared to the vehicle were selected for the 
heatmap. E=escitalopram, Ve=venlafaxine, F=fluoxetine, L=lithium, Va=valproate, 
A=aripiprazole 
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At the phylum level, lithium induced a significant increase in Actinobacteria and a 
decrease in Bacteroidetes; valproate induced an increase in Actinobacteria, Firmicutes 
and a decrease in Bacteroidetes; fluoxetine induced a decrease in Deferribacteres and 
aripiprazole induced an increase in Firmicutes (Fig. S.2.2, Table S.2.1). At the family 
level, lithium, valproate and aripiprazole increased significantly the levels of 
Peptostreptococcaceae, Clostridiaceae and Ruminococcaceae (Figure S.2.3, Table 
S.2.2). Other families were increased by the different treatments, while some of the 
less abundant families were decreased (refer to Supplemental Material for details). At 
the genus level of the most abundant taxa, lithium increased the relative abundance of 
Ruminococcaceae uncultured and decreased the relative abundance of Bacteroides 
and Ruminococcus 1; valproate decreased the relative abundance of S24-7 uncultbact 
and increased the relative abundance of Ruminococcaceae uncultured; while 
aripiprazole decreased the relative abundance of Ruminococcus 1 (Figure 2.4, Table 
S.2.3). None of the treatments significantly affected the genera Lachnospiraceae 
uncultured, Akkermansia, S24-7 uncultbact and Oscillibacter. 
Interestingly, the relative abundance of minor genera including Clostridium Sensu 
Stricto 1, Ruminiclostridium 5, Intestinibacter, Eubacterium coprostanoligens, 
Peptoclostridium, Eubacterium oxidoreducens, Christensenellaceae uncultured and 
Clostridia Family XIII, was increased by lithium, valproate and aripiprazole 
administration (Figure 2.5), while antidepressants administration did not influence 
significantly the abundance of these taxa. Among the antidepressants assessed, 
fluoxetine induced a marked depletion of the genera Prevotella 7, Prevotella 9 and 
Succinivibrio (Figure 2.6). 
 
 





Figure 2.4 Psychotropic drugs 
differentially affect bacterial 
composition at genus level of the 
most abundant taxa. Lithium 
increased the relative abundance of 
Ruminococcaceae uncultured and 
decreased the relative abundance of 
Bacteroides and Ruminococcus 1. 
Valproate decreased the relative 
abundance of S24-7 uncultbact and 
increased the relative abundance of 
Ruminococcaceae uncultured. 
Aripiprazole decreased the relative 
abundance of Ruminococcus 1. Data 
are expressed as median and min-to-
max values. *p<0.05 (n=8/group). 
Data was analysed using Kruskal-
Wallis non-parametric test followed 
by Mann-Whitney U test and 
corrected for multiple comparisons 
using the Benjamin-Hochberg false 
discovery rate (pFDR) method (refer 











Figure 2.5 Psychotropic drugs 
differentially affect bacterial 
composition at genus level of the 
less abundant taxa. Lithium, 
valproate and aripiprazole induced 
an increase in the relative abundance 






and Clostridia Family XIII. Data are 
expressed as median and min-to-
max values. *p<0.05 (n=8/group). 
Data was analysed using Kruskal-
Wallis non-parametric test followed 
by Mann-Whitney U test and 
corrected for multiple comparisons 
using the Benjamin-Hochberg false 
discovery rate (pFDR) method 
(refer to Supplemental Material for 
details on statistics 
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Figure 2.6 Fluoxetine-sensitive genera in vivo. The genera Prevotella 7, Prevotella 9 and 
Succinivibrio were all depleted in the caecum of animals treated with fluoxetine. Data are 
expressed as median and min-to-max values. *p<0.05 (n=8/group). Data was analysed using 
Kruskal-Wallis non-parametric test followed by Mann-Whitney U test and corrected for 
multiple comparisons using the Benjamin-Hochberg false discovery rate (pFDR) method 
(refer to Supplemental Material for details on statistics) 
 
 
Valproate and aripiprazole alter the levels of cecal short chain fatty acids 
(SCFAs)  
A key function of gut bacteria is the catabolism of non-digestible dietary fibres 
resulting in the production of SCFAs, which in turn modulate a number of 
physiological processes (den Besten et al., 2013; Koh et al., 2016; Morrison and 
Preston, 2016). We decided to examine the abundance of short-chain fatty acids 
(SCFAs) in the caecal content in response to psychotropic drugs. Valproate 
administration induced a significant decrease in the levels of propionate and butyrate 
while augmenting the levels of isovalerate. Aripiprazole administration induced a 
significant increase in the levels of acetate and isovalerate (Figure 2.7). Two other 
SCFAs, valerate and isobutyrate, were also quantified and were not affected by any 
psychotropic treatment (Figure S.2.4). 
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Figure 2.7 Short chain fatty acid (SCFAs) caecal levels. Statistics: all SCFAs had p<0.05 
in one-way ANOVA. Acetate: Dunnett’s t-test p=0.035 for aripiprazole VS vehicle. 
Propionate: Dunnett’s t-test p=0.029 for valproate VS vehicle. Butyrate: Dunnett’s t-test 
p=0.042 for valproate VS vehicle. Isovalerate: Dunnett’s t-test p=0.002 for valproate VS 




Escitalopram, venlafaxine, fluoxetine and aripiprazole administration increases 
ileal but not colonic permeability 
We assessed paracellular intestinal permeability of treated animals in both ileum and 
colon tissues ex vivo. Among the drugs tested, escitalopram, venlafaxine, fluoxetine 
and aripiprazole administration significantly increased epithelial permeability in the 
distal ileum as compared to vehicle-treated animals (Figure 2.8). None of the drugs at 
the doses tested affected permeability in the distal colon.   
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Figure 2.8 Effect of drug treatments on epithelial permeability in small and large 
intestine. In the different panels, each treatment is compared to the vehicle. (A) In distal 
ileum, escitalopram-, venlafaxine-, fluoxetine- and aripiprazole-treated rats showed a 
significant increase in FITC paracellular permeability. (B) In the colon, none of the drugs 
induced significant changes in intestinal permeability. Data were analysed with a mixed 
between-within subjects ANOVA. Statistics: Distal ileum F(5;235)=385.037, p<0.001 for the 
effect of Time, F(6;47)=4.181, p<0.01 for the effect of Treatment, F(30;235)=3.490, p<0.01 for the 
Time×Treatment interaction. Distal colon F(5;235)=298.307, p<0.001 for the effect of Time, but 
no effects for Treatment or Time×Treatment interaction. F=F-statistic. Mean values in each 
time point were further compared to the vehicle with unpaired t-test. Statistical outcomes for 
the t-test are described in Supplemental Material. Data are expressed as mean+SEM. *p<0.05, 
**p<0.01 and ***p<0.001 (n=7-8/group)  
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Discussion 
There is an increasing emphasis on the interactions between gut microbiota and drug 
action across different therapeutic areas including oncology, cardiovascular medicine 
and even psychiatry. Here we assessed whether orally administered psychotropics can 
affect microbial and intestinal function in healthy adult rats. Escitalopram and 
fluoxetine showed differential antimicrobial activity in vitro, whereas lithium, 
valproate and aripiprazole induced significant changes in gut microbiota composition 
and SCFAs levels in vivo. Fluoxetine also induced minor but significant changes in 
bacterial genera in vivo. Escitalopram, venlafaxine, fluoxetine and aripiprazole 
increased the intestinal permeability in the ileum but not colon. 
Limited studies have investigated the effect of psychotropic medications on growth of 
microbial strains. We found that both SSRIs escitalopram and fluoxetine have diverse 
antimicrobial activity in vitro against E.coli and L. rhamnosus, two bacteria residing 
in the human gut (Thursby and Juge, 2017; Walter, 2008). These results are in line 
with previous work showing that SSRIs possess antimicrobial action in vitro especially 
against gram-positive bacteria such as Staphylococcus and Enterococcus (Ayaz et al., 
2015; Coban et al., 2009). Moreover, the antimicrobial activity of some 
antidepressants has been previously confirmed by the synergistic effects of some 
SSRIs in combination with antibiotics; as well as their effects against some antibiotic-
resistant bacteria (Bohnert et al., 2011; Munoz-Bellido et al., 1996, 2000). 
Interestingly the two drugs, despite both belonging to the same class of 
antidepressants, showed different effects, with fluoxetine having strong antimicrobial 
activity and escitalopram being a weak antimicrobial. A possible mechanism through 
which fluoxetine and escitalopram might inhibit bacterial growth is through their 
action as efflux pump inhibitors, which interferes with the normal functioning of the 
bacteria (Bohnert et al., 2011). Intriguingly, among the drugs assessed in vitro, only 
fluoxetine induced overt shifts in gut microbiota composition in vivo. Moreover, 
differences in drug doses might occur in the two experimental settings, making it 
challenging to directly compare the experiments. These data highlight that some 
caution is required in extrapolating the results of in vitro assays to predict the effects 
of drugs on complex gut microbial ecology.  
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The composition of the gut microbiota was substantially changed in vivo in lithium-, 
valproate-, and aripiprazole- treated animals. Interestingly, the microbial shifts were 
often consistent across groups, with a significant increase in the relative abundance of 
minor genera (Figure 2.5); while highly abundant genera were generally not affected 
and were decreased in few instances (Figure 2.4; i.e. Lachnospiraceae NK4A136, 
Ruminococcus 1, Bacteroides). Consistent with changes in bacterial genera, the alpha 
diversity was also augmented in animals treated with lithium, valproate and 
aripiprazole, suggesting an increase in microbial richness and diversity. 
Administration of the SSRI fluoxetine also induced changes in microbiota 
composition, specifically decreasing the genera Prevotella 7, Prevotella 9 and 
Succinivibrio (Figure 2.6).  
Some previous studies have shown that, among psychotropic medications, 
antipsychotics in particular exert an effect on the gut microbiota. Both atypical 
antipsychotics olanzapine (Davey et al., 2013; Morgan et al., 2014) and risperidone 
(Bahr et al., 2015b) induced changes in gut microbiota composition in rodents and 
children, respectively. Chronic treatment with risperidone was associated with 
significantly lower ratio of Bacteroidetes:Firmicutes in healthy young males and with 
an increase in gut microbiota diversity when compared to control participants. 
Interestingly, we found the same trend in our animals treated with aripiprazole (a 
compound that belongs to the same therapeutic class of risperidone): at the genus level, 
21 of the 26 genera belonging to Firmicutes were significantly increased and 2 genera 
belonging to Bacteroidetes were decreased. In addition, the microbial alpha-diversity 
of aripiprazole-treated rats was significantly increased, in line with data on 
risperidone-treated children. The results, however, are not always consistent. In a 
bipolar disease cohort, for example, treatment with atypical antipsychotics induced a 
decrease in microbial diversity, with the effect being present in females but not in 
males (Flowers et al., 2017). In the same study, the bipolar cohort treated with atypical 
antipsychotics showed, at the microbiota genus level, a significant increase in 
Lachnospiraceae abundance and a significant decrease in Akkermansia. Also, a recent 
large-scale study in vitro looking at the effect of several non-antibiotic drugs on human 
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gut bacteria in vitro, found that Akkermansia was significantly more sensitive than all 
other strains to atypical antipsychotics (Maier et al., 2018). In contrast with these 
findings, treatment with the atypical antipsychotic aripiprazole did not affect the two 
aforementioned genera in our rats. The fact that antipsychotics cluster together on 
microbiome despite different chemical structures and CNS effects, implicates that 
direct bacterial activity may be part of their mechanism of action or at least their side 
effects. An important aspect of this study would be to understand the biological and 
physiological relevance of the bacteria that were altered in response to psychotropics 
administration. Even though some of the affected genera have not been fully 
characterised, others have been previously associated to diverse conditions and are 
described in Table 2.2.  
It is important to note that further work is required to measure the level of these drugs 
in the caecum, in order to clarify whether these medications reach the caecum at 
adequate concentrations and are not completely absorbed in the upper gastrointestinal 
tract. This investigation will further elucidate if the drugs are having a direct microbial 
effect or are affecting the gut microbiome through indirect mechanisms (such as the 
gut-brain signalling). Moreover, future studies might want to assess the microbiome-
targeted effects of these medications at lower doses, such as those translational to a 
human setting. 
While some knowledge existed of the impact exerted by antipsychotics on the gut 
microbiota, other classes of psychotropics (see Table 2.1) have not previously been 
investigated in vivo. Here we show that chronic administration of the mood stabiliser 
lithium and the anticonvulsant valproate significantly affected the microbial 
composition and richness in rats. The increase in richness might be directly due to the 
effect of the drugs on the microbial stability and the presence of different bacteria 
competing for the same niche. This effect on richness might also be time and dose 
dependent. Principal coordinate analysis of Bray-Curtis (beta-diversity) showed that 
lithium, valproate and aripiprazole had a significant separation from the vehicle group. 
On the contrary, psychotropics belonging to the class of antidepressants (specifically 
escitalopram, venlafaxine and fluoxetine) did not markedly affect this aspect of 
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microbial richness and diversity. Only fluoxetine clustered far from the vehicle group 
in the principal coordinate analysis of Bray-Curtis (Figure 2.3B).  
 
Table 2.2 List of bacterial genera that were altered by psychotropics and their 
associations with physiological/pathological conditions. Bacterial genera were selected 
from Figures 4, 5 and 6 of the manuscript according to the following criteria: taxa that were 
significantly different from the vehicle in at least one treatment group. Among those taxa, 
Ruminococcus 1, Clostridia Family XIII, Ruminiclostridium 5, Peptoclostridium, 
Eubacterium oxidoreducens and Succinivibrio were not included in the table due to lack of 
information on their physiological role. Abbreviations: ↑ increase, ↓ decrease, BMI body mass 
index, CD coeliac disease, CDI Clostridium difficile infection, DSS dextran sulphate sodium, 
FA food allergy, HIV human immunodeficiency virus, NAFLD non-alcoholic fatty liver 
disease, SAMP8 senescence-accelerated mouse prone 8, T2D type 2 diabetes  
 
 
Bacteria Genus Physiological / Pathological Condition(s) Reference(s) 
Phylum Firmicutes 
Lachnospiraceae NK4A136 Associated with intestinal barrier function in mice 
with DSS-induced colitis. ↑ in mice fed a meat 
protein diet. ↓ in SAMP8 mice. Altered in statin 
therapy in mice. Lachnospiraceae strains restrict 
intestinal inflammation 
(Caparrós-Martín et al., 
2017; Chen et al., 2017; 
Li et al., 2017; Xie et al., 
2018; Zhan et al., 2018) 
Ruminococcaceae uncult Ruminococcaceae ↑ in mice fed a high-fat diet. ↓ in 
NAFLD patients. ↓ in CDI patients 
(Kim et al., 2012; Raman 
et al., 2013; Schubert et 
al., 2014) 
Clostridium sensu stricto 1 ↑ in infants with high genetic risk of developing 
CD.  
↑ in infants with IgE-mediated FA 
(Ling et al., 2014; 
Olivares et al., 2014) 
Intestinibacter ↓ in metformin therapy in patients with T2D (Forslund et al., 2015; 
Wu et al., 2017a) 
Eubacterium 
coprostanoligenes 
Cholesterol-lowering effects (Freier et al., 1994; Li et 
al., 1998; Li et al., 1995; 
Ren et al., 1996) 
Christensenellaceae uncult ↑ in longevity. Highly heritable. Associated to low 
BMI (anti-obesity) 
(Goodrich et al., 2016; 
Kong et al., 2016; López-
Contreras et al., 2018) 
Phylum Bacteroidetes 
S_24_7 uncultbact ↑ in aging  (Scott et al., 2017a) 
Bacteroides HLA-B27 transgenic rats colonised with 
Bacteroides develop colitis and gastritis. Positively 
associated to immunoregulation in HIV-1 infection 
in humans 
(Paquin-Proulx et al., 
2016; Rath et al., 1996) 
Prevotella 7 
Prevotella 9 
Prevotella species ↑ in healthy subjects who 
exhibit improved glucose metabolism following 3-
day consumption of fibers 
(Kovatcheva-Datchary et 
al., 2015) 
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Short chain fatty acids (SCFAs) are produced in the caecum by microbial fermentation 
(den Besten et al., 2013; Morrison and Preston, 2016) and are key regulators of several 
host processes such as metabolism (De Vadder et al., 2014), behaviour (Schroeder et 
al., 2007) and CNS function (Erny et al., 2015; Huuskonen et al., 2004). With marked 
alterations present at the microbiota level, it was perhaps not surprising that changes 
in SCFAs occurred. Valproate and aripiprazole influenced SCFAs abundance in the 
caecum, with acetate and isovalerate being increased by aripiprazole treatment and 
propionate, butyrate and isovalerate being differentially altered by valproate (Figure 
2.7). We next investigated whether changes in SCFAs levels were associated with 
specific microbial taxa that are known producers of SCFAs. Clostridium spp., a known 
producer of the SCFA acetate (Koh et al., 2016), was found to be increased in 
aripiprazole-treated animals, while valproate-treated rats showed a decrease in 
Bacteroidetes, which might explain the reduction in propionate in this experimental 
group. However, in our study the correlations between bacterial taxa and SCFAs were 
limited and sometimes discordant, for example Prevotella which is a producer of 
acetate (Koh et al., 2016) was decreased by aripiprazole administration. Therefore, the 
medications might have a different and direct influence on SCFA levels that are not 
mediated by the intestinal bacteria and still need to be teased apart. 
The impact of psychotropic drugs on gut functionality is poorly understood. Thus, we 
assessed epithelial permeability in the small and large intestine and found that the three 
antidepressants escitalopram, venlafaxine and fluoxetine, together with the atypical 
antipsychotic aripiprazole, increased epithelial permeability in the ileum. 
Escitalopram, venlafaxine and fluoxetine share a common mechanism of action that is 
the blockade of the serotonin (5-HT) transporter (SERT) leading to increases in 
intrasynaptic 5-HT levels. SERT is not only present in the brain, it is also widely 
expressed on epithelial cells of the intestinal mucosa where it removes 5-HT from the 
interstitial space following release by enterochromaffin cells (Chen et al., 2001; Chen 
et al., 1998; Coates et al., 2004; Wade et al., 1996). 5-HT is involved in the control of 
intestinal permeability (Bischoff et al., 2009; Haub et al., 2010; Yamada et al., 2003), 
thus it is plausible to speculate that the changes observed in ileal permeability might 
be dependent on direct effects of the three antidepressants on SERT. In addition to the 
antidepressants, also the atypical antipsychotic aripiprazole increased permeability in 
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the ileum, however, this effect is not SERT-mediated and may be due to its effects on 
other 5-HT receptors. On the other hand, aripiprazole induced a concomitant shift in 
gut microbiota and future studies are needed to determine if there is a causal link 
between microbiota and permeability in this specific treatment group. Interestingly, 
the action of psychotropics on intestinal permeability was region-specific, with the 
colon being largely unaffected.  
Interestingly, some studies have demonstrated that the gut microbiota of depressed 
(Kelly et al., 2016; Naseribafrouei et al., 2014) and bipolar (Evans et al., 2017) patients 
has an abnormal composition. This suggests that the gut-targeted effects of 
psychotropics might be part of the mechanism of action of these medications, however, 
this needs to be further investigated and confirmed. In this vein, future studies 
examining the impact of these drugs on microbiota composition in animal models of 
mental disorders and subsequently on human cohorts are warranted. 
The functional consequences of drug-induced microbiome changes maybe at multiple 
levels including drug efficacy, kinetics, side effects and safety. Regarding side effects, 
weight gain has been the most studied in the context of the microbiome due to the 
relationship between microbiota composition and obesity (Torres-Fuentes et al., 2017) 
and appetite regulation (Cani et al., 2009; van de Wouw et al., 2017). Indeed, weight 
gain induced by antipsychotics (including olanzapine and risperidone) can be 
modulated by targeting the microbiome with antibiotics and prebiotics (Bahr et al., 
2015a; Bahr et al., 2015b; Kao et al., 2018; Morgan et al., 2014). In a recent meta-
analysis, all of the antidepressants tested here increased weight gain in a population 
cohort (Gafoor et al., 2018), suggesting a dissociation between their effects on 
microbiome and bodyweight per se.  
In conclusion, the present study demonstrates that psychotropic medications 
differentially affect gut microbiota composition and intestinal permeability in healthy 
adult rats. Interestingly, such changes do not parallel with the impact of these drugs 
on in vitro isolated bacterial strains or on intestinal permeability per se. Together, these 
data highlight the importance of investigating the impact of drugs used for the 
treatment of psychiatric disorders on microbiota-gut-brain axis function. 




Table S.2.1 Statistics values for relative abundance of bacterial PHYLA in each treatment group as compared to the vehicle.  
PHYLUM 
Escitalopram Venlafaxine Fluoxetine Lithium Valproate Aripiprazole 
 
p (i/m)Q p (i/m)Q p (i/m)Q p (i/m)Q p (i/m)Q p (i/m)Q 
Firmicutes  
0.505 0.042 0.505 0.050 0.721 0.075 0.083 0.025 0.003 * 0.017 * 0.015 * 0.017 * 
Bacteroidetes  
0.959 0.075 0.234 0.025 0.328 0.042 0.001 * 0.017 * 0.005 0.025 0.195 0.025 
Verrucomicrobia  
0.328 0.025 0.442 0.042 0.234 0.033 0.959 0.092 0.105 0.033 0.195 0.033 
Proteobacteria  
1.000 0.083 0.195 0.017 0.130 0.025 0.798 0.075 0.505 0.058 0.328 0.05 
Actinobacteria  
0.382 0.033 0.050 0.008 0.505 0.050 0.000 * 0.008 * 0.002 * 0.008 * 0.195 0.017 
Cyanobacteria  
0.574 0.050 0.721 0.075 0.105 0.017 0.105 0.033 0.505 0.050 0.234 0.042 
Deferribacteres  
0.328 0.017 0.234 0.033 0.007 * 0.008 * 0.959 0.083 0.130 0.042 0.442 0.058 
Tenericutes  
0.279 0.008 0.959 0.083 0.878 0.083 0.574 0.058 0.574 0.067 0.505 0.067 
Noblasthit  
0.645 0.058 0.574 0.058 0.645 0.058 0.130 0.042 0.878 0.092 0.878 0.083 
*p<0.05, Mann-Whitney U test, Benjamini-Hochberg critical value [(i/m)Q] with a Q (false-discovery rate) of 0.2. N=8/group. Red colour indicates an 
increase; blue colour indicates a decrease in the relative abundance of bacterial taxa as compared to vehicle 
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Table S.2.2 Statistics values for relative abundance of bacterial FAMILIES in each treatment group as compared to the vehicle.  
FAMILY Escitalopram Venlafaxine Fluoxetine Lithium Valproate Aripiprazole 




0.959 0.187 0.505 0.068 0.798 0.162 0.000 *  0.013 * 0.000 * 0.013 * 0.279 0.098 
Coriobacteriaceae 
(Coriobacteriales) 
0.279 0.034 0.195 0.080 0.959 0.183 0.000 * 0.017 * 0.721 0.153 0.382 0.110 
Nocardiaceae 
(Actinomycetales) 




0.878 0.157 0.130 0.025 0.279 0.076 0.021 * 0.034 * 0.382 0.119 0.382 0.106 
S 24_7 
(Bacteroidales) 








0.382 0.055 0.798 0.153 0.195 0.059 0.130 0.098 0.038 * 0.055 * 0.161 0.068 
Lactobacillaceae 
(Lactobacillales) 
0.959 0.174 0.083 0.030 0.105 0.042 0.083 0.076 0.000 * 0.004 * 0.328 0.102 




0.279 0.030 0.959 0.034 0.015 * 0.017 * 0.000 * 0.004 * 0.000 * 0.008 * 0.002 * 0.017 * 
Christensenellaceae 
(Clostridiales) 
0.574 0.089 0.083 0.089 0.083 0.029 0.015 * 0.029 * 0.003 * 0.017 * 0.001 * 0.013 * 
Clostridiaceae 1 
(Clostridiales) 
0.083 0.008 0.645 0.051 0.279 0.080 0.000 * 0.008 * 0.007 * 0.021 * 0.000 * 0.004 * 
Defluviitaleaceae 
(Clostridiales) 
0.878 0.166 0.505 0.106 0.083 0.034 0.007 * 0.025 * 0.083 0.068 0.003 * 0.025 * 
Family XIII 
(Clostridiales) 
0.878 0.162 0.130 0.085 0.645 0.132 0.038 * 0.055 * 0.279 0.106 0.065 0.042 
Eubacteriaceae 
(Clostridiales) 
0.798 0.150 0.083 0.119 0.505 0.123 0.028 * 0.051 * 0.234 0.094 0.234 0.089 
Peptococcaceae 
(Clostridiales) 
0.721 0.123 0.130 0.047 0.328 0.094 0.021 * 0.038 * 0.028 * 0.047 * 0.161 0.059 
Ruminococcaceae 
(Clostridiales) 
0.645 0.098 0.050 0.008 0.161 0.055 0.028 * 0.047 * 0.021 * 0.030 * 0.021 * 0.034 * 
Erysipelotrichaceae 
(Erysipelotrichales) 
0.328 0.042 0.195 0.042 0.959 0.179 0.050 0.064 0.021 * 0.038 * 0.234 0.076 
Veillonellaceae 
(Veillonellales) 
0.021 0.004 0.279 0.127 0.000 * 0.004 * 0.002 * 0.021 * 0.010 * 0.025 * 0.000 * 0.008 * 
Staphylococcaceae 
(Bacillales) 








0.442 0.068 0.878 0.114 0.798 0.170 0.442 0.128 0.442 0.123 0.003 * 0.030 * 
Uncult (Mollicutes) 0.645 0.119 0.505 0.102 0.382 0.102 0.234 0.102 0.105 0.076 0.028 * 0.038 * 
  89  
 
*p<0.05, Mann-Whitney U test, Benjamini-Hochberg critical value [(i/m)Q] with a Q (false-discovery rate) of 0.2. N=8/group. Red colour indicates an 
increase; blue colour indicates a decrease in the relative abundance of bacterial taxa as compared to vehicle. The following families where not significantly 
different from the vehicle in either treatment group and therefore are not reported in the table:  Lachnospiraceae, Verrucomicrobiaceae, Prevotellaceae, 
Porphyromonadaceae, ClostridialesvadinBB60, Rhodospirillaceae, Gastranaerophilales uncult, Rikenellaceae, Anaeroplasmataceae, Noblasthit1, 




Table S.2.3 Statistics values for relative abundance of bacterial GENERA in each treatment group as compared to the vehicle. This table can be found in the 
excel file “Table S3” at the following link: https://link.springer.com/article/10.1007%2Fs00213-018-5006-5#SupplementaryMaterial 
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SUPPLEMENTAL FIGURES  
Figure S.2.1 Open field test indicating the total distance moved (locomotor activity). 
N=8/group. Data were homogeneous and normally distributed so were analysed with a one-
way ANOVA followed by Dunnett’s test. 
 
Figure S.2.2 Significant differences at phylum level. *p<0.05, Mann-Whitney U test with a 
Q (false-discovery rate) of 0.2. N=8/group. 
 
 
  91  
 
 
Figure S.2.3 Significant differences at family level. *p<0.05, Mann-Whitney U test with a Q 








Figure S.2.4 Concentrations of the two SCFAs valerate and isobutyrate in the caecum. Data 
are expressed as mean + SEM (n=8/group). 
  




Caecal microbiota composition and short chain fatty acids (SCFAs) analysis  
Caecum was harvested, snap frozen and stored at -80ºC prior to the analysis. Caecal 
content was further split into halves for the 16S sequencing and SCFAs analysis. 
 
 Caecal content DNA extraction  
 
DNA extraction was performed using the QIAmp Fast DNA Stool Mini Kit (Qiagen, 
Sussex, UK) coupled with an initial bead-beating step. Briefly, 200 mg of each caecal 
sample were vortex-mixed in a 2 ml screw-cap tubes (Sarstedt, Wexford, Ireland) 
containing 0.25 g of a 1:1 mix of 0.1 mm and 1.0 mm sterile zirconia beads plus a 
single 3.5 mm diameter bead (BioSpec Products, Bartlesville, USA) with 1 ml of 
Qiagen InhibitEX® buffer. Following steps were according to manufacturer’s 
instructions. DNA was quantified using the QubitTM 3.0 Fluorometer (Bio-Sciences, 
Dublin, Ireland) and the Qubit® dsDNA HS Assay Kit (Life Technologies, Oregon, 
USA). Extracted DNA was kept frozen at -20ºC until further analysis. 
 
 16S rRNA Gene Sequence-based microbiota analysis  
 
The V3-V4 hypervariable region of the 16S rRNA gene were amplified and prepared 
for sequencing as outlined in the Illumina 16S Metagenomic Sequencing Library 
Protocol (http://www.illumina.com/content/dam/illumina-
support/documents/documentation/chemistry_documentation/16s/16s-metagenomic-
library-prep-guide-15044223-b.pdf). Briefly, first PCR was done using forward 
primer (5’- 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCA
G-3') and reverse primer (5’- 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATC
TAATCC-3'). Each 25 μl PCR reaction contained 5 ng/μl microbial genomic DNA, 1 
μM of each primer and 12.5 μl 2X Kapa HiFi Hotstart ReadyMix (Kapa Biosystems 
Ltd., UK). The PCR conditions follow as: initial denaturation at 95 ºC x 3 min; 25 
cycles of 95 ºC x 30 s, 55 ºC x 30 s, 72 ºC x 30 s; and 72 ºC x 5 min for final extension. 
PCR products were purified with Agencourt AMPure XP system (Beckman Coulter 
Genomics, Takeley, UK). In the next step, dual indices and Illumina sequencing 
adapters were attached to PCR products using the Nextera XT Index Kit (Illumina, 
San Diego, CA). Each 50 μl PCR reaction contained 5 μl purified DNA, 5 μl index 
primer 1 (N7xx), 5 μl index primer 2 (S5xx), 25 μl 2x Kapa HiFi Hot Start Ready mix 
and 10 μl PCR grade water. PCR amplification was completed using the previous 
program but with only 8 amplification cycles instead of 25. Following this, a second 
clean-up step with the Agencourt AMPure XP system was done. PCR products were 
quantified, normalised and pooled in an equimolar fashion using the Qubit® dsDNA 
HS Assay Kit (Life Technologies, Oregon, USA). Next steps in the library preparation 
were carried out by Teagasc Next Generation DNA Sequencing Facility (Teagasc, 
Moorepark, Food Research Centre) prior to 2×250 (bp) paired-end sequencing on the 
Illumina MiSeq platform, using standard Illumina sequencing protocols. 
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 Bioinformatic sequence analysis  
 
Bioinformatic sequence analysis was performed as previously described (Murphy et 
al., 2017). Briefly, paired-end sequences were assembled using FLASH (Magoč and 
Salzberg, 2011) and analysed using QIIME v1.8.0 (Quantitative Insights Into 
Microbial Ecology) (Caporaso et al., 2010). Sequences were quality checked and the 
remaining sequences were clustered into operational taxonomic units using 
USEARCH (v7-64bit) (Edgar, 2010). Taxonomic ranks were assigned with a BLAST 
search against the SILVA SSURef database release 123 (Quast et al., 2013). Alpha 
and beta diversities and Bray-Curt dissimilarities were generated in RStudio (version 
1.1.419) using the “vegan” and “car” packages. Principal coordinate analysis (PCoA) 
plots were visualised with ggplot2 (V 2.2.1) using OTU values normalised with the 
wisconson function in the vegan package (v. 2.5-1). Ellipses of the PCoA were 
calculated using the stat_ellipse function in ggplot2 (v 2.2.1) with confidence interval 
(CI) set to 0.90.  Explained percent variance was calculated and plotted for x and y 
axis. Adonis function (PERMANOVA, permutations=999) in the vegan package (v 
2.5-1) was performed on Bray-Curtis matrix on three dimensions. Relative abundance 
of bacterial taxa was expressed as % of identified sequences.  
 
 Heatmap construction  
 
Log2 ratios were calculated from group medians of highly abundant bacteria at the 
genus level using R (version 3.3.2) and R Studio (version 1.0.136). Heatmaps were 
created in R and imported into InkScape to refine the image. 
 
 Short chain fatty acids concentration analysis from cecum content  
 
Analysis of the main SCFA (acetate, propionate and butyrate) and a branched chain 
fatty acid (BCFA) (iso-butyrate) were carried out in supernatants of homogenised 
caecal content by gas chromatography (GC), as previously described (Wall et al., 
2012). Briefly, at least 100 mg of each caecal sample were vortex-mixed with MilliQ 
water and incubated at room temperature for 10 min. Following this, the supernatant 
was obtained by centrifugation (24000 g, 5 min, 4°C), filtered through 0.2μm filters 
and mixed with 2-Ethylbutyric acid (Sigma Aldrich Ireland Ld, Wicklow, Ireland) as 
an internal standard. A gas chromatograph Varian 3800 GC flame-ionization system, 
fitted with a Zebron ZB-FFAP column (30m x 0.32mm x 0.25µm) (Phenomenex, 
Macclesfield, UK) was used for quantification of SCFA. Chromatographic conditions 
were as follow: GC oven temperature was held initially at 50 °C for 0.5 min, then 
raised stepwise, by 10 °C/min, until it reached 140 °C. It was then raised by 20 °C/min 
up to 240 °C, and held for 5 min. The temperature of the injector and the detector were 
set at 240°C and 300°C, respectively. Helium was used as the carrier gas at a flow rate 
of 1.3 ml min-1. A standard curve was built with increasing concentrations of a 
standard mix containing the SCFAs and BCFA analysed (Sigma Aldrich Ireland Ld, 
Wicklow, Ireland). Peaks were integrated by using the Varian Star Chromatography 
Workstation v6.0 software. The concentration of each SCFA was calculated using the 
linear regression equations (R2 ≥ 0.999) from the corresponding standard curves. 
Standards were included in each run to check calibration. Data were presented as 
µmol/wet caecum weight (g). 




Statistical output of the t-test related to Figure 2.2 (Effect of psychotropic drugs on 
growth of Lactobacillus rhamnosus 6118 and Escherichia coli APC105 in vitro) 
 
Escitalopram effect on E.coli: t(4)=8.99, p<0.01 for 600µg/mL at 2h, t(4)=16.396, 
p<0.001 for 600µg/mL at 3h, t(4)=45.962, p<0.001 for 600µg/mL at 4h, t(4)=40.531, 
p<0.001 for 600µg/mL at 5h, t(4)=32.087, p<0.001 for 600µg/mL at 6h, t(4)=37.523, 
p<0.001 for 600µg/mL at 7h. Fluoxetine effect on L. rhamnosus: t(4)=3.487, p<0.05 
for 600µg/mL at 2h, t(4)=3.7, p<0.05 for 400µg/mL at 2h, t(2.051)=5.75, p<0.05 for 
600µg/mL at 3h, t(2.099)=5.530, p<0.05 for 400µg/mL at 3h, t(4)=8.451, p<0.05 for 
600µg/mL at 4h, t(4)=7.82, p<0.01 for 400µg/mL at 4h, t(4)=14.223, p<0.001 for 
600µg/mL at 5h, t(4)=14.778, p<0.001 for 400µg/mL at 5h, t(4)=4.479, p<0.05 for 
600µg/mL at 6h, t(4)=4.450, p<0.05 for 400µg/mL at 6h, t(4)=5.335, p<0.01 for 
600µg/mL at 7h, t(4)=5.335, p<0.01 for 400µg/mL at 7h. Fluoxetine effect on E.coli: 
t(2.021)=12.261, p<0.01 for 600µg/mL at 2h, t(4)=12.908, p<0.001 for 400µg/mL at 2h, 
t(4)=11.144, p<.001 for 100µg/mL at 2h, t(4)=19.036, p<0.001 for 600µg/mL at 3h, 
t(4)=21.205, p<0.001 for 400µg/mL at 3h, t(4)=21.952, p<0.001 for 100µg/mL at 3h, 
t(4)=49.952, p<0.001 for 600µg/mL at 4h, t(4)=40.429, p<0.001 for 400µg/mL at 4h, 
t(4)=64.846, p<0.001 for 100µg/mL at 4h, t(4)=22.224, p<0.001 for 600µg/mL at 5h, 
t(4)=26.379, p<0.001 for 400µg/mL at 5h, t(4)=40.844, p<0.001 for 100µg/mL at 5h, 
t(4)=48.543, p<0.001 for 600µg/mL at 6h, t(4)=43.874, p<0.001 for 400µg/mL at 6h, 
t(4)=47.115, p<0.001 for 100µg/mL at 6h, t(4)=33.638, p<0.001 for 600µg/mL at 7h, 
t(4)=35.601, p<0.001 for 400µg/mL at 7h, t(4)=32.824, p<0.001 for 100µg/mL at 7h. 
 
 
Statistical output of the t-test related to Figure 2.8 (Effect of drug treatments on 
epithelial permeability in small and large intestine) 
 
Escitalopram on ileum: t(13)= -2.517, p<0.05 at 120min, t(13)= -3.785, p<0.01 at 
150min, t(13)= -4.196, p<0.01 at 180min. Venlafaxine on ileum: t(13)= -2.294, p<0.05 
at 150min, t(13)= -2.245, p<0.05 at 180min. Fluoxetine on ileum: t(13)= -2.36, p<0.05 
at 120min, t(13)= -2.492, p,0.05 at 180min. Aripiprazole on ileum: t(13)= -3.46, p<0.01 
at 90min, t(13)= -4.233, p<0.001 at 120min, t(13)= -5.184, p<0.001 at 150min, t(13)= -
4.401, p<0.01 at 180min.  
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Abstract  
Background: Lithium (mood stabiliser) and valproate (antiepileptic and mood 
stabiliser) are two psychotropic medications widely used in clinical practice. There is 
a growing appreciation of the impact of drugs, especially psychotropic drugs, on the 
microbiome composition. Given the crucial role played by intestinal microbes in bile 
acid (BA) biotransformation, we wanted to investigate the effects of lithium and 
valproate on bile acid composition and bile-metabolising bacteria in the intestine.  
Results: Chronic (4 weeks) administration of lithium and valproate in rats increased 
all types of BAs in circulation, faecal content and liver, except for tauro-conjugated 
bile acids. These effects were accompanied by an increase in some key bile-
metabolising bacteria in the gut, such as Clostridium, Eubacterium and 
Bifidobacterium, measured through 16S rRNA sequencing. Intestinal and hepatic 
regulation of BA synthesis and transport was disrupted by both medications. Two 
possible mediators of such changes, liver damage and disruption of intestinal 
permeability, did not seem to play any overt role in the observed effects.  
Conclusions: These findings reveal that the mood stabilisers lithium and valproate 
influence the composition of bile and correspondent bile-metabolising bacteria in the 
intestine. Future studies focused on the possible causality and direction of the 
interaction between drug-induced changes in microbiota and alterations in bile acids 
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Introduction  
Lithium and valproate are two widely used psychotropic medications (from the Greek 
root psychè=mind and tropòs=turning, literally “mind-turning”) used as mood 
stabilisers (both drugs) and antiepileptic (valproate). In the context of the microbiota-
gut-brain axis, we have recently shown that many medications and especially these 
two drugs alter substantially the microbiome composition and diversity in rodents 
(Cussotto et al., 2019b; Davey et al., 2013; Maier et al., 2018). Given that the liver is 
a crucial component of drug metabolism and because the gut and the microbiota are 
connected to the liver through a gut-liver axis (Tripathi et al., 2018), it is possible that 
such changes may result in  lithium and valproate also impacting on hepatic function 
and bile acid (BA) composition. 
BA composition is determined by (1) the biosynthesis of primary BAs from 
cholesterol in the liver and subsequent conjugation to glycine or taurine; (2) bacterial 
modifications within the large intestine including deconjugation by bacteria with bile 
salt hydrolase activity (BSH, EC 3.5.1.24), allowing further microbial modification to 
secondary and tertiary BAs by 7α-dehydroxylating bacteria (EC 1.17.99.5) (Ramirez-
Perez et al., 2017). Under physiological conditions, activation of farnesoid X receptor 
(FXR) is the key regulator of BA synthesis (Tu et al., 2000). FXR induces target genes 
in both the liver and the intestine, including hepatic small heterodimer partner (SHP) 
and intestinal fibroblast growth factor 19 (Fgf19), which in turn inhibit BA synthesis 
via repression of CYP7A1, CYP8B1 and CYP27A1 gene transcription (Kong et al., 
2012). FXR activation is strongly influenced by BA composition with 
chenodeoxycholic acid (CDCA) being a stronger activator than deoxycholic acid 
(DCA). DCA, in turn, is stronger than lithocholic acid (LCA) and cholic acid (CA) 
(Parks et al., 1999). The complex pathways and mediators involved in BA synthesis 
and transport are described in Figure 3.1. 
 




Figure 3.1 Transporters and 
enzymes involved in the synthesis 
and enterohepatic circulation of 
bile acids. The transcript levels of 
transporters and enzymes are 
described in Figure 3.6. 
Abbreviations: ASBT apical sodium-
bile acid transporter, BSEP bile salt 
export pump, BSH bile salt hydrolase, 
CYP cytochrome P450, FGF19 
fibroblast growth factor 19, FGFR4 
fibroblast growth factor receptor 4, 
FXR farnesoid X receptor, G/T-CA 
glyco/tauro-cholic acid, G/T-CDCA 
glyco/tauro-chenodeoxycholic acid, 
HMGCR 3-hydroxy-3-
methylglutaryl-CoA reductase, ILBP 
ileal lipid binding protein, MRP 
multidrug resistance protein, NTCP 
Na+-taurocholate cotransporting 
polypeptide, Ost α/β organic solute 
transporter α/β, SHP small 
heterodimer partner, SREBF1 sterol 
regulatory element binding 
transcription factor 1, TGs 
triglycerides. 
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Functionally, altered bile acid levels play a role in intestinal epithelial function (Hegyi 
et al., 2018), circadian rhythm regulation (Govindarajan et al., 2016; Ma et al., 2009), 
colon cancer (Ajouz et al., 2014)  and glucose metabolism in health and disease 
(Shapiro et al., 2018). Information regarding the impact of psychotropic medications 
on microbiome composition is limited; however, in a recent study on rats, we have 
shown for the first time that certain psychotropic medications including lithium and 
valproate influence significantly the gut microbiome (Cussotto et al., 2019b). 
Moreover, in a tour de force in vitro screening of more than 1,000 drugs against 40 
representative gut bacterial strains, it was found that 24% of human-targeting drugs, 
including the psychotropic valproate, inhibited the growth of at least one microbial 
strain (Maier et al., 2018). The authors argued that, based on drug excretion patterns 
from published work, the chosen concentration of 20 μM was below the median colon 
concentration of the human-targeted drugs tested and therefore had translational 
validity (Maier et al., 2018). The microbial changes observed in lithium- and 
valproate-treated animals might predict the influence of these medications on BA 
composition and consequently FXR activation. In clinical practice long-term 
administration of both lithium and valproate can be associated to a certain degree of 
hepatotoxicity (Hayes et al., 2016), giving further rationale for investigating BA 
metabolism and liver function. The aims of the current study were: (1) to determine 
whether lithium and valproate altered BA concentrations, (2) to determine whether 
such changes were associated with alterations in specific BA-metabolising bacterial 
taxa, (3) to examine some of the most obvious mechanisms at the hepatic and 
gastrointestinal level that may underpin such effects. To this end, we assessed whether 
genes involved in hepatic inflammation or changes in intestinal permeability were 
major contributors to the BA dysregulation observed following chronic administration 
of the two drugs. 
  




Adult male Sprague Dawley rats (n=8/group; 200-250g on arrival) were obtained from 
Envigo UK. They were housed 2 per cage and maintained under a 12-h light/dark 
cycle, provided with chow and water ad libitum. Rats in the same cage underwent the 
same treatment to avoid confounding factors such as coprophagy. Animals were 
acclimated to housing conditions for one week prior to experimental treatment. 
Experiments were conducted in accordance with European Directive 2010/63/EU. 
Approval by the Animal Experimentation Ethics Committee of University College 
Cork was obtained before commencement of all animal-related experiments.  
 
Drug administration 
The drug treatment was administered as previously described (Cussotto et al., 2019b). 
The control group received a standard diet (Ssniff, SM Teklad Global 18% Protein 
Rodent diet, item no. S9912-S710) and drinking water. A second group received 0.2% 
lithium-supplemented diet, corresponding to approx. 150mg/kg/day, and hypertonic 
saline water (1.5% NaCl, in order to prevent lithium-induced ionic imbalance). A third 
group received 2% valproate-supplemented diet, corresponding to approx. 
1.5g/kg/day. The concentration of each drug in drinking water and in the chow was 
determined from the average daily water/food consumption and the average body 
weight per rat. These dosing regimens have been previously used in chronic 
behavioural and neurochemical studies in rodents (Monti et al., 2010; O’Leary et al., 
2012; Watase et al., 2007). The chow was stored at 4 ºC during the experiment. 
 
Bile acid levels in plasma, colon content and liver 
Plasma, colon and liver tissues were collected at sacrifice and immediately stored at -
80 ºC until further analysis. Bile acids and salts were assessed as previously described 
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(Joyce et al., 2014). Briefly, they were extracted following addition of deuterated 
internal standards. Extracted acids were resuspended in 50% methanol, injected in 
triplicate and assessed in negative electrospray mode through a C18 Acquity column 
using an LCT Premier mass spectrometer (Waters Corp). Assessment of extraction 
efficiency was performed using internal standards, and samples were quantified by 
standard curve construction for individual bile moieties using targetlynx software 
(Waters) (refer to Supplemental Methods). 
 
Microbiota composition analysis in the caecal content 
The caecum microbiota was analysed as previously described (Cussotto et al., 2019b). 
Briefly, caecum was harvested and immediately snap-frozen and stored at -80ºC prior 
to the analysis. DNA was extracted using the Qiagen QIAmp Fast DNA Stool Mini 
Kit coupled with an initial bead-beating step. The V3-V4 hypervariable region of the 
16S rRNA gene was amplified and prepared for sequencing as outlined in the Illumina 
16S Metagenomic Sequencing Library protocol. Samples were sequenced at Teagasc 
Sequencing Facility (TFRC, Moorepark) on the Illumina MiSeq platform using a 
2×250 bp kit. Reads were assembled, processed and analysed following the pipeline, 
described in Supplemental Methods. 
 
RNA extractions, reverse transcription and quantitative RT-qPCR  
The intestinal tissue and frontal lobe of the liver were rapidly dissected from individual 
animals and stored at -80 °C. Total RNA was extracted with the mirVanaTM miRNA 
isolation kit (Thermo Fisher Scientific/Ambion) following the manufacturer’s 
protocol. A Nanodrop 1000 (Thermo Scientific, UK) was used to determine RNA 
concentration. RNA was reverse transcribed using a high capacity cDNA reverse 
transcription kit (Thermo Fisher Scientific/Applied Biosystems) in a G-storm 
thermocycler (G-storm, Surrey, UK). Genes of interest (listed in Supplemental 
material) were amplified using SYBR Green primers. Each transcript value was 
calculated as the average of triplicate samples across experimental conditions. Values 
were normalized to β-actin. Data were analysed with the comparative cycle threshold 
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Intestinal permeability ex vivo 
Intestinal permeability was carried out essentially as described previously (Golubeva 
et al., 2017). Briefly, freshly isolated ileum samples from 10 naïve adult SD rats were 
placed in Krebs solution and cut along the mesenteric border. Tissues then underwent 
seromuscular stripping (to remove the serosal and muscular layers) and were mounted 
into the Ussing chamber apparatus (Harvard Apparatus, Kent, UK, exposed area of 
0.12 cm2). 4kDa FITC-dextran was added to the mucosal chamber at a final 
concentration of 2.5 mg/mL; 200 μL samples were collected from the serosal chamber 
every 30 minutes for the following 3 hours. FITC was measured at 485 nm excitation 
/ 535 nm emission wavelengths. Short-circuit current (Isc) was recorded in a zero 
voltage clamp mode; transepithelial electrical resistance (TEER) was measured by 
discharging a 2 mV pulse. To minimize the influence of the intrinsic neuromuscular 
system, seromuscular stripping was performed. The serosa (visceral peritoneum) and 
the longitudinal/circular muscle layers of the intestinal wall were removed, leaving 
only the underlying submucosal elements, remnants of muscle and the epithelium. The 
experimental design of the study can be found in Figure S.3.1. 
 
Dose relevance for the ex vivo intestinal permeability assessment 
For the assessment of intestinal permeability ex vivo, we deduced the concentrations 
of lithium and valproate in the distal ileum (site of reabsorption of bile acids) on the 
basis of daily dose consumption and specific assumptions described in detail in Figure 
S.3.2. Based on these approximations, 5 mM lithium and 10 mM valproate mimicked 
the concentrations found in the rat distal ileum. To further examine the dose-response 
relationship between drug concentration and intestinal permeability, we assessed the 
same drugs in concentrations 10 times higher (50 mM lithium and 100 mM valproate).  
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Statistical analysis  
Data are presented as mean + SEM. Data that satisfied both homogeneity and 
normality tests, were analysed using one-way ANOVA followed by Dunnett’s test. 
Data that did not satisfy either homogeneity or normality tests, were analysed using 
Kruskal-Wallis non-parametric test followed by Mann-Whitney U test and corrected 
for multiple comparisons using the Benjamin-Hochberg false discovery rate (FDR) 
method. Grubbs method was employed to test for any outlier (Grubbs, 1950). 
Threshold for statistical significance was set at p<0.05. 
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Results  
3.1 Lithium and valproate increase the proportion of primary and secondary bile 
acids in circulation, colon content and liver 
We assessed changes in the BA composition at three key sites: portal plasma, colonic 
content, and liver (as unlike humans rats do not have a gallbladder). BA species have 
been reported to have FXR agonistic ability (CDCA; DCA; LCA), no agonistic 
potential (ursodeoxycholic acid, UDCA) or unknown potential (hyodeoxycholic acid, 
HDCA; hyocholic acid, HCA; muricholic acid, MCA) (Pereira-Fantini et al., 2014). 
Measurement of portal BA composition was performed to determine the BAs being 
transported into the liver and therefore most likely to impact liver function and 
production of new bile. The BA composition of portal blood was markedly altered by 
lithium and valproate (Figure 3.2A, Table S.3.1). Lithium and valproate induced an 
increase in the proportion of all circulating BA species except tauro-conjugated BAs, 
which were not significantly different from control animals (Figure 3.2A). 
Assessment of the BA composition of colonic content samples allowed us to directly 
assess the impact of drug-induced dysbiosis. The BA composition of the colon content 
of both lithium- and valproate-treated rats was significantly altered when compared to 
control animals. Specifically, the proportion of primary, secondary and tertiary BAs 
was increased, together with glyco-conjugated BAs. Tauro-conjugated BAs were 
decreased by both treatment groups. UDCA was affected by lithium only and HCA 
was not affected (Figure 3.3A, Table S.3.2). Hepatic levels of bile acids reflected the 
same concentrations found in circulation, with the only difference that hydrophobic 
tauro-conjugated BAs were significantly decreased by both medications (Figure 3.3B, 
Table S.3.3). The BA heatmaps (Figure 3.4) show the marked differences between 
vehicle-, lithium- and valproate-treated rats both in the liver (the key site for BA 
synthesis) and in the colon content (being the colon the key site for bacteria-mediated 
BA modifications). 
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Figure 3.2 Lithium and valproate induce an increase in bile acids and microbial 
alterations. (A) Alterations in bile acid composition in portal plasma obtained at sacrifice. 
Except from tauro-conjugated BAs, all other moieties of BAs are increased by lithium and 
valproate compared to the vehicle group. Data are expressed as mean ± SEM. *p < 0.05 (n = 
7-8/group). Details on statistics are described in Table S1. Abbreviations: CA cholic acid, 
CDCA chenodeoxycholic acid, DCA deoxycholic acid, HCA hyocholic acid, HDCA 
hyodeoxycholic acid, LCA lithocholic acid, MCA muricholic acid, UDCA ursodeoxycholic 
acid. (B) Alterations in the relative abundance of bacteria responsible for biotransformation 
of bile acids in caecum content obtained at sacrifice. The relative abundance of taxa belonging 
to the genera Clostridium and Eubacterium is increased by both lithium and valproate 
administration. Data are expressed as median and min-to-max values. *p < 0.05 (n = 8/group). 
Data was analysed using Kruskal-Wallis non-parametric test followed by Mann-Whitney U 
test and corrected for multiple comparisons using the Benjamin-Hochberg false discovery rate 
(pFDR) method (refer to Supplemental Material for details on statistics).  
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Figure 3.3 Lithium and valproate differentially alter bile acids concentrations. (A) 
Alterations in bile acid composition in colon content obtained at sacrifice. Data are expressed 
as mean ± SEM. *p < 0.05 (n = 7-8/group). Details on statistics are described in Table S2. (B) 
Alterations in bile acid composition in the liver obtained at sacrifice. Data are expressed as 
mean ± SEM. *p < 0.05 (n = 7-8/group). Details on statistics are described in Table S3.  
Abbreviations: CA cholic acid, CDCA chenodeoxycholic acid, DCA deoxycholic acid, HCA 
hyocholic acid, HDCA hyodeoxycholic acid, LCA lithocholic acid, MCA muricholic acid, 
UDCA ursodeoxycholic acid. 
  
  107  
 
 
Figure 3.4 Heatmaps of bile acid composition in the liver and colon content. (A) Heatmap 
of hepatic BA concentrations in vehicle-, lithium- and valproate-treated rats. (B) Heatmap of 
faecal BA concentrations in vehicle-, lithium- and valproate-treated rats. BAs are shown along 
the y-axis; individual animals are shown along the x-axis. Spearman correlation of absolute 
quantified bile acid profile was performed. Abbreviations (in order of appearance): CA cholic 
acid; CDCA chenodeoxycholic acid; MCA muricholic acid; LCA lithocholic acid; UDCA 
ursodeoxycholic acid; DCA deoxycholic acid; HDCA hyodeoxyhcolic acid; HCA hyocholic 
acid; TCA taurocholic acid; TCDCA taurochenodeoxycholic acid; TMCA tauromuricholic 
acid; TLCA taurolitocholic acid; TDCA taurodeoxycholic acid; TUDCA tauroursodeoxycholic 
acid; THDCA taurohyodeoxycholic acid; THCA taurohyocholic acid; GCA glycocholic acid; 
GCDCA glycochenodeoxycholic acid; GLCA glycolithocholic acid; GDCA glycodeoxycholic 
acid; GUDCA glycoursodeoxycholic acid; GHDCA glycohyodeoxycholic acid; GHCA 
glycohyocholic acid.  
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3.2 Lithium and valproate induce significant alterations in bile-transforming 
bacteria in caecum content 
The gut microbiota is essential in shaping the bile acid composition. We examined 
16S rRNA sequencing data to determine if administration of lithium and valproate was 
associated with alterations in the relative abundance of bile acid-biotransforming 
bacteria. The genera Clostridium (Coleman and Hudson, 1995; Gopal-Srivastava and 
Hylemon, 1988; Rossocha et al., 2005), Bacteroides (Kawamoto et al., 1989; Stellwag 
and Hylemon, 1976; Yoon et al., 2017), Lactobacillus (Chae et al., 2013; Corzo and 
Gilliland, 1999; Elkins et al., 2001; Gu et al., 2014; Jayashree et al., 2014; Lambert et 
al., 2008; McAuliffe et al., 2005; Ren et al., 2011; Wang et al., 2012) and 
Bifidobacterium (Grill et al., 1995; Kim et al., 2005; Kim et al., 2004a; Kim et al., 
2004b; Tanaka et al., 2000; Wang et al., 2012) all carry bile salt hydrolase (BSH) 
activity; while Eubacterium carries 7α-dehydroxylase activity (Coleman et al., 1987; 
Dawson et al., 1996; Edenharder and Schneider, 1985; Mallonee et al., 1990; Masuda 
et al., 1984). Following lithium and valproate administration, the proportion of genera 
Clostridium, Bifidobacterium and Eubacterium was significantly increased (Figure 
3.2B and Table S.3.4). Bacteroides and Lactobacillus were not increased by either 
drug. Rather, lithium decreased the levels of Bacteroides, and valproate decreased 
Lactobacillus (Figure 3.2B).  
 
3.3 Lithium- and valproate-induced reduction in hepatic levels of taurine is 
accompanied by a decreased expression of taurine transporter TauT 
At the hepatic level, lithium and valproate had opposite effects on glyco-conjugated 
and tauro-conjugated BAs, which were significantly increased and decreased, 
respectively (Figure 3.3B). We hypothesised that the reduction in tauro-conjugated 
BAs might be due to a low availability of taurine in the liver and our data confirmed 
this hypothesis, as hepatic taurine was significantly decreased in both treatment groups 
(Figure 3.5A). The two transporters responsible for taurine uptake in the liver are Gat2 
and TauT (Kubo et al., 2016; Zhou et al., 2012), thus we measured the gene expression 
of these transporters to see whether they were affected by medications. Gat2 gene 
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expression was unaffected by either drug, while Taut2 was significantly decreased in 
the liver of both lithium- and valproate-treated rats (Figure 3.5B). We hypothesise 
that the increase in glyco-conjugated BAs in the liver (Figure 3.5B) might be due to 
a compensatory mechanism for the lack of tauro-conjugated BAs.  
 
 
Figure 3.5 Taurine levels in the liver. qRT-PCR analysis of taurine transporters in the 
liver. (A) Both lithium and valproate decrease the levels of taurine in the liver (KW p=0.000, 
U=0, p=0.000 for both drugs). (B) Both lithium and valproate decrease the gene expression of 
Taut (One-way ANOVA F(2;22)=12.01, p<0.001; t-test p<0.01 for lithium, p<0.001 for 
valproate). Gat2 is not affected. Data are expressed as mean + SEM. *p<0.05 (n=7-8/group).   
 
3.4 Intestinal and hepatic regulation of bile synthesis and transport is altered by 
lithium and valproate administration  
Given that the levels of circulating bile acids were significantly influenced by both 
medications, we looked at the gene expression of enzymes and transporters involved 
in bile acid synthesis and transport in the liver and ileum. The entero-hepatic 
circulation of BA and the negative-feedback regulation of BA synthesis is a complex 
system. The relevance of genes analysed in this section is described schematically in 
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Figure 3.1. Bile acid composition strongly influences FXR activation (Degirolamo et 
al., 2014; Vaquero et al., 2013) thus we examined the gene expression of key 
downstream FXR targets. Although the expression of FXR itself was not altered in the 
liver, two crucial enzymes involved in bile acid synthesis, CYP7A1 and CYP27A1 
were both increased by lithium and valproate (Figure 3.6A). Despite the fact that FXR 
was unchanged, the expression of the repressor Shp was increased by valproate 
(Figure 3.6A). Hmgcr, the rate-limiting enzyme responsible to produce cholesterol in 
the liver, was increased by valproate but not lithium (Figure 3.6A). There was no 
change in the hepatic levels of transporters Mrp2, Bsep and Ntcp (being Ntcp the main 
responsible for the reuptake of BA in the liver); however, the expression of the minor 
transporters Mrp3 and Mrp4 was differentially increased by the two drugs (Figure 
3.6B). In the ileum, surprisingly, the expression of the repressor Fgf19 was 
dramatically depleted in both treatment groups, despite an increase in the expression 
of FXR (Figure 3.6C), suggesting a blunted ability to repress target gene expression. 
Ilbp was decreased in both treatment groups and the transporter Asbt was increased 
following valproate administration (Figure 3.6D). In addition, we measured the levels 
of circulating Fgf19, as this factor is inversely correlated to bile acid synthesis 
(Gälman et al., 2011; Lundasen et al., 2006; Pattni et al., 2012). Although lithium- and 
valproate-treated rats showed a decrease in circulating Fgf19, the difference from 
control animals was not significant (Fig. S.3.4). 
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Figure 3.6 qRT-PCR analysis of genes involved in bile acid synthesis and transport 
pathways in the liver and ileum. (A) Both lithium and valproate increase the gene expression 
of CYP7A1 (KW p=0.000, U=1, p=0.002 for lithium; KW p=0.000, U=0, p=0.001 for 
valproate) and CYP27A1 (One-way ANOVA F(2;22)=19.62, p<0.001; t-test p=0.028 for 
lithium, p=0.000 for valproate). Valproate increases the gene expression of Shp (One-way 
ANOVA F(2;23)=2.35, p<0.05; t-test p=0.013) and Hmgcr (One-way ANOVA F(2;21)=5.23, 
p<0.05; t-test p=0.010). (B) Both lithium and valproate increase the gene expression of Mrp3 
(One-way ANOVA F(2;22)=11.83, p<0.001; t-test p=0.011 for lithium, p=0.000 for valproate). 
Valproate increases the gene expression of Mrp4 (One-way ANOVA F(2;23)=4.74, p<0.05; t-
test p=0.013). (C) Both lithium and valproate decrease the gene expression of Fgf19 (KW 
p=0.000, U=9, p=0.002 for lithium; KW p=0.000, U=2, p=0.002 for valproate). Valproate 
increases the gene expression of Fxr (One-way ANOVA F(2;22)=7.51, p<0.001; t-test p=0.000). 
(D) Lithium decreases the gene expression of Ilbp (One-way ANOVA F(2;23)=6.62, p<0.001; 
t-test p=0.000). Valproate decreases the gene expression of Asbt (One-way ANOVA 
F(2;23)=14.34, p<0.001; t-test p=0.000). Data are expressed as mean + SEM. *p<0.05 (n=7-
8/group).    
 
3.5 Targeted gene expression does not suggest liver or ileum inflammation 
following lithium and valproate administration  
The marked increase in circulating and hepatic levels of bile acids suggested that the 
liver of lithium- and valproate-treated rats might be damaged or inflamed (Allen et al., 
2011). For this reason, we assessed the gene expression of pro-inflammatory and pro-
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fibrosis mediators in the liver and in the ileum. However, gene expression of target 
factors did not suggest inflammation in either liver or ileum level (Figure 3.7A,C). 
Tnf-α was significanlty decreased in the ileum of valproate-treated rats. Moreover, 
liver enzymatic function, measured via circulating levels of alanine aminotransferase  
(ALT) and aspartate transaminase (AST) was not disrupted in drug-treated rats 
(Figure 3.7B).  
 
 
Figure 3.7 qRT-PCR analysis of genes involved in inflammation, fibrosis and hepatic 
enzymatic function. (A) None of the treatments induce inflammation or fibrosis in the liver 
as assessed by gene expression. (B) None of the treatments alter hepatic enzymatic activity as 
assessed by AST (aspartate transaminase) and ALT (alanine aminotransferase) plasma levels. 
(C) Valproate decreases the gene expression of Tnf-α in the ileum (KW p=0.039, U=5, 
p=0.008). Data are expressed as mean + SEM. *p<0.05 (n=7-8/group).   
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3.6 Bile acid dysregulation by lithium and valproate is independent of changes in 
intestinal permeability    
In distal ileum, bile acids are absorbed into the enterocytes through the apical 
transporter Asbt and in turn activate a negative feedback response to the liver (Figure 
3.1). We hypothesised that abundant levels of BAs in circulation might be the result 
of functional deficits at the ileum level. Here, as a result of disrupted barrier function, 
BAs could bypass the enteric wall and be passively reabsorbed in circulation, failing 
to activate the negative feedback loop to the liver. To characterise epithelial 
permeability in the distal ileum, we measured the efficacy of macromolecular 
diffusion across the epithelium ex vivo (4 kDa FITC flux). We also assessed changes 
in ion conductance (transepithelial electrical resistance, TEER). To minimize the 
influence of the intrinsic neuromuscular system, we performed seromuscular 
stripping: the serosa (visceral peritoneum) and the longitudinal/circular muscle layers 
of the intestinal wall were removed, leaving only the underlying submucosal elements, 
remnants of muscle and the epithelium. At translational concentrations of the two 
drugs (see Figure S.3.2 for calculation of these), the intestinal permeability was not 
disrupted (Figure 3.8A,B). Valproate at a concentration of 100 mM significantly 
increased the permeability to macromolecules (Figure 3.8A) and decreased TEER 
(Figure 3.8B), suggesting a disruption in barrier function (less tight). Short-circuit 
current (Isc), a measure positively correlated with active absorption of Na
+ from the 
lumen (Tai et al., 1977), was increased by valproate 100 mM and decreased by lithium 
50 mM (Figure 3.8B). 
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Figure 3.8 Dose-dependent effects of lithium and valproate on permeability in distal 
ileum. (A) Valproate at a concentration of 100 mM increased FITC paracellular permeability. 
(B) Valproate at a concentration of 100 mM decreased transepithelial resistance (TEER) and 
increased short-circuit current (Isc). Lithium at a concentration of 50 mM decreased short-
circuit current (Isc). Data were analysed with a mixed between-within subjects ANOVA. 
Statistics: Panel A F(5;225)=164.88, p<0.001 for the effect of Time, F(4;45)=4.18, p<0.01 for the 
effect of Treatment, F(20;225)=7.82, p<0.001 for the Time×Treatment interaction. Panel B-
TEER F(5;220)=196.75, p<0.001 for the effect of Time, F(4;44)=5.14, p<0.01 for the effect of 
Treatment, F(20;220)=3.07, p<0.001 for the Time×Treatment interaction. Panel B-Isc 
F(5;220)=58.67, p<0.001 for the effect of Time, F(4;44)=29.31, p<0.001 for the effect of 
Treatment, F(20;220)=16.49, p<0.001 for the Time×Treatment interaction. Mean values in each 
time point were further compared to the vehicle with unpaired t-test. Statistical outcomes for 
the t-test are described in Supplemental Material. Data are expressed as mean + SEM. *p<0.05 
(n=10/group).  
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Discussion 
There is increasing focus on the role of the gut microbiota in drug efficacy and toxicity 
(Li et al., 2016; Walsh et al., 2018; Wilson and Nicholson, 2009; Zimmermann et al., 
2019a). The term pharmacomicrobiomics was recently coined to indicate the effect of 
microbiome variations on drug disposition, action, and toxicity (ElRakaiby et al., 
2014; Rizkallah et al., 2010). In this study we show that the mood stabilisers lithium 
and valproate increase many BA species in circulation, in the colon content and the 
liver. These changes were accompanied by an increase in some key intestinal bile acid-
metabolising bacteria, mainly belonging to the Firmicutes phylum. Lithium and 
valproate also altered substantially the gene expression of enzymes and transporters 
involved in bile acid metabolism. Two possible mediators of such effects, liver 
damage and disruption of intestinal permeability, did not seem to play a role in these 
drug-mediated bile effects. Taurine levels in the liver, circulation and colon content 
were markedly decreased by lithium and valproate administration. While some 
knowledge already existed on the effects of lithium and valproate on bile acid 
composition (Kersten and Barth, 1985; Watkins and Klaassen, 1981), here we employ 
a more comprehensive approach, taking into account the microbiota-gut-liver axis and 
examining microbial taxa which might play a role in BA metabolism. 
We have recently shown that a four weeks administration of psychotropic drugs to 
adult rats significantly altered the gut microbiota composition (Cussotto et al., 2019b). 
Here we drill deeper into this dataset to show that specific bile-metabolising taxa 
(having BSH and 7α-dehydroxylase activity), such as Clostridium, Bifidobacterium 
and Eubacterium were significantly increased in the circulation of rats undergoing 
lithium and valproate treatment (Figure 3.2B). These microbial changes were 
accompanied by important changes in BA composition. Independent of BA class 
(primary, secondary or tertiary), and with the exception of tauro-conjugated BAs, all 
BAs were significantly increased by lithium and valproate administration (Figure 
3.2A). FXR is a highly specific BA receptor that is activated by the BAs CDCA, DCA 
and LCA at physiological concentrations to directly stimulate the transcription of 
genes that mediate BA transport and synthesis, inhibiting CYP7A1 and CYP27A1 
transcription (Figure 3.1) (Zhang and Chiang, 2001). We therefore measured target 
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FXR genes involved in BA synthesis and transport in the gut-liver axis. The dominant 
feedback pathway leading to repression of CYP7A1 is via FXR-mediated activation of 
Fgf19 (Figure 3.1). Despite an increase in FXR agonist BAs, we observed a failure in 
the FXR-Fgf19 pathway to appropriately feedback to the liver and stop the de novo 
synthesis of BAs, reflected by an increase in both CYP7A1 and CYP27A1 gene 
expression. Strikingly, Fgf19 gene expression was completely inhibited by both drugs 
(Figure 3.6). The Fgf19 depletion was unexpected, particularly in the presence of high 
levels of CDCA, a strong FXR agonist (Soisson et al., 2008), in the circulation and the 
liver. For compensatory mechanisms, primary and secondary bile acids are often 
inversely correlated such that an increase in primary would correspond in a decrease 
in secondary/tertiary and vice versa. This was not observed in our study, as all BA 
species were increased, and no compensatory mechanisms seemed to occur. Regarding 
conjugated BAs, however, while glyco-conjugated species were increased, tauro-
conjugated were often unaltered or decreased, which was reflective of low levels of 
taurine in all compartments. The decrease in the expression levels of ileal lipid-binding 
protein Ilbp (Figure 3.6D) was also reflective of an impaired negative feedback 
mechanism, being Ilbp vital for the maintenance of bile acid homeostasis in the 
enterohepatic circulation (Praslickova et al., 2012). 
Evidence suggests that psychotropic medications can bear a certain degree of 
hepatotoxicity (Sedky et al., 2012; Selim and Kaplowitz, 1999; Telles-Correia et al., 
2017). With such high levels of circulating BAs, we hypothesised that the liver or 
distal ileum (site of reabsorption of BAs) might be damaged and we assessed the 
expression of genes involved in inflammation and fibrosis. According to gene 
expression levels, neither the liver nor the intestine showed signs of inflammatory state 
(Figure 3.7). On the contrary, the expression of Tnf-α, a cytokine involved in systemic 
inflammation, was decreased in the intestine of valproate-treated rats. It was recently 
shown that UDCA attenuates the release of pro-inflammatory cytokines from colonic 
epithelial cells in vitro and it is protective against the development of colonic 
inflammation in vivo (Ward et al., 2017). The anti-inflammatory activity of UDCA 
also acts in the liver (Rodrigues et al., 1998). Thus, high levels of UDCA in circulation 
and colon content might be exerting an anti-inflammatory effect. Whether UDCA is 
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the main mediator of anti-inflammatory effects and how this counteracts with the 
increase in other BA species remains unclear.  
We then hypothesized a different mechanism, at the ileum level, which might be 
responsible for the disruption of the negative feedback loop: the intestinal barrier 
potentially loosened by lithium and valproate might allow BAs to be passively 
absorbed into circulation and therefore fail to activate Fgf19. To assess this, we 
measured intestinal permeability to macromolecules and ions in an ex vivo setting 
employing Ussing chambers. Following seromuscular stripping, distal ileum tissue 
from naïve rats was tested in a dose-curve response with exposure to a low and high 
dose of each drug. Unexpectedly, translationally relevant doses of lithium and 
valproate (5 mM and 10 mM, respectively) did not exert any effect on permeability 
(Figure 3.8). However, a log fold higher dose of valproate increased permeability to 
FITC and decreased TEER, implying an increase in intestinal permeability. Short-
circuit current (Isc), which is positively correlated to the active absorption of Na
+ from 
the lumen (Tai et al., 1977), was increased by valproate 100 mM and decreased by 
lithium 50 mM, both non-translational doses. A possible limitation of the ex vivo 
experiment is that the drugs were tested acutely at a given dose, while the animals that 
showed drug-induced BA alterations did receive a chronic treatment. However, in our 
previous study we did assess intestinal permeability on tissue collected after chronic 
treatment with lithium and valproate (with the difference that there was no 
seromuscular stripping) and the two drugs did not affect permeability in distal ileum 
(Cussotto et al., 2019b). These data altogether suggest that the disruption in BA 
feedback loop is independent of changes in intestinal permeability.  
It is worth noting that we observed a decreased body weight in animals receiving 
lithium and valproate (Figure S.3.3). This finding is not in accordance with clinical 
human observations, as usually these two medications induce body weight gain 
(Martin et al., 2009; Peselow et al., 1980). Interestingly, BAs might be able to function 
not only as regulators of BA homeostasis but also as general metabolic integrators. In 
fact, a recent study has shown that bile acid signalling through TGR5 receptor 
promoted mitochondrial fission and beige remodelling of white adipose tissue 
(Velazquez-Villegas et al., 2018). Corroborating these findings, a different study has 
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shown that administration of BAs to mice increased energy expenditure in brown 
adipose tissue, preventing obesity and resistance to insulin (Watanabe et al., 2006). 
Thus, the decrease in bodyweight, epididymal fat and levels of circulating triglycerides 
observed in lithium- and valproate-treated rats (Figure S.3.3) might be the result of 
massively increased levels of circulating BAs. We hypothesized also the opposite 
assumption, i.e. the decrease in body weight caused an increase in circulating BAs. 
This, however, is probably not the case, as studies in humans have proved that body 
weight gain and levels of total BAs are positively correlated (Alemán et al., 2018; 
Prinz et al., 2015). It is important to remember that there is an intricate link between 
bile acids, Fgf19, FXR and body weight. In mice fed a high-fat diet, Fgf19 
administration reduced the body weight and improved metabolic function (Fu et al., 
2004). Moreover, Fgf19 also plays a role in regulating food intake and appetite (Ryan 
et al., 2013).  
Following de novo production of BAs, the final step prior to secretion in the intestine 
consists of the conjugation of BAs to either glycine or taurine, a process that increases 
their solubility for secretion into biliary fluid (Figure 3.1). Hydrophobic conjugated 
BAs represent the highest proportion of hepatic BAs. Interestingly, we noticed that 
lithium and valproate induced a strong decrease in hydrophobic tauro-conjugated BAs 
in the liver. This effect was probably the result of low availability of hepatic taurine, 
which was decreased ten-fold in comparison to control animals (Figure 3.5A). We 
hypothesized that lithium and valproate may have depleted the hepatic pool of taurine 
available for BA conjugation, resulting in an increase in glycine conjugation for 
compensatory mechanism (Figure 3.4B, note that hydrophobic glyco-conjugated BAs 
are increased). Intrigued by these findings, we measured the gene expression of two 
crucial transporters responsible for the uptake of taurine in the liver, Gat2 and TauT 
(Figure 3.5B). Lithium and valproate reduced the expression of the taurine transporter 
TauT, explaining the reduction in hepatic taurine levels and subsequent reduction in 
tauro-conjugated BAs. Taurine is an organic compound widely distributed in animal 
tissues with many fundamental biological roles, including antioxidation (Jong et al., 
2012; Yildirim and Kilic, 2011), osmoregulation (Schaffer et al., 2000), cardiovascular 
function (Schaffer et al., 2010; Xu et al., 2008) and brain function (Wu and Prentice, 
2010). Taurine can cross the blood-brain barrier (Salimäki et al., 2003; Tsuji and 
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Tamai, 1996; Urquhart et al., 1974) and produces a central anxiolytic effect, probably 
through activation of the glycine receptor (Kong et al., 2006; Zhang and Kim, 2007). 
In our animals treated with lithium and valproate, taurine was depleted not only in the 
liver but also in circulation (Table S.3.1), potentially causing a shortage in distal 
tissues such as the central nervous system. Importantly, the two transporters TauT and 
Gat2 are also responsible for the uptake of the neurotransmitter GABA. However, 
TauT is reported to have lower affinity (1.5 mM) for GABA than Gat2 (<80 µM) 
(Borden, 1996; Tomi et al., 2008), therefore we  suppose that the reduced expression 
of TauT did not impact GABAergic uptake and function. A few studies have looked 
at the effects of taurine on gut microbiota composition; however, the results to date 
are conflicting and certainly not conclusive (Sasaki et al., 2017; Yu et al., 2016). Some 
evidence exists on how the mood stabilisers lithium and valproate can influence brain 
levels of taurine (Anyanwu and Harding, 1993; Pettegrew et al., 2001) and here we 
hypothesize a mechanism that is linked to inhibition of the transporter TauT, which is 
also expressed in the brain (Pow et al., 2002). Future studies investigating the 
relationship between psychotropic drug action and taurine levels are now warranted. 
There are some limitations of the current study worth noting. Changes in body weight 
have been previously associated to microbiome variations (Duncan et al., 2008; 
Remely et al., 2015; Santacruz et al., 2009). Although we hypothesise that the 
decreased bodyweight might be due to the fat-burning and metabolism-regulating 
properties of BAs, a food intake record of the animals is not provided, therefore we 
cannot rule out a possible association between weight loss and microbiome 
composition. Regarding the classification of BA-metabolising bacteria, a limitation of 
16S sequencing consists in detecting microorganisms at genus level, without allowing 
investigation of individual species. Throughout the study, we assume that the 
abundance of a BA-metabolising genus will be positively correlated to its relevant BA-
metabolising species, however a more targeted approach with shotgun sequencing is 
warranted to confirm our results at species level. 
Interestingly, antibiotic administration in mice has been shown to induce BA 
dysmetabolism and impaired activation of the intestinal FXR/Fgf19 axis with elevated 
CYP7A1 gene expression (Sayin et al., 2013), thus corroborating the idea that the gut 
  120  
 
microbiota plays a role in BA composition. At this stage we cannot, however, define 
the direction and/or causality of the microbiota-bile interaction. One common property 
the two drugs share is their HDAC (histone deacetylase) inhibition ability (Krämer et 
al., 2003; Wu et al., 2013). Thus, it is not odd to suppose that lithium and valproate 
might block, at epigenetic level, the activation of downstream targets of FXR such as 
Fgf19 and Ilbp; and more research is warranted to investigate this hypothesis. 
Provocatively, both psychotropic medications targeted a similar pattern of microbial 
species, despite their differences in chemical structure and mechanism of action in the 
brain. This raises the possibility that the microbial action may manifest as side effect 
or mechanism of action of these drugs. Interestingly, this concept was also 
hypothesized by Maier and colleagues with regards to antipsychotics, a class of 
psychotropics that clustered together on the microbiome despite differences in 
chemical structure (Maier et al., 2018). 
In conclusion, in the present study we have demonstrated that the mood stabilisers 
lithium and valproate induce a bile acid and taurine dysmetabolism which is consistent 
with changes in key bile acid-metabolising genera in the gut. These data highlight the 
importance of examining the effects of psychotropic drugs on the microbiome and the 
microbiota-gut-liver axis, beside the well characterised effects exerted in the central 
nervous system. Future studies are warranted to examine the causality and direction 
of the interaction between drug-induced changes in microbiota and changes in bile, as 














Table S.3.1 Bile acids levels in the plasma of rats treated with different psychotropic medications (ng/mL) 









Unconjugated bile acids 
α/ω-Muricholic acid α/ω-MCA 
513.6 (548.1) 9711 (16567) [0.0138] 
* 
6041 (7952) [0.0086] 
* 
β-Muricholic acid βMCA 
435.8 (557.3) 1987 (2684) [0.0396] 
* 
2995 (3603) [0.0103] 
* 
Chenodeoxycholic acid CDCA 




Cholic acid CA 




Deoxycholic acid DCA 
381.2 (402.1) 1857 (1682) [0.0086] 
* 
1012 (1440) [0.0327] 
* 
Hyocholic acid HCA 
215.6 (244.8) 1722 (1096) [0.0121] 
* 
1404 (1208) [0.0069] 
* 
Hyodeoxycholic acid HDCA 




Lithocholic acid LCA 
13.13 (3.684) 108 (349.14) [0.0052] 
* 
35.08 (43.96) [0.0034] 
* 
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Ursodeoxycholic acid UDCA 
34.51 (19.01) 486.8 (935.3) [0.0069] 
* 
378.7 (310.8) [0.0052] 
* 
Tauro-conjugated bile acids 
Taurochenodeoxycholic acid TCDCA 
65.99 (33.46) 87.11 (61.78)    41.12 (22.48) [0.0396] 
* 
Taurocholic acid TCA 233.4 (153.2) 92.6 (156.05)    218.9 (140.1)  
Taurodeoxycholic acid TDCA 
84.07 (60.35) 24.5 (21.51) [0.0448] 
* 
19.95 (20.88) [0.0362] 
* 
Taurohyocholic acid THCA 2.257 (2.755) 1.528 (1.381)     2.013 (3.811)  
Taurohyodeoxycholic acid THDCA 8.422 (4.441) 8.977 (3.583)     6.213 (4.127)  
Taurolithocholic acid TLCA 
1.678 (0.644) 5.707 (2.002) [0.0172] 
* 
1.573 (1.63)  
Tauromuricholic acid TMCA 367.2 (231.9) 382.4 (322)    349.4 (149.8)  
Tauroursodeoxycholic acid TUDCA 8.32 (4.067) 7.79 (11.386)    4.97 (2.663)  
Glyco-conjugated bile acids 
Glycochenodeoxycholic acid GCDCA 
5.104 (6.969) 275.9 (443.94) 
[0.0189] * 
52.01 (81.08) [0.0396] 
* 
Glycocholic acid GCA 
112.2 (116.81) 819.5 (1092.7) 
[0.0207] * 
748.9 (339.7) [0.0155] 
* 
Glycodeoxycholic acid GDCA 
12.33 (18.624) 246 (116.3) [0.0224] * 92.31 (115.01) 
[0.0172] * 
Glycohyocholic acid GHCA 
5.432 (11.405) 29.33 (37.12) [0.0431] 
* 
8.545 (12.792)  
Glycolithocholic acid GLCA 
0.7683 (0.674) 6.587 (7.767) [0.0345] 
* 
1.317 (0.988)  
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Glycoursodeoxycholic acid GUDCA 





Taurine (ng/mL)  





Data that did not satisfy homogeneity of variance and/or normality: * p<0.05, Kruskal-Wallis nonparametric test followed by Mann-Whitney U test. Reported 
is the Benjamini-Hochberg critical value [(i/m)Q] with a Q (false-discovery rate) of 0.05.  
Data that satisfied homogeneity of variance and normality: # p<0.05 one-way ANOVA. Reported is the p value of Dunnett’s t-test VS vehicle. 
N=7-8/group. Red indicates an increase; blue indicates a decrease in plasma bile acids levels compared to vehicle. 
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Table S.3.2. Bile acids levels in the colon content (faeces) of rats treated with lithium and valproate (ng/mg) 




Median (IQR) [(i/m)Q] 
Valproate 
Median (IQR) [(i/m)Q] 
Unconjugated bile acids 
α/ω-Muricholic acid α/ω-MCA 433.2 (215.9) 637.3 (330.7) [p=0.041] # 664.8 (520.9) [p=0.035] # 
β-Muricholic acid βMCA 113 (65.21) 127.7 (61.6)  241.5 (293.3) [0.0458] * 
Chenodeoxycholic acid CDCA 2.7 (2.767) 9.543 (10.384) [0.0251] * 7.089 (16.311) [0.0375] * 
Cholic acid CA 2.562 (1.775) 6.28 (2.788) [0.0319] * 8.093 (6.326) [0.0250] * 
Deoxycholic acid DCA 220.7 (107.5) 436.2 (167.2) [0.0028] * 393.2 (411.2) [0.0417] * 
Hyocholic acid HCA 3.797 (6.005) 8.722 (5.454)  3.214 (5.675)  
Hyodeoxycholic acid HDCA 13.53 (21.901) 52.62 (27.09) [0.0347] * 37.79 (9.94) [0.0306] * 
Lithocholic acid LCA 13.66 (4.2) 65.87 (39.97) [0.0014] * 18.61 (10.34) [0.0444] * 
Ursodeoxycholic acid UDCA 2.407 (1.126) 12.4 (11.112) [0.0333] * 1.762 (8.361)  
Tauro-conjugated bile acids 
Taurochenodeoxycholic acid TCDCA 0.7492 (0.3443) 0.5961 (0.4235)  0.1601 (0.2484) [0.0208] * 
Taurocholic acid TCA 4.29 (1.667) 0.6898 (0.0873) [0.0056] * 0.7219 (0.4819) [0.0028] * 
Taurodeoxycholic acid TDCA 2.102 (0.767) 0.4165 (0.3691) [0.0069] * 0.1697 (0.1481) [0.0056] * 
Taurohyocholic acid THCA 0.1386 (0.0728) 0.1012 (0.0285)  0.1479 (0.0847)  
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Taurohyodeoxycholic acid THDCA 0.1761 (0.069) 0.1148 (0.0674) [0.0403] * 0.0824 (0.0157) [0.0069] * 
Taurolithocholic acid TLCA 0.1822 (0.0803) 0.1211 (0.0837)  0.0366 (0.0155) [0.0042] * 
Tauromuricholic acid TMCA 12.07 (6.861) 2.392 (1.12) [0.0083] * 1.943 (1.917) [0.0083] * 
Tauroursodeoxycholic acid TUDCA 0.4522 (0.1541) 0.2738 (0.1542)  0.1407 (0.0614) [0.0181] * 
Glyco-conjugated bile acids 
Glycochenodeoxycholic acid GCDCA 0.0477 (0.0153) 0.7781 (0.1506) [0.0278] * 0.2149 (0.2142) [0.0208] * 
Glycocholic acid GCA 0.3905 (0.5762) 2.606 (0.819) [0.0097] * 2.287 (1.276) [0.0222] * 
Glycodeoxycholic acid GDCA 0.0664 (0.035) 0.3664 (0.1206) [0.0292] * 0.2606 (0.426) [0.0278] * 
Glycohyocholic acid GHCA 0.0846 (0.024) 0.1409 (0.0637) [0.0417] * 0.1788 (0.061) [0.0292] * 
Glycolithocholic acid GLCA 0.01995 (0.0058) 0.0910 (0.0438) [0.0111] * 0.0334 (0.0342) [0.0389] * 
Glycoursodeoxycholic acid GUDCA 0.03471 (0.0332) 0.1239 (0.0901) [0.0125] * 0.06932 (0.0191) [0.0264] * 
 
Taurine (ng/mg)  54.31 (60.8) 4.764 (6.567) [0.0444] * 4.557 (2.114) [0.0472] * 
Data that did not satisfy homogeneity of variance and/or normality: * p<0.05, Kruskal-Wallis nonparametric test followed by Mann-Whitney U test. Reported 
is the Benjamini-Hochberg critical value [(i/m)Q] with a Q (false-discovery rate) of 0.05. Data that satisfied homogeneity of variance and normality: # p<0.05 
one-way ANOVA. Reported is the p value of Dunnett’s t-test VS vehicle. N=7-8/group. Red indicates an increase; blue indicates a decrease in plasma bile acids 
levels compared to vehicle. 
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Table S.3.3 Bile acids levels in the liver of rats treated with lithium and valproate (ng/mg) 




Median (IQR) [(i/m)Q] 
Valproate 
Median (IQR) [(i/m)Q] 
Unconjugated bile acids 
α/ω-Muricholic acid α/ω-MCA 0.287 (0.3761) 2.651 (16.155) [0.0083] * 5.090 (2.871) [0.0117] * 
β-Muricholic acid βMCA 0.3029 (1.0848) 1.552 (7.5656) [0.0450] * 5.471 (5.31) [0.0133] * 
Chenodeoxycholic acid CDCA 0.02844 (0.0364) 0.2859 (0.674) [0.0033] * 0.1207 (0.2396) [0.0033] 
Cholic acid CA 0.649 (0.7545) 1.906 (3.867) [0.0433] * 9.087 (9.209) [0.0050] * 
Deoxycholic acid DCA 0.06368 (0.0728) 0.1332 (0.1108) [p=0.026] # 0.1599 (0.1121) [p=0.022] # 
Hyocholic acid HCA 0.2151 (0.2957) 1.060 (1.2973) [0.0350] * 3.405 (4.893) [0.0100] * 
Hyodeoxycholic acid HDCA 0.0091 (0.0089) 0.087 (0.3059) [0.0050] * 0.1012 (0.0464) [0.0067] * 
Lithocholic acid LCA 0.00546 (0.00284) 
0.01052 (0.00769) [p=0.010] 
# 
0.0086 (0.00618) 
Ursodeoxycholic acid UDCA 0.02014 (0.0158) 0.1070 (0.4678) [0.0383] * 0.04171 (0.0342) [0.0467] * 
Tauro-conjugated bile acids 
Taurochenodeoxycholic acid TCDCA 9.301 (4.719) 16.08 (6.45) [p=0.001] # 4.019 (4.184) [p=0.014] # 
Taurocholic acid TCA 68.31 (4.07) 41.50 (17.7) [p=0.000] # 32.95 (5.18) [p=0.000] # 
Taurodeoxycholic acid TDCA 11.17 (5.112) 4.767 (5.161) [p=0.000] # 2.761 (2.076) [p=0.000] # 
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Taurohyocholic acid THCA 0.2239 (0.0808) 0.2686 (0.1989)  0.07879 (0.0242) [0.0283] * 
Taurohyodeoxycholic acid THDCA 0.5304 (0.2369) 0.8630 (0.6109) [0.0467] * 0.2201 (0.122) [0.0183] * 
Taurolithocholic acid TLCA 0.06486 (0.0479) 0.3092 (0.1653) [0.0117] * 0.03216 (0.0503) [0.0500] * 
Tauromuricholic acid TMCA 97.42 (49.19) 76.75 (17.78) [p=0.039] # 37.21 (23.48) [p=0.000] # 
Tauroursodeoxycholic acid TUDCA 2.12 (0.308) 2.884 (1.179) [p=0.028] # 0.5649 (0.4501) [p=0.000] # 
Glyco-conjugated bile acids 
Glycochenodeoxycholic acid GCDCA 0.1075 (0.0184) 14.70 (10.432) [0.0150] * 1.795 (2.219) [0.0300] * 
Glycocholic acid GCA 3.046 (3.084) 64.05 (23.26) [0.0167] * 26.15 (10.22) [0.0317] * 
Glycodeoxycholic acid GDCA 0.2062 (0.1313) 8.677 (4.681) [0.0200] * 2.764 (3.624) [0.0350] * 
Glycohyocholic acid GHCA 0.0564 (0.0168) 4.132 (3.11) [0.0233] * 0.5586 (0.6213) [0.0383] * 
Glycolithocholic acid GLCA 0.00161 (0.00145) 0.1066 (0.1591) [0.0133] * 0.01096 (0.0112) [0.0200] * 
Glycoursodeoxycholic acid GUDCA 0.02697 (0.0056) 1.781 (2.139) [0.0183] * 0.2489 (0.252) [0.0333] * 
 
Taurine (ng/mg)  85.94 (61.4) 13.09 (5.02) [0.0017] * 16.11 (3.5) [0.0017] * 
Data that did not satisfy homogeneity of variance and/or normality: * p<0.05, Kruskal-Wallis nonparametric test followed by Mann-Whitney U test. Reported 
is the Benjamini-Hochberg critical value [(i/m)Q] with a Q (false-discovery rate) of 0.05. Data that satisfied homogeneity of variance and normality: # p<0.05 
one-way ANOVA. Reported is the p value of Dunnett’s t-test VS vehicle. N=7-8/group. Red indicates an increase; blue indicates a decrease in plasma bile acids 
levels compared to vehicle.
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p (i/m)Q p (i/m)Q 
Clostridium Sensu Stricto (Firmicutes) 
0.000 * 0.0027211 * 0.007 * 0.016327 * 
Peptoclostridium (Firmicutes) 
0.000 * 0.0013605 * 0.000 * 0.002721 * 
Ruminiclostridium (Firmicutes) 
0.005 * 0.0217687 * 0.028 * 0.031293 * 
Bifidobacterium (Actinobacteria) 
0.0000 * 0.0040816 * 0.000 * 0.004082 * 
Eubacterium oxidoreducens 
(Firmicutes) 
0.003 * 0.0190476 * 0.001 * 0.009524 * 
Eubacterium coprostanoligenes 
(Firmicutes) 
0.001 * 0.0122449 * 0.003 * 0.012245 * 
Bacteroides (Bacteroidetes) 
0.021 * 0.0380952 * 0.382 0.09932 
Lactobacillus (Firmicutes) 
0.083 0.06531 0.000 * 0.001361 * 
 
*p<<0.05, Mann-Whitney U test, Benjamini-Hochberg critical value [(i/m)Q] with a Q (false-discovery rate) of 0.2. N=8/group. Red indicates an increase; 
blue indicates a decrease in the relative abundance of bacterial taxa compared to vehicle.  
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Table S.3.5 List of SybrGreen probes used in the study 
Gene Common gene name 
Sequence (5’ → 3’) 
left 
Sequence (5’ → 3’) 
right 
Acta2 Alpha-actin-2 CCAGTCGCCATCAGGAAC TGTGCTGTCTTCCTCTTCACA 













Apical sodium-dependent bile acid transporter 
Bile salt export pump 
Apical sodium-dependent bile acid transporter 
Cytochrome P450 family 7 subfamily A member 1 
Cytochrome P450 family 7 subfamily B member 1 
Cytochrome P450 family 27 subfamily A member 1 
Fibroblast growth factor 19 
Farnesoid X receptor 
3-hydroxy-3-methylglutaryl-CoA reductase 
Ileal lipid-binding protein 






































Interleukin 10  
Multidrug resistance-associated protein 2 
Multidrug resistance-associated protein 3 
Multidrug resistance-associated protein 4 
Myeloid differentiation primary response 88 
Na+/taurocholate cotransporting polypeptide 
Organic solute transporter alpha subunit 
Organic solute transporter beta subunit 
Small heterodimer partner 
Superoxide dismutase 2 
Toll-like receptor 4 
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SUPPLEMENTAL FIGURES 
Figure S.3.1 Experimental timeline. Abbreviations: BA bile acid, BW body weight. 
 
Figure S.3.2 Dose calculation of lithium and valproate for the assessment of intestinal 
permeability ex vivo. Abbreviations: BW body weight, MW molecular weight. Reference for 
assumption 1: (Al-Ansari et al., 2002). Reference for assumption 2: (Sidlo et al., 1995). 
References for assumption 3: (Baer, 1973) and (Gugler and von Unruh, 1980). 
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Figure S.3.3 Body weight and fat content. (A) Change in body weight throughout the 
experiment. Administration of lithium and valproate significantly decreases the body weight. 
A mixed between-within subjects ANOVA revealed a significant effect for Time 
[F(4;196)=250.06, p<0.001], Treatment [F(6;49)=14.15, p<0.001] and a Time × Treatment 
interaction [F(24;196)=12.75, p<0.001]. Lithium and valproate induced a decrease in body 
weight on weeks 1, 2, 3 and 4 (all p<0.001). (B) Epididymal white adipose tissue content 
expressed as g/100g of body weight. Both lithium and valproate decrease the levels of 
epididymal fat (One-way ANOVA F(6;55)=13.237, p=0.000; t-test p=0.000 for lithium and 
p=0.020 for valproate). (C) Plasmatic levels of triglycerides expressed as mmol/L plasma. 
Both lithium and valproate decrease circulating levels of triglycerides (One-way ANOVA: 
F(2;23)=7.54, p=0.003; t-test p=0.004 for lithium and p=0.009 for valproate). Data are expressed 
as mean ± SEM. *p<0.05 (n=8/group).    
 
Figure S.3.4 Circulating plasma levels of Fgf19 measured by ELISA kit. Plasma was 
collected following centrifugation of trunk blood and stored at -80 ºC for further analysis. 
Triglycerides levels were determined by using the EnzyChromTM Triglyceride Assay kit 
(ETGA-200; BioAssay Systems). 
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SUPPLEMENTAL METHODS 
Caecal microbiota composition  
Caecum was harvested, snap frozen and stored at -80ºC prior to the analysis 
 
 Caecal content DNA extraction  
DNA extraction was performed using the QIAmp Fast DNA Stool Mini Kit (Qiagen, 
Sussex, UK) coupled with an initial bead-beating step. Briefly, 200 mg of each caecal 
sample were vortex-mixed in a 2 ml screw-cap tubes (Sarstedt, Wexford, Ireland) 
containing 0.25 g of a 1:1 mix of 0.1 mm and 1.0 mm sterile zirconia beads plus a 
single 3.5 mm diameter bead (BioSpec Products, Bartlesville, USA) with 1 ml of 
Qiagen InhibitEX® buffer. Following steps were according to manufacturer’s 
instructions. DNA was quantified using the QubitTM 3.0 Fluorometer (Bio-Sciences, 
Dublin, Ireland) and the Qubit® dsDNA HS Assay Kit (Life Technologies, Oregon, 
USA). Extracted DNA was kept frozen at -20ºC until further analysis. 
 
 16S rRNA Gene Sequence-based microbiota analysis  
The V3-V4 hypervariable region of the 16S rRNA gene were amplified and prepared 
for sequencing as outlined in the Illumina 16S Metagenomic Sequencing Library 
Protocol (http://www.illumina.com/content/dam/illumina-
support/documents/documentation/chemistry_documentation/16s/16s-metagenomic-
library-prep-guide-15044223-b.pdf). Briefly, first PCR was done using forward 
primer (5’- 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCA
G-3') and reverse primer (5’- 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATC
TAATCC-3'). Each 25 μl PCR reaction contained 5 ng/μl microbial genomic DNA, 1 
μM of each primer and 12.5 μl 2X Kapa HiFi Hotstart ReadyMix (Kapa Biosystems 
Ltd., UK). The PCR conditions follow as: initial denaturation at 95 ºC x 3 min; 25 
cycles of 95 ºC x 30 s, 55 ºC x 30 s, 72 ºC x 30 s; and 72 ºC x 5 min for final extension. 
PCR products were purified with Agencourt AMPure XP system (Beckman Coulter 
Genomics, Takeley, UK). In the next step, dual indices and Illumina sequencing 
adapters were attached to PCR products using the Nextera XT Index Kit (Illumina, 
San Diego, CA). Each 50 μl PCR reaction contained 5 μl purified DNA, 5 μl index 
primer 1 (N7xx), 5 μl index primer 2 (S5xx), 25 μl 2x Kapa HiFi Hot Start Ready mix 
and 10 μl PCR grade water. PCR amplification was completed using the previous 
program but with only 8 amplification cycles instead of 25. Following this, a second 
clean-up step with the Agencourt AMPure XP system was done. PCR products were 
quantified, normalized and pooled in an equimolar fashion using the Qubit® dsDNA 
HS Assay Kit (Life Technologies, Oregon, USA). Next steps in the library preparation 
were carried out by Teagasc Next Generation DNA Sequencing Facility (Teagasc, 
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Moorepark, Food Research Centre) prior to 2×250 (bp) paired-end sequencing on the 
Illumina MiSeq platform, using standard Illumina sequencing protocols. 
 
 Bioinformatic sequence analysis  
Bioinformatic sequence analysis was performed as previously described (Murphy et 
al., 2017). Briefly, paired-end sequences were assembled using FLASH (Magoč and 
Salzberg, 2011) and analysed using QIIME v1.8.0 (Quantitative Insights Into 
Microbial Ecology) (Caporaso et al., 2010). Sequences were quality checked and the 
remaining sequences were clustered into operational taxonomic units using 
USEARCH (v7-64bit) (Edgar, 2010). Taxonomic ranks were assigned with a BLAST 
search against the SILVA SSURef database release 123 (Quast et al., 2013). 
 
Bile acids levels in plasma and faecal material  
Bile acids were extracted according to Joyce et al. (Joyce et al., 2014). For the faeces, 
80 mg of faecal material was added to dynabeads (Roche) with 300 μl of ice cold 50% 
methanol containing deuterated internal standards of both Cholic acid and 
Chenodeoxycholic acid, then subjected to five  30 second rounds of extraction in a 
dyna-lyser machine (Roche) at 6000 rpm. For plasma extractions, 100 μl was mixed 
with 300 μl of ice cold 50% methanol also containing deuterated internal standards. 
Each mixture was vortexed and then centrifuged for 10 mins at 10000 g and the 
supernatant transferred to a fresh tube. Ice cold acetonitrile (ACN) with formic acid 
measuring 2 ml was added to each tube, vortexed and agitated at room temperature for 
1 hour.  Samples were centrifuged again to pellet the debris and the supernatant was 
added to fresh tubes containing 1 ml of ice cold 100 % ACN.  The samples were 
vortexed and dried under vacuum at +4°C. The dried extracted acids were re-
suspended in 150 μl of ice cold 50 % methanol. 
 
 Chemicals  
Standard Conjugated bile salts and free bile acids were purchased from Sigma Aldrich 
and from Steraloids, Inc. (Newport, Rhode Island).  HPLC-grade methanol, 
acetonitrile, water, ammonium acetate, ammonium formate, ammonium hydroxide, 
formic acid, and acetic acid and water were obtained from Fisher Scientific (Fair 
Lawn, NJ). Deuterated cholic acid (D-2452) and deuterated chenodeoxycholic acid 
(D-2772) were purchased from CDN Isotopes Inc.  Standards were constructed as 
1mg/ml stock solutions of individual sulfated BAs were prepared in water:MeOH 
(1:1).  They were subsequently combined to a final volume of 1.0 ml in water to give 
a stock concentration of 40 mg/ml for each.  Subsequent dilutions were made to which 
the same volume of deuterated standards was added.  Fatty acids were treated similarly 
  134  
 
but were resuspended in 100% methanol. These standards were utilized to create 
standard curves for each analyte examined (Table S4). 
 
 Ultra Performance Liquid Chromatography Tandem Mass Spectrometry  
UPLC-MS was performed using a modified method of Joyce et al. (Joyce et al., 2014). 
Briefly, 5μL from each sample were injected onto a C18 Acquity column (Waters 
Corp.). Each sample was run in triplicate. Extracts were eluted using a 25-min gradient 
of 100 % A to 100 % B (A, water, 0.1 % formic acid; B, acetonitrile, 0.1 % formic 
acid) at a flow rate of 500 μL/min and column temperature of 40°C. Samples were 
analyzed using an Acquity system (Waters Ltd.) coupled online to an LCT Premier 
mass spectrometer (Waters MS Technologies, Ltd.) in negative electrospray mode 
with a scan range of 50–1,000 m/z. Bile acids ionize strongly in negative mode, 
producing a prominent [M-H]− ion. Capillary voltage was 2.4 Kv, sample cone was 
35 V, desolvation temperature was 350°C, source temperature was 120°C, and 
desolvation gas flow was 900 L/h. Analysis was performed using Waters software 
Targetlynx for exact quantification against a standard curve for each analyte and 





Statistical output of the t-test related to Figure 8 (Dose-dependent effects of lithium 
and valproate on permeability in distal ileum) 
PANEL A (FITC): Valproate 100 mM  t(18)=-2.113, p<0.05 at 90min, t(18)=-3.183, 
p<0.01 at 120min, t(18)=-4.038, p<0.01 at 150min, t(18)=-4.232, p<0.01 at 180min. 
PANEL B (TEER): Valproate 100 mM  t(18)=2.053, p=0.055 at 60min, t(18)=3.511, 
p<0.01 at 90min, t(18)=4.538, p<0.001 at 120min, t(18)=5.118, p<0.001 at 150min, 
t(18)=5.873, p<0.001 at 180min 
PANEL B (Isc): Lithium 50 mM  t(17)=5.946, p<0.001 at 30min, t(17)=5.752, p<0.001 
at 60min, t(17)=3.437, p<0.01 at 90min, t(17)=4.97, p<0.001 at 120min, t(17)=5.2, 
p<0.001 at 150min, t(17)=4.837, p<0.001 at 180min. Valproate 100 mM  t(18)=-5.833, 
p<0.001 at 30min, t(18)=-5.178, p<0.001 at 60min, t(18)=-4.245, p<0.001 at 90min, 
t(18)=-5.798, p<0.001 at 120min, t(18)=-5.717, p<0.001 at 150min, t(18)=-5.497, 
p<0.001 at 180min 
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Abstract 
The role of the gut microbiome in drug absorption and metabolism has recently come 
under scrutiny. It remains poorly understood whether the gut microbiome influences the 
pharmacokinetic parameters of psychotropic drugs and thus potentially alters patient 
responses. In this study, we investigated the pharmacokinetics of two commonly 
prescribed antipsychotics, olanzapine and risperidone, in rats whose microbiota had been 
depleted with an antibiotic cocktail or following administration of the multi-strain 
probiotic VSL#3.  
The bioavailability of olanzapine, but not risperidone, was significantly increased in rats 
pre-treated with antibiotics. There was no direct effect of the microbiota depletion on the 
expression of CYP450 enzymes involved in antipsychotic metabolism, as assessed by RT-
qPCR and Western blotting. Tight junction transcript level in the duodenum revealed that 
gut barrier function was not affected by either probiotic or microbiota depletion. The 
antibiotics, however, significantly altered the metabolic activity of the gut microbiota 
including faecal β-glucuronidase and β-glucosidase activity. Among the bacterial genera 
detected by 16S sequencing, the relative abundance of Alistipes significantly correlated 
with the AUC in olanzapine- but not risperidone-treated rats, suggesting that this 
bacterium might play a role in the pharmacokinetic alterations observed for olanzapine.   
These results suggest that the gut microbiome is an important variable determining the 
bioavailability of orally administered olanzapine but not risperidone. Additional research 
is warranted to understand the implications and the role of the gut microbiota in the 
pharmacokinetics of olanzapine in humans, both in terms of the therapeutic and adverse 




Keywords: Antipsychotic, Microbiome, Pharmacokinetics, Diversity, AUC, CYP 
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Introduction 
The gut microbiome plays a pivotal role in dictating host physiology and health. In 
recent times, the gut microbiota is coming under increasing scrutiny as a potential 
determinant of drug pharmacokinetics (Clarke et al., 2019). The traditional role of the 
gut microbiome on drug pharmacokinetics was thought to be mostly limited to the re-
absorption of drug metabolites generated by the host (for example glucuronide 
conjugates) leading to prolonged half-life of some drugs.  Recent studies have 
highlighted how the microbiome may directly metabolise or degrade drugs 
(Zimmermann et al., 2019a). In addition, the microbiome can produce metabolites 
which compete with drugs for drug-metabolizing enzymes or can modulate the latter’s 
gene expression (Carmody and Turnbaugh, 2014; Clarke et al., 2019), albeit few 
studies to date have demonstrated a clinically significant change in drug 
pharmacokinetics (estimated to be >20% change in amount of drug reaching the 
systemic circulation) as a result of altered microbiome (European Medicines, 2010; 
Vertzoni et al., 2018). 
Previous work from our laboratory has linked the gut microbiome to alterations in drug 
pharmacodynamics; antibiotic-induced microbiota depletion attenuated olanzapine 
(OLZ)-associated metabolic dysfunction in rats (Davey et al., 2013; Davey et al., 
2012). This is consistent with studies in germ-free (GF) mice who do not gain weight 
following oral delivery of OLZ (Morgan et al., 2014). Although the mechanistic basis 
for this association is not yet settled, most attention has been placed on the 
antimicrobial effects of OLZ (Maier et al., 2018; Morgan et al., 2014). A similar role 
of the gut microbiome in risperidone (RISP)-associated metabolic side effects has also 
been suggested (Bahr et al., 2015b) and a recent meta-analysis of both animal and 
human studies linked antipsychotic-induced metabolic dysfunction to the gut 
microbiome (Skonieczna-Zydecka et al., 2018). The aim of this study was to further 
extend this research to assess whether perturbations to the gut microbiome could also 
alter the pharmacokinetic profile of these antipsychotics. 
OLZ and RISP are both centrally active, highly lipophilic BCS Class II drugs with 
comparable half-lives, that are widely used clinically (see Table 4.1). Although both 
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have been associated with microbiome-mediated weight gain in vivo (Bahr et al., 
2015b; Davey et al., 2013) and antimicrobial effects in vitro (Maier et al., 2018; 
Morgan et al., 2014), they exhibit some differences in pharmacokinetic profiles as well 
as chemical structure and microbiota exposure. OLZ is well absorbed after oral 
administration and is cleared primarily via hepatic metabolism, with less than 10% of 
the drug excreted unchanged in the urine (Korprasertthaworn et al., 2015) and 30% 
detected in faecal material (FDA, 2019; Sheehan et al., 2010). OLZ is metabolized by 
the cytochrome CYP system; principally by CYP1A2 and to a lesser extent by 
CYP2D6. More than 40% of the oral dose of OLZ is subject to pre-systemic 
metabolism, first-pass effect. OLZ is also subject to glucuronidation via phase 2 
enzymes UGT1A4 and to a lesser extent UGT2B10. Knowledge on the phase 2 
metabolism of OLZ in rats is currently limited. The metabolism of RISP differs to 
OLZ. RISP is also well absorbed and its absolute bioavailability is 70%. It is mainly 
metabolized by CYP2D6 into 9-hydroxyrisperidone (9-OH RISP); CYP3A4 also 
plays a minor role in the propagation of this active metabolite (Mannens et al., 1993). 
RISP undergoes little to no phase 2 hepatic metabolism and most of the oral dose, 
approximately 70%, is recovered unchanged in the urine (Mannens et al., 1993; 
Markowitz et al., 2002). On this basis, we predicted that OLZ would be more likely to 
be impacted by the gut microbiome. 
It is intriguing to speculate whether perturbations to the gut microbiota 
could differentially alter the pharmacokinetics of OLZ and RISP and may, in turn, 
underpin variability in patient response to antipsychotics. In the present study, 
we depleted the gut microbiota with an antibiotic cocktail to assess whether the 
microbiota was involved in antipsychotic pharmacokinetics. We also used a more 
translationally relevant microbiota-directed intervention in the form of a widely used 
commercially available cocktail of probiotics, VSL#3 (Sarkar et al., 2018). 
  139  
 
Table 4.1 Overview of the physiochemical properties of the antipsychotics 
Drug name 
and structure a 






MW Log P pKa Solubility 



















































Abbreviations : Log P partition co-efficient, MW molecular weight, 2y secondary, N/A not applicable 
*(@12hr post dose) 
Refs: a www.drugbank.ca; b www.pubchem.ncbi.nlm.ni.gov; c (Hiemke et al., 2011) 




Adult male Sprague Dawley rats (n=6-7/group; 200-250g on arrival) were obtained 
from Envigo UK. They were housed 3-4 per cage and maintained under a 12-h 
light/dark cycle, provided with chow and water ad libitum. Rats in the same cage 
underwent the same treatment to avoid confounding factors such as coprophagy. 
Animals were acclimated to housing conditions for one week prior to experimental 
treatment. Experiments were conducted in accordance with European Directive 
2010/63/EU. Approval by the Animal Experimentation Ethics Committee of 
University College Cork (AE19130/P049) was obtained before commencement of all 
animal-related experiments.  
 
Antibiotic and probiotic treatment 
Antibiotics or probiotics were administered for 14 days in water. The antibiotic 
cocktail consisted of ampicillin 1g/L, vancomycin 500mg/L and imipenem 250mg/L 
[adapted from (Hoban et al., 2016)] and the solution was provided fresh every second 
day. The probiotics consisted in VSL#3, a commercially available multi-strain 
preparation which was administered in a dose of 5·1010 bacteria/kg/day (Rashid et al., 




Rats pretreated with vehicle, probiotic or antibiotic had a 1-day break and 
subsequently received an acute dosage of either OLZ 20 mg/kg or RISP 15 mg/kg by 
gavage. Following administration of the antipsychotics, whole blood samples were 
collected into heparinized tubes from the tip of the tail at different timepoints (30 min, 
1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h). The plasma was harvested by centrifugation at 10,000G 
for 10 min and stored at -20°C until further analysis. 
  141  
 
 
High performance liquid chromatography (HPLC) detection of the drugs in 
plasma and caecal contents  
The liquid-liquid extraction (LLE) protocol and HPLC conditions employed for the 
detection of OLZ and RISP in plasma samples was based on previously published 
methods with some modifications (Avenoso et al., 2000; Dusci et al., 2002). Detailed 
information on plasma and caecum preparation as well as drug extraction can be found 
in the Supplemental material. For analyte identification and quantification, calibration 
standards were prepared by spiking 10 µl or 20 µl of working standard solutions 
(RISP or OLZ) into 90 µl of blank rat plasma or 200 µl of blank rat caecal 
contents respectively at final concentrations of 15.6–2000 ng/ml. The calibration 
standards were treated as described in supplemental material before the analysis. 
Calibration curves were generated by plotting the peak area ratio (OLZ) or peak area 
(RISP) of the analyte to internal standard versus the concentration of the analyte using 
least-square linear regression. The correlation coefficients of the calibration curves 
were greater than 0.99. The co-efficient of variation (% CV) for the HPLC method, 
assessed over a 5-day period, was less than 15% for both drugs. The accuracy of the 
technique was determined by carrying out the extraction procedure on plasma samples 
spiked with known concentrations of the drug of interest followed by HPLC 
analysis. Specific information on the HPLC equipment employed can be found in the 
supplemental material. 
 
Pharmacokinetic and statistical analysis  
The maximum plasma concentration (Cmax) and time taken to reach Cmax (Tmax) 
for OLZ and RISP were estimated directly from the plasma concentration-time 
profiles. Pharmacokinetic parameters including the area under the plasma drug curve 
(AUC), clearance (Cl) and mean residual time (MRT) were all calculated using a non-
compartmental model. AUC was calculated using the linear trapezoidal method from 
the first to the last measured plasma concentration i.e. AUC0-8hr. Antipsychotic drug 
clearance from plasma was estimated by dividing AUC by the administered 
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drug dose and MRT was calculated by dividing AUC0-8hr by the area under the first 
moment curve (AUMC0-8hr). Data are represented as mean ± standard error of the mean 
(SEM) apart from the plasma pharmacokinetic curve and parameters where data is 
represented as mean ± standard deviation (S.D.).  
 
Microbiota composition of the caecal content 
Caecum was harvested and immediately snap-frozen and stored at -80ºC prior to the 
analysis. DNA was extracted using the Qiagen QIAmp Fast DNA Stool Mini Kit 
coupled with an initial bead-beating step. The V3-V4 hypervariable region of the 16S 
rRNA gene was amplified and prepared for sequencing as outlined in the Illumina 16S 
Metagenomic Sequencing Library protocol. Samples were sequenced at Teagasc 
Sequencing Facility (TFRC, Moorepark) on the Illumina MiSeq platform using a 
2×250 bp kit. Reads were assembled, processed and analysed following the pipeline 
described in Supplemental Methods.  
 
RNA extractions, reverse transcription and quantitative RT-qPCR  
The duodenum and frontal lobe of the liver were rapidly dissected from individual 
animals and stored at -80 °C. Total RNA was extracted from the intestinal tissue and 
the front lobe of the liver with the mirVanaTM miRNA isolation kit (Thermo Fisher 
Scientific/Ambion) following the manufacturer’s protocol. A Nanodrop 1000 
(Thermo Scientific, UK) was used to determine RNA concentration. RNA was reverse 
transcribed using a high capacity cDNA reverse transcription kit (Thermo Fisher 
Scientific/Applied Biosystems) in a G-storm thermocycler (G-storm, Surrey, UK). 
Genes of interest (listed in supplemental material) were amplified using SybrGreen 
probes. Each transcript value was calculated as the average of triplicate samples across 
experimental conditions. Values were normalized to β-actin. Data were analysed with 
the comparative cycle threshold method (2-ΔΔCt) (Livak and Schmittgen, 2001) and 
presented as a fold change vs. vehicle group. 
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Protein extraction and Western blots 
Total proteins from liver samples were extracted through sonication, BCA 
quantification (Thermo Fisher Scientific) and heat denaturation. Protein levels were 
detected on SDS-page gels using appropriate primary antibody dilutions against 
CYP1A2 (1:5000; Abcam ab22717), CYP2D1 (1:1000; Enzo BML-CR3210), 
CYP3A1 (1:1000; Millipore AB1253), secondary antibody HRP-conjugated to rabbit 
or mouse (1:10000; Thermo Fisher Scientific). Primary antibody against β-actin 
(1:1000; Santa Cruz, sc-47778) was used as control for protein loading. Quantification 
of protein bands was performed using ImageJ software and protein levels were 
normalized to the β-actin and presented as fold change relative to the vehicle group. 
Significance was determined by a one-way ANOVA followed by Dunnett’s test. 
 
Fecalase assay  
Fecalase was prepared from approximately 70 mg fresh-frozen rat faeces collected on 
day 12 of the 14-day intervention period, according to a modified method previously 
described (Lee et al., 2002). Briefly, the faecal pellet was suspended in 1 
mL phosphate buffer (0.01 M, pH 7.4) and homogenised using a 
mini BeadBeater machine for 1.5 minutes. The faecal suspension was centrifuged at 
2,000 rpm for 5 minutes and the resulting supernatant was centrifuged at 10,000 rpm 
for 20 minutes. The supernatant from the second centrifugation step (fecalase) was 
then used for the assay of enzyme activity. For quantification of enzymatic activity, 
the reaction mixture, containing 50 µl fecalase, 100 µl phosphate buffer (0.01M, pH 
7.4) and 100 µl 4-nitrophenyl-β-D-glucopyranoside (1mM, Sigma Aldrich) for β-
glucosidase or 100 µl 4-nitrophenyl-β-D-glucuronide (1mM, Sigma Aldrich) for β-
glucuronidase, was incubated at 37 °C for 15 minutes. After incubation, 250 µl 
NaOH (0.5N) was added to stop the reaction and the absorbance was measured at 
405 nm (UV-vis spectrophotometer). The Pierce BCA Protein Assay 
Kit (ThermoFisher Scientific) was used, in accordance with the kit protocol, to 
measure the total protein concentration in the fecalase samples. Enzyme activity was 
indicated as the amount required to catalyse the formation of 1 nmole of p-nitrophenol 
per minute under the standard assay conditions.  
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Statistical analysis  
Data that satisfied both homogeneity and normality tests, were analysed using one-
way ANOVA followed by Dunnett’s test. Data that did not satisfy either homogeneity 
or normality tests, were analysed using Kruskal-Wallis non-parametric test followed 
by Mann-Whitney U test and corrected for multiple comparisons using the Benjamin-
Hochberg false discovery rate (FDR) method. Grubbs method was employed to test 
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Results  
Body weight does not change during probiotic and antibiotic administration. 
Antibiotics increase caecum weight  
Rats’ body weight was monitored daily. There were no differences across the 14 days 
period between vehicle-receiving rats and probiotic or antibiotic-treated animals 
(Figure 4.1B). Upon cessation of the study and collection of organs, the caecum 




Figure 4.1 Experimental timeline, body weight and caecum weight. (A) Neither probiotic 
nor antibiotic administration influence the body weight gain. (B) Antibiotic administration 
increases caecum weight (KW p=0.000, U=0, p=0.000). Data are expressed as mean + SEM. 
*p<0.05 (n=13-14/group). 
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Antibiotics and probiotics differentially impact the caecal microbiota 
composition  
To confirm the effect of antibiotics on the microbiota composition and to examine 
whether probiotics also had a microbial effect, we performed 16S sequencing of 
bacterial rRNA of the caecum content. As expected, the sequencing revealed a 
significant decrease in the bacterial richness and diversity of rats treated with 
antibiotics as compared to the vehicle group (Figure 4.2B). Moreover, separation 
according to group was further illustrated through principal coordinate analysis 
(PCoA), with statistical support of the significant separation between the antibiotic 
and the vehicle group (p<0.001, Figure 4.2C). The marked difference between the 
antibiotic and the vehicle group was also detected at the genus level, with several 
genera being depleted in the antibiotic group (Figure 4.2A, Table S.4.3). The phylum 
and family microbiome signatures were also significantly disrupted by antibiotics 
(Figure S.4.1).  On the contrary, rats that received probiotics for 2 weeks did not show 
any marked different at the genus level, alpha or beta diversity (Figure 4.2).  
To assess whether the acute administration of antipsychotics would impact the 
microbiome per se, we checked the alpha diversity in the vehicle group and no 
significant differences were detected between OLZ- and RISP-treated rats (Figure 
4.2B).
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Figure 4.2 Caecum microbiota composition 
(16S sequencing). (A) Bar charts representing 
the taxa abundance at the genus level. The 20 
most abundant taxa are shown. (B) Alpha 
diversity. Kruskal-Wallis test for Chao1 
(p=0.000) and Shannon (p=0.000). Mann-
Whitney U test for: Chao1 and Shannon: 
antibiotic p<0.001 compared to vehicle. Data 
are expressed as median and min-to-max 
values. Samples are rarefied to read depth of 
32817. (C) Beta diversity, principal 
coordinate analysis of Bray-Curtis compiled 
distance matrix of all microbial relative 
abundances compared to the vehicle group. 
Antibiotic animals show significant variation 
from the vehicle (Adonis PERMANOVA 
p<0.001, R2=0.764), independent of drug 
treatment. (n=6-7/group).  
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At the phylum and family level, several bacteria were altered in the two microbiome-
targeted treatments (Figure S.4.1, Tables S.4.1 and S.4.2), with antibiotics causing 
mainly a depletion in several families. At the genus level, antibiotics induced a wide 
depletion, while the genera Anaeroplasma was significantly increased in antibiotic-
treated rats and Lachnospiraceae UCG006 was increased but not significantly (Figure 
4.3, Table S.4.3). The three bacterial strains present in the VSL#3 probiotic 
formulation belongs to the genera Lactobacillus, Streptococcus and Bifidobacterium. 
Among these three taxa, only Streptococcus was significantly increased in the caecum 
of probiotic-treated rats compared to vehicle-treated rats. Other taxa that were 
significantly increased in probiotic-treated rats included Erysipelatoclostridium, 
Marvinbryantia and Odoribacter (Figure 4.3).  
 
 
Figure 4.3 Probiotics and antibiotics differentially affect bacterial composition at genus 
level. Many bacterial genera are completely depleted in antibiotic-treated rats. The genus 
Anaeroplasma is significantly increased in antibiotic-treated rats. Lachnospiraceae UCG006 
are also increased but not significantly in antibiotic-treated rats. Streptococcus, 
Erysipelatoclostridium, Marvinbryantia and Odoribacter are significantly increased in 
probiotic-treated rats compared to the vehicle group. Data are expressed as median + SEM. 
*p<0.05, **p<0.01, ***p<0.001 (n=13-14/group). Data was analysed using Kruskal-Wallis 
non-parametric test followed by Mann-Whitney U test and corrected for multiple comparisons 
using the Benjamin-Hochberg false discovery rate (pFDR) method (refer to Supplemental 
Material for details on statistics). 
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Microbiota-depletion but not probiotic administration influences the absorption 
of OLZ  
The plasma concentration levels of OLZ were determined after oral administration to 
the vehicle-, probiotic- and antibiotic-treated animals. The mean plasma 
concentration-time profile of OLZ and AUC (area under the curve) are shown in 
Figure 4.4. The resultant pharmacokinetic parameters are described in Figure 4.4C. 
Antibiotic treatment significantly increased the AUC0-8hr of OLZ after a single oral 
dose. Neither of the microbiome manipulations influenced significantly the absorption 
of RISP although probiotics showed a trend toward a decrease of RISP absorption. 
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Figure 4.4 Pharmacokinetic profile of OLZ and RISP after oral administration in rats 
pre-treated with vehicle, probiotic or antibiotic. (A) Plasma levels and area under the curve 
(AUC) of OLZ. OLZ (20 mg/kg) was orally administered to rats pre-treated with vehicle, 
probiotic or antibiotic for 14 days following a 24-hr break (n=7/group, n=3 @1hr timepoint) 
The AUC (Area Under the Curve) of OLZ is increased by antibiotic administration (One-way 
ANOVA F(2;20)=3.58, p<0.05; t-test p=0.033). (B) Plasma levels and area under the curve 
(AUC) of RISP. RISP (15 mg/kg) was orally administered to rats pre-treated with vehicle, 
probiotic or antibiotic for 14 days following a 24-hr break (n=6-7/group). (C) Pharmacokinetic 
parameters of OLZ and RISP after oral administration in rats pre-treated with vehicle, probiotic 
or antibiotic. Data are expressed as mean ± SD. 
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The parameter AUC correlates with the relative abundance of the genera 
Alistipes in OLZ- but not RISP-treated rats 
After demonstrating that changes in the microbiome occurred in parallel with changes 
in the systemic absorption of OLZ (Figure 4.4A), we wanted to examine whether the 
relative abundance of specific taxa was associated to pharmacokinetic parameters 
[including AUC (area under the curve), Cmax (maximum serum concentration), Tmax 
(time at which the Cmax is observed) and CL (clearance)] in both antipsychotic-
receiving groups. In OLZ-treated rats, the relative abundance of Alistipes negatively 
and significantly correlated with AUC (Figure 4.5). This correlation was not observed 
in RISP-treated rats. All other taxa including Bifidobacterium (shown in Figure 4.5) 
did not show significant correlations with pharmacokinetics parameters after adjusting 
for multiple testing.  
 
Figure 4.5 Spearman correlations between AUC and the relative abundance of two 
bacteria in OLZ- and RISP-treated rats. (A) In OLZ-treated rats, AUC significantly 
correlates with the relative abundance of Alistipes (p=0.002245, adj p=0.045, R2=-0.64). 
N=21. Bifidobacterium does not correlate with AUC. (B) In RISP-treated rats, no significant 
correlations are observed between AUC and bacterial abundance. N=20. Data are normalized 
and CLR-transformed. Ns = not significant. 
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Antibiotics and probiotics do not alter the gene expression of CYPs involved in 
OLZ and RISP metabolism 
To test whether the probiotics or antibiotics had any direct effect on the hepatic 
expression of cytochromes (CYP) relevant for the metabolism of antipsychotics, RT-
qPCR was employed to examine the CYP gene expression at the transcript level. 
Interspecies comparison of CYPs isoforms present in rats and humans are described 
in (Martignoni et al., 2006) (Figure 4.6A). Neither the probiotic nor antibiotic 
treatment altered the hepatic mRNA expression of the rat equivalent human 
isoenzymes implicated in the metabolism of OLZ and RISP (Figure 4.6A). To further 
confirm the transcript findings at protein level, Western blotting analysis was 
performed for detection of the same CYPs. As shown in Figure 4.6A, there was no 
difference in CYP1A2 or CYP2D1 protein in the livers of probiotic- and antibiotic-
treated rats. Conversely, both microbiota-targeted interventions significantly 
upregulated CYP3A1 protein; the magnitude of the affect being larger in the case of 
the antibiotic-treated rats (p<0.001 vs Probiotic p<0.05). As CYP3A1 is, however, 
only a minor metabolizer of RISP, the significance of this finding is somewhat limited. 
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Figure 4.6 (A) Gene expression and protein levels of relevant CYPs in the liver. 
Probiotic/antibiotic administration does not alter the gene expression and protein levels of 
CYP1A2 and CYP2D1 compared to the vehicle group. Both probiotics and antibiotics increase 
the protein levels of CYP3A1 (One-way ANOVA F(2;19)=19.25, p<0.001; t-test p=0.049 for 
probiotic VS vehicle, p=0.000 for antibiotic VS vehicle) without altering gene expression. The 
protein bands of two representative samples per group are shown. Data are expressed as mean 
± SEM. *p<0.05, ***p<0.001, ns=not significant (n=5-7/group). (B) Gene expression of 
relevant tight junctions and MDR in the duodenum. No significant differences are noted 
across groups. Data are expressed as mean ± SEM (n=5-7/group).  
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Antibiotics and probiotics do not alter the gene expression of tight junctions and 
MDR-1a in the duodenum 
Previous studies have suggested that antibiotic administration can induce a 
dysregulation in intestinal barrier function (Spiller, 2018; Tulstrup et al., 2015) and 
the presence of the gut microbiota is important to maintain normal barrier function. 
For this reason, we assessed the gene expression of two key tight junctions, occludin 
and zonula occludens-1 (ZO-1) in the duodenum, main site of absorption of 
xenobiotics. This was carried out to rule out the possibility that an antibiotic-induced 
barrier dysfunction in the duodenum might be responsible for the increased absorption 
of OLZ in circulation; therefore, we analysed the two antipsychotic groups separately. 
Independently of the acute antipsychotic administered, neither probiotics nor 
antibiotics induced significant changes in the expression of tight junctions (Figure 
4.6B). We also assessed the gene expression of multidrug resistance protein 1a (MDR-
1a) which is responsible for pumping xenobiotic back in the intestinal lumen 
potentially affecting drug absorption. The isoform 1a was selected in the duodenum 
because of its prevalent distribution in this tissue (Cui et al., 2009). Neither probiotics 
nor antibiotic induced changes in the expression of MDR-1a in the duodenum (Figure 
4.6B). 
 
Antibiotics deplete the metabolic activity of the gut microbiota  
An ex-vivo metabolism assay, fecalase, has been previously utilized to elucidate the 
role of the gut microbiota in the metabolism of lovastatin, aspirin and amlodipine (Kim 
et al., 2016; Yoo et al., 2014; Yoo et al., 2016). The activity of two microbial-derived 
enzymes was investigated as a surrogate readout of the metabolic activity of the gut 
microbiota. The microbiota depletion induced by the antibiotic treatment markedly 
downregulated the expression of β-glucuronidase faecal enzymatic activity by the end 
of antibiotic treatment (i.e. day 12 of 14-days intervention period) (Figure S.4.2B). 
Similarly, there was a significant decrease of β-glucosidase activity relative to vehicle-
only rats following microbiota depletion. Probiotic treatment significantly decreased 
β-glucosidase activity (Figure S.4.2B).   
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Discussion 
The field of pharmacomicrobiomics studies the effects of microbiome variations on 
drug disposition, action and toxicity (ElRakaiby et al., 2014; Saad et al., 2012), and 
has become increasingly investigated in recent years. In this study, we focus our 
attention on two commonly prescribed antipsychotics with distinct pharmacokinetic 
profiles, OLZ and RISP, and how their pharmacokinetic properties might be 
influenced by microbiome manipulations. Our results show that microbiome depletion 
in adult rats increased the absorption of OLZ following acute administration. On the 
contrary, RISP’s absorption was not influenced by microbiome perturbations.  
The main site of absorption of antipsychotics is generally considered to be the stomach 
and the small intestine, areas of the gastrointestinal tract that are markedly less 
colonised with bacteria (101 and 103 bacteria/g respectively) than the bacterial dense 
large intestine (1012 bacteria/g) (O'Hara and Shanahan, 2006; Walsh et al., 2018). The 
potential effects of the gut microbiota on the absorption or biotransformation of OLZ 
and RISP would be presumed to be negligible. Our data, however, provides the first 
evidence that the gut microbiome may play an important role in the pharmacokinetics 
of OLZ. Lipophilic compounds, including these antipsychotics, have the same or 
higher permeability coefficients in the distal colon compared with the upper small 
intestine culminating in greater risk of poor drug absorption from the small intestine.  
Antibiotic-associated perturbations of the gut microbiota significantly altered the 
bioavailability of OLZ; the mean AUC for OLZ in the plasma of the antibiotic group 
was over 1.5-fold greater than the corresponding value in the vehicle group. These 
results suggested that the uptake of OLZ from the intestinal tract was increased 
following microbiota depletion, which may result from the suppression of the 
metabolic activity of gut microbiota and consequently, reduced pre-systemic 
metabolism of OLZ. Interestingly, the effect was only present in OLZ, with RISP’s 
absorption not being affected by probiotics or antibiotics. 
The observed increase in caecum weight in antibiotic-treated rats has been well 
characterized previously (Koopman and Kennis, 1980; Savage and Dubos, 1968). In 
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our study, the antibiotics induced a broad depletion of several genera, allowing 
Anaeroplasma and Lachnospiraceae UCG006 to survive and colonise the entire niche. 
Previous studies have shown that psychotropic medications can impact the gut 
microbiome composition (Cussotto et al., 2019b; Davey et al., 2012; Maier et al., 
2018), thus we assessed whether the microbial diversity (both alpha and beta diversity) 
was affected by acute administration of either OLZ or RISP. Importantly, our data 
show that acute antipsychotic-use does not influence the composition of the gut 
microbiome per se (Figure 4.2B).    
Across 156 genera detected by 16S sequencing, Alistipes only correlated with blood 
levels (area under the curve, AUC) of OLZ- but not RISP-treated rats, suggesting that 
this specific bacterium might potentially play a role in the pharmacokinetic alterations 
of OLZ. Alistipes has been shown to be increased in mice exposed to chronic 
intermittent vapourised ethanol (Peterson et al., 2017) in mice receiving faecal 
microbiota transfer from alcoholic patients with severe hepatitis (Llopis et al., 2016). 
An increased population of Alistipes has also been observed in depression (Jiang et al., 
2015b; Naseribafrouei et al., 2014) and in response to stress (Bangsgaard Bendtsen et 
al., 2012). Intriguingly, the genus Alistipes has been previously linked to patient 
response to chemotherapy. Specifically, the abundance of Alistipes correlated 
positively with the immunotherapy-induced production of TNF in mice with normal 
microbiota (Iida et al., 2013). Administration of an antibiotic cocktail (vancomycin, 
imipenem, and neomycin in drinking water) significantly disrupted the microbiome, 
impaired immunotherapy efficacy and therefore TNF production (Iida et al., 2013). 
Furthermore, a recent study investigated the ability of 76 bacterial strains to metabolise 
over 270 drugs and aimed to identify causal links between microbiota gene content 
and drug metabolising activities of human gut bacteria. Alistipes indistinctus (DSM 
22520) was identified as one bacterial strain linked to the chemical modification, or 
metabolism, of approximately 40 drugs; half of these substrate drugs were greater than 
80% metabolised (Zimmermann et al., 2019a). Interestingly, the authors showed 
greater than 50% of RISP was metabolised after 12hours incubation with this bacterial 
strain. Our data, however, did not find an association with RISP and Alistipes. 
Although the evidence on the role played by specific taxa on drug response is still 
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limited, the research by Iida, and Zimmermann, and colleagues’ sheds light upon the 
potential role of Alistipes in drug efficacy.  
Evidence suggests that antibiotics can induce a barrier dysfunction in the GI tract 
(Spiller, 2018; Tulstrup et al., 2015). With increased levels of OLZ in the blood of 
antibiotic-treated rats, we wanted to rule out the possibility that a disruption in 
intestinal permeability might be the cause of an increased absorption at the duodenum 
level. According to gene expression of the two tight junctions occluding and ZO-1, 
antibiotics (and microbiota depletion) did not induce an alteration in duodenal 
permeability and is unlikely to explain the observations reported here. Finally, the 
gene expression of multidrug resistance protein 1a (MDR-1a; which is responsible for 
pumping xenobiotic back in the intestinal lumen) was not disrupted by microbiome 
manipulations suggesting that MDR1 might not play an overt role in the 
pharmacokinetic differences seen in OLZ-treated rats.   
The increased level of OLZ in the plasma of microbiome-depleted rats was not, 
however, reflected in the caecum (Figure S.4.2A). We hypothesised that the microbial 
enzyme β-glucuronidase could convert a glucuronide-conjugated metabolite of OLZ 
(OLZ 10-N glucuronide or OLZ 4-N glucuronide) into the parent compound; however, 
our findings did not support this hypothesis. 
Antibiotic treatment significantly depleted the enzymatic activity of two microbial 
enzymes, with the activity of β-glucuronidase falling to levels below the limit of 
detection (LOD) of the assay (Figure S.4.2B). Thus, it seems likely that the increase 
in plasma OLZ levels might be mediated via an alternative mechanism rather than by 
antibiotic-mediated interference of enterohepatic recirculation or inhibition of MDR1. 
The suggested mechanism could be further investigated by comparing the metabolism 
of OLZ and/or the formation rate of the OLZ metabolite in fecalase from antibiotic-
treated rats versus vehicle-only rats.  
The antibiotic-induced effects on drug pharmacokinetics appear to be drug specific. 
Microbiota depletion significantly elevated the plasma levels of OLZ but had no 
impact on another antipsychotic, RISP. Despite some reports in the literature 
illustrating a potential role of the gut microbiota in the metabolism of RISP, 
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perturbations of the gut microbiota in our study did not significantly alter 
any pharmacokinetic parameter of RISP. Previous work has hinted that the isoxazole 
ring present in RISP may be liable to cleavage by the gut microbiota (Kim, 2015; 
Meuldermans et al., 1994). Antibiotic-treatment, such as rifampin, has been previously 
shown to alter the metabolism of RISP in the liver, albeit via induction of hepatic CYP 
gene expression (Baciewicz et al., 2013).   
Additionally, it is worth noting that, in order to limit pharmacokinetic drug-drug 
interaction issues, there was a 24-hour intervention-free period to facilitate the 
excretion of the antibiotics and probiotics from the body prior to acute drug dosing. 
Moreover, the choice of antibiotics was made to limit their direct effect on host hepatic 
metabolism. Neither the probiotic or antibiotic cocktail altered the hepatic expression 
of CYP1A2 and CYP2D1 implicated in the host metabolism of OLZ and RISP both at 
transcript and protein level (Figure 4.6). This finding shows that the pharmacokinetic 
alteration following antibiotic treatment may be mainly due to a microbiota depletion 
effect rather than inhibition of hepatic pathways. The protein expression of CYP3A1, 
which was significantly increased in antibiotic-treated rats, has been previously shown 
to be induced by macrolide antibiotics in both rat and human hepatocytes (Ledirac et 
al., 2000). CYP3A1, however, only plays a minor role in the metabolism of 
antipsychotics. 
Little is known regarding the effect of VSL#3 on the expression of various drug-
metabolizing enzymes in the liver. Previous research administered VSL#3 
probiotics to both conventional and germ-free (GF) mice in the drinking water for 28 
days (dose 4.5x106 CFU/ml) and found the probiotic cocktail to have a relatively 
minor effect on hepatic drug-metabolizing enzyme expression, albeit this finding 
being in mice (Selwyn et al., 2016). In our study, VSL#3 administration did not impact 
the pharmacokinetics of antipsychotics, but future studies employing different dosages 
and time-courses of this multi-strain combination, or examining each probiotic strain 
individually, are warranted.   
To our knowledge, the present study is the first to demonstrate the microbiota-
mediated alteration of OLZ pharmacokinetics in a preclinical in vivo setting. 
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Therefore, it is imperative that additional research is carried out in this area to facilitate 
the critical evaluation of the role the gut microbiota plays in the distribution of 
antipsychotics in humans. In addition, the mechanisms underpinning the increased 
OLZ concentration in the systemic circulation of the microbiome-depleted rats 
remains elusive and need to be clarified. A question arises as to whether the effects of 
microbiota variations on the absorption of antipsychotic drugs might be dose-
dependent or duration-dependent (i.e. acute versus chronic) and future research is now 
warranted to investigate this important aspect. 
Our findings suggest that inter-individual variations in OLZ response might be linked 
to the gut microbiome composition of the host, with a potential role for the bacterium 
Alistipes. Also, the information here provided might be crucial for clinical settings 
where antipsychotics and antibiotics are co-administered (Beovic et al., 2016). 
Unravelling the potential role of antibiotics and prebiotics in modulating the 
pharmacokinetics of orally administered antipsychotics will provide important new 
insight into potential drug-drug interactions relevant for clinical practice.  
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Supplemental Material  
SUPPLEMENTAL TABLES 
Table S.4.1 Statistics values for relative abundance of bacterial PHYLA in each treatment 









*p<0.05, Mann-Whitney U test, Benjamini-Hochberg critical value [(i/m)Q] with i=rank; 
m=total number of tests; Q (false-discovery rate)=0.2. N=13-14/group. Red indicates an 
increase, blue a decrease compared to the vehicle group. ns=not significant 
 
Table S.4.2 Statistics values for relative abundance of bacterial FAMILIES in each 
treatment group (probiotic or antibiotic) as compared to the vehicle. 
 Family Probiotic Antibiotic 
 p value (i/m)·Q p value (i/m)·Q 
Desulfovibrionaceae ns ns 0.000 0.004878 * 
Rhodospirillaceae ns ns 0.000 0.009756 * 
Ruminococcaceae ns ns 0.000 0.014634 * 
Peptostreptococcaceae ns ns 0.000 0.019512 * 
Lactobacillaceae ns ns 0.000 0.02439 * 
Caldicoprobacteraceae ns ns 0.000 0.029268 * 
Christensenellaceae 0.043 0.019512 * 0.000 0.034146 * 
Flavobacteriaceae ns ns 0.000 0.039024 * 
Clostridiaceae_1 ns ns 0.000 0.043902 * 
 Phylum Probiotic Antibiotic 
 p value (i/m)·Q p value (i/m)·Q 
Firmicutes ns ns 0.000 0.0181 * 
Verrucomicrobia ns ns 0.000 0.0363 * 
Bacteroidetes ns ns 0.000 0.0545 * 
Saccharibacteria ns ns 0.000 0.0727 * 
Tenericutes ns ns 0.000 0.0909 * 
Deferribacteres ns ns 0.000 0.1090 * 
Proteobacteria ns ns 0.000 0.1454 * 
Lentisphaerae ns ns 0.000 0.1636 * 
Unclassified ns ns 0.000 0.1818 * 
Actinobacteria ns ns 0.016 0.2 




ns ns 0.000 0.04878 * 
uncultured_rumen_bact
erium 
ns ns 0.000 0.053659 * 
Peptococcaceae ns ns 0.000 0.058537 * 
Streptococcaceae 0.012 0.009756 * 0.000 0.063415 * 
Bifidobacteriaceae ns ns 0.000 0.068293 * 
Victivallaceae ns ns 0.000 0.073171* 
Prevotellaceae ns ns 0.000 0.078049 * 
Anaeroplasmataceae ns ns 0.000 0.082927 * 
Bacteroidaceae ns ns 0.000 0.087805 * 
Micrococcaceae ns ns 0.000 0.092683 * 
Porphyromonadaceae 0.008 0.004878 0.000 0.097561 * 
Eubacteriaceae ns ns 0.000 0.102439 * 
Coriobacteriaceae ns ns 0.000 0.107317 * 
Family_XIII ns ns 0.000 0.112195 * 
Unknown_Family ns ns 0.000 0.117073 * 
Deferribacteraceae ns ns 0.000 0.121951 * 
Erysipelotrichaceae ns ns 0.000 0.126829 * 
uncultured_organism ns ns 0.000 0.131707 * 
Alcaligenaceae ns ns 0.000 0.136585 * 
Verrucomicrobiaceae ns ns 0.000 0.141463 * 
Rikenellaceae ns ns 0.000 0.146341 * 
uncultured_bacterium ns ns 0.000 0.15122 * 
Unclassified ns ns 0.000 0.156098 * 
Clostridiales_vadinBB
60_group 
ns ns 0.001 0.160976 * 
Pasteurellaceae ns ns 0.001 0.165854 * 
Thermoanaerobacterac
eae 
ns ns 0.008 0.170732 * 
Lachnospiraceae ns ns 0.012 0.17561 * 
Staphylococcaceae 0.033 0.014634 * ns ns 
*p<0.05, Mann-Whitney U test, Benjamini-Hochberg critical value [(i/m)Q] with i=rank; 
m=total number of tests; Q (false-discovery rate)=0.2. N=13-14/group. Red indicates an 
increase, blue a decrease compared to the vehicle group. ns=not significant 
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Table S.4.3 Statistics values for relative abundance of bacterial GENERA in each treatment 
group (probiotic or antibiotic) as compared to the vehicle. p<0.05, Mann-Whitney U test, 
Benjamini-Hochberg critical value [(i/m)Q] with i=rank; m=total number of tests; Q (false-
discovery rate)=0.2. N=13-14/group. Red indicates an increase, blue a decrease compared to 
the vehicle group. Values in red bold are significantly different from vehicle. 
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Table S.4.4 List of SybrGreen probes used in the study. Provider company: Eurofins 
Genomics. 
Gene Common gene name 
Sequence (5’ → 3’) 
left 
Sequence (5’ → 3’) 
right 
















CYP1A2 Cytochrome P450 Family 1 





CYP3A1 Cytochrome P450 Family 3 





CYP2D1 Cytochrome P450 Family 2 
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SUPPLEMENTAL FIGURES 
Figure S.4.1 Bar charts representing the taxa abundance at the phylum (A) and family (B) 
levels. The 20 most abundant taxa are shown. 
 
Figure S.4.2 (A) 
Antipsychotic concentration 
in the caecum after oral 
administration in rats pre-
treated with vehicle, 
probiotic or antibiotic. 
Neither antibiotic or probiotic 
treatment significantly altered 
the concentration of OLZ 
(n=7) or RISP (n=5-7) in the 
caecum. Data are expressed as 
mean + SEM. (B) Impact of 
microbiota-targeted 
interventions on the 
metabolising enzyme activity 
of rat faecal samples (faecal 
extract, fecalase). β-
glucuronidase and β-
glucosidase activity in rat 
faecal samples from vehicle, 
probiotic and antibiotic-treated rats. Data are expressed as mean + SEM. *p<0.05 ***p<0.001 
(n=9-10). 
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SUPPLEMENTAL METHODS 
Caecal microbiota composition  
 
Caecum was harvested, snap frozen and stored at -80ºC prior to the analysis. 
 
 Caecal content DNA extraction  
 
DNA extraction was performed using the QIAmp Fast DNA Stool Mini Kit (Qiagen, 
Sussex, UK) coupled with an initial bead-beating step. Briefly, 200 mg of each caecal 
sample were vortex-mixed in a 2 ml screw-cap tubes (Sarstedt, Wexford, Ireland) 
containing 0.25 g of a 1:1 mix of 0.1 mm and 1.0 mm sterile zirconia beads plus a 
single 3.5 mm diameter bead (BioSpec Products, Bartlesville, USA) with 1 ml of 
Qiagen InhibitEX® buffer. Following steps were according to manufacturer’s 
instructions. DNA was quantified using the QubitTM 3.0 Fluorometer (Bio-Sciences, 
Dublin, Ireland) and the Qubit® dsDNA HS Assay Kit (Life Technologies, Oregon, 
USA). Extracted DNA was kept frozen at -20ºC until further analysis. 
 
 16S rRNA Gene Sequence-based microbiota analysis  
 
The V3-V4 hypervariable region of the 16S rRNA gene were amplified and prepared 
for sequencing as outlined in the Illumina 16S Metagenomic Sequencing Library 
Protocol (http://www.illumina.com/content/dam/illumina-
support/documents/documentation/chemistry_documentation/16s/16s-metagenomic-
library-prep-guide-15044223-b.pdf). Briefly, first PCR was done using forward 
primer (5’- 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCA
G-3') and reverse primer (5’- 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATC
TAATCC-3'). Each 25 μl PCR reaction contained 5 ng/μl microbial genomic DNA, 1 
μM of each primer and 12.5 μl 2X Kapa HiFi Hotstart ReadyMix (Kapa Biosystems 
Ltd., UK). The PCR conditions follow as: initial denaturation at 95 ºC x 3 min; 25 
cycles of 95 ºC x 30 s, 55 ºC x 30 s, 72 ºC x 30 s; and 72 ºC x 5 min for final extension. 
PCR products were purified with Agencourt AMPure XP system (Beckman Coulter 
Genomics, Takeley, UK). In the next step, dual indices and Illumina sequencing 
adapters were attached to PCR products using the Nextera XT Index Kit (Illumina, 
San Diego, CA). Each 50 μl PCR reaction contained 5 μl purified DNA, 5 μl index 
primer 1 (N7xx), 5 μl index primer 2 (S5xx), 25 μl 2x Kapa HiFi Hot Start Ready mix 
and 10 μl PCR grade water. PCR amplification was completed using the previous 
program but with only 8 amplification cycles instead of 25. Following this, a second 
clean-up step with the Agencourt AMPure XP system was done. PCR products were 
quantified, normalized and pooled in an equimolar fashion using the Qubit® dsDNA 
HS Assay Kit (Life Technologies, Oregon, USA). Next steps in the library preparation 
were carried out by Teagasc Next Generation DNA Sequencing Facility (Teagasc, 
Moorepark, Food Research Centre) prior to 2×250 (bp) paired-end sequencing on the 
Illumina MiSeq platform, using standard Illumina sequencing protocols. 
 
 Bioinformatic sequence analysis  
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Bioinformatic sequence analysis was performed as previously described (Murphy et 
al., 2017). Briefly, paired-end sequences were assembled using FLASH (Magoč and 
Salzberg, 2011) and analysed using QIIME v1.8.0 (Quantitative Insights Into 
Microbial Ecology) (Caporaso et al., 2010). Sequences were quality checked and the 
remaining sequences were clustered into operational taxonomic units using 
USEARCH (v7-64bit) (Edgar, 2010). Taxonomic ranks were assigned with a BLAST 
search against the SILVA SSURef database release 123 (Quast et al., 2013). Alpha 
and beta diversities and Bray-Curt dissimilarities were generated in Calypso (version 
8.84) Principal coordinate analysis (PCoA) plots were visualized with ggplot2 (V 
2.2.1) using OTU values normalized with the wisconson function in the vegan package 
(v. 2.5-1). Adonis function (PERMANOVA, permutations=999) in the vegan package 
(v 2.5-1) was performed on Bray-Curtis matrix on three dimensions. Relative 
abundance of bacterial taxa was expressed as % of identified sequences.  
 
 
High performance liquid chromatography (HPLC) detection of the drugs in plasma 
and caecal contents  
 
1. Plasma Sample Preparation and HPLC Conditions  
Olanzapine: The liquid-liquid extraction (LLE) protocol and HPLC conditions 
employed for the detection of olanzapine in plasma samples was based on (Dusci et 
al., 2002), with some modifications. 20 µl of the internal standard (I.S.), clozapine, 
was added to 50 µl of plasma sample (to yield final clozapine concentration of 400 
ng/ml) (Discovery Fine Chemicals, UK). After sample alkalinisation with 100 µl of 
Na2CO3 (2M), 750 µl of hexane: dichloromethane: (85:15, v/v) was added as an 
extraction solvent. Tubes were mixed on an eppendorf shaker at maximum speed 
(1400 rpm) for 5minutes at 4 °C, followed by sonication for 4 minutes (Bransonic 
Ultrasonic Cleaner 5510EDTH, Sigma). The clear supernatant was isolated in a new 
eppendorf. A further 750 µl of the extraction solvent was added to the cloudy pellet. 
Samples were mixed vigorously for 30 minutes and centrifuged at maximum speed for 
10 minutes. The supernatant was again isolated. The tubes were dried under a stream 
of nitrogen (approx.15-20 minutes) to evaporate the extraction solvent and 
reconstituted with 100 µl of mobile phase. Compounds were eluted isocratically over 
a 16 min runtime at a flow rate of 1 ml/min. The mobile phase consists of 14% 
acetonitrile in water (containing 0.25% H3PO4 and 0.05% triethylamine). The limit of 
quantitation for risperidone was 15.6 ng/ml.   
Risperidone: The liquid-liquid extraction (LLE) protocol and HPLC conditions 
employed for the detection of risperidone in plasma samples was based on (Avenoso 
et al., 2000), with some modifications. Briefly, 100 µl of NaOH (2M) was added to 50 
µl plasma samples spiked with 20 µl of I.S. (to yield final clozapine concentration of 
2000 ng/ml). Tubes were vortex-mixed for 30s and 1ml diisopropyl ether-isoamyl 
alcohol (99:1, v/v) was added as extraction solvent. Following 10 minutes of vigorous 
mixing, samples are centrifuged at 4000rpm for 10 minutes. The organic phase was 
back extracted with 100 µl of potassium phosphate (0.1M, pH 2.2) and 30 µl of the 
acid solution was injected onto the HPLC column. The mobile phase consisted of 
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acetonitrile: potassium dihydrogenphosphate [0.05M pH 3.7, pH adjusted with 25% 
phosphoric acid] (30:70) and was filtered through Millipore 0.22 µm Durapore filters 
(Millipore, Ireland). Compounds were eluted isocratically over a 12 min runtime at a 
flow rate of 1 ml/min. The column was maintained at room temperature and 
samples/standards were kept at 8 °C in the cooled autoinjector prior to analysis. The 
limit of quantitation for risperidone was 62.5 ng/ml.   
 
2. Sample Preparation and Drug Extraction from Caecal Contents 
To quantify the amount of risperidone and olanzapine present in the caecum of the 
rats, 200mg of caecal contents from each animal was isolated and suspended in 1 ml 
of HPLC grade water and homogenised using a bead-beater for 3·1minute intervals. 
The same LLE procedure was used to process the caecal samples as that detailed for 
the plasma samples; the only difference involving the volume of starting material, 100 
µl of the homogenised caecal content was used instead of 50 µl plasma. 
 
3. HPLC Equipment 
The HPLC with ultraviolet detection (HPLC-UV) system consisted of Agilient 1260 
Infinity Binary LC (Agilient Technologies). System components were used in 
conjunction with EZChrom Elite software (Mason Technology). The detector used 
was the 1260 Infinity II Diode Array. All samples for both drugs were injected onto a 
reversed phase Synergi RP 4 μm MAX-RP HPLC Column 4.60 X 250 mm column 
(Phenomenex), which was protected by a SecurityGuard HPLC (Phenomenex). 
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Abstract  
Increasing evidence suggests that medications used for the treatment of psychiatric 
disorders can influence the gut microbiome composition. The aim of this study was to 
investigate relations between intake of psychotropic drugs and microbiome 
composition in a human cohort. Whole genome shotgun sequencing of the gut 
microbiomes of 1,126 participants from a Dutch population-based cohort shows minor 
but significant relations between the microbiome and intake of psychotropic 
medications, particularly antidepressants. Interestingly, alterations in the genus 
Roseburia, which has previously been shown to be altered in rat studies was found to 
be affected by psychotropic intake in this study. However, many previously identified 
psychotropic-induced changes in microbiota composition did not persist in a human 
cohort. Possible reasons for not detecting other overlapping common bacterial taxa 
might be the different methods used for microbiome sequencing (whole genome 
shotgun versus 16S) and the presence of species-specific bacteria associated to human 








Keywords: shotgun sequencing, SSRIs, TCAs, diversity, Roseburia 
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Introduction 
Increasing evidence suggests that different host-targeting drugs can affect the gut 
microbiota in vitro and in vivo (Falony et al., 2016; Maier et al., 2018). Moreover, we 
have recently shown that psychotropic medications such as antidepressants and 
antipsychotics can induce microbiome modifications in a preclinical rodent model 
(Cussotto et al., 2019b). Other medications that target human cells have been 
associated with changes in microbiome composition, including antidiabetics (Forslund 
et al., 2015), proton pump inhibitors (PPIs) (Imhann et al., 2016; Jackson et al., 2016), 
nonsteroidal anti-inflammatory drugs (NSAIDs) (Rogers and Aronoff, 2016) and 
atypical antipsychotics (Flowers et al., 2017). The role played by the gut microbiota 
in both beneficial and undesirable effects of medications is rarely considered. The aim 
of our study was to assess, in a large cohort of 1,126 individuals, associations between 
intake of psychotropic medications (antiepileptics, benzodiazepines and 
antidepressants) and gut microbiota composition. This study represents a follow-up 
analysis of previously published work which demonstrated that 126 exogenous and 
intrinsic host factors, including drug intake, collectively explained 18.7% of the 
variation seen in the inter-individual microbial composition (Zhernakova et al., 2016). 
Based on these previous findings (Zhernakova et al., 2016), we narrowed down the 
investigation to focus on psychotropic drugs which were classified according to class, 
chemical structure (i.e. SSRIs versus TCAs) and individual compound. In addition, 
we excluded individuals who consumed more than one psychotropic drug. We then 
discuss the results of our analysis comparing them with previously published work in 
rodents.  
  




This study includes stool samples from 1,126 LifeLines-DEEP participants from the 
general population of the northern part of the Netherlands (58% females, mean age 45 
years, range 18-81 years). The demographic information of this population is 
described in detail in the previously published metagenomics study from Zhernakova 
and colleagues (Zhernakova et al., 2016). The phenotyping and processing of 
LifeLines-DEEP has been described previously (Zhernakova et al., 2016). The 1,126 
LifeLines-DEEP participants collected stool samples at home. These were 
immediately stored in the freezer, then collected on dry ice within a few days and 
transferred to a -80°C facility. All samples were collected over a short period of 3 to 
4 months. Sample collection, DNA preparation, processing, and sequence and data 
analysis were all performed in a standardized manner using laboratory space and 
equipment described previously (Zhernakova et al., 2016). 
We initially divided 1,135 participants in 5 groups based on the class of drugs 
consumed: 
 Antiepileptics (N=5) 
 Benzodiazepines, BDZs (N=28) 
 Other antidepressants (N=10) 
 Selective serotonin reuptake inhibitors, SSRIs (N=29) 
 Tricyclic antidepressants, TCAs (N=11) 
 Non-users (N=1,052) 
Participants who were administered a combination of psychotropic drugs (N=9) were 
excluded from the analysis resulting in 1,126 individuals, distributed as follows: 
 Antiepileptics (N=5) 
 Benzodiazepines, BDZs (N=22) 
 Other antidepressants (N=7) 
 Selective serotonin reuptake inhibitors, SSRIs (N=22) 
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 Tricyclic antidepressants, TCAs (N=9) 
 Non-users (N=1,061) 
Inclusion criteria consisted in the intake of at least one, but not multiple, psychotropic 
drug recorded for the cohort. There were no exclusion criteria for the participants, with 
the exception of poly-intake of psychotropic drugs.  










N03AX09 Lamotrigine 1 
5 
N03AF01 Carbamazepine 2 
N03AG01 Valproic acid 2 
N03AX11 Topiramate 0 
Benzodiazepines 
N03AE01 Clonazepam 1 
28 
N05BA05 Clorazepate 1 
N05BA06 Lorazepam 1 
N05CD06 Lormetazepam 1 
N05CD09 Brotizolam 1 
N05BA04 Oxazepam 7 
N05CD07 Temazepam 7 
N05BA01 Diazepam 9 
Other antidepressants 
N06AX11 Mirtazapine 5 
10 
N06AX16 Venlafaxine 5 
N06AX05 Trazodone 0 
N06AX21 Duloxetine 0 
Selective serotonin 
reuptake inhibitors 
N06AB06 Sertraline 2 
29 
N06AB03 Fluoxetine 3 
N06AB04 Citalopram 3 
N06AB10 Escitalopram 3 
N06AB08 Fluvoxamine 4 
N06AB05 Paroxetine 14 
Tricyclic antidepressants 
N06AA04 Clomipramine 2 
11 
N06AA09 Amitriptyline 9 
 
DNA extraction and next generation sequencing  
Following storage of the faecal samples at -80°C, DNA was isolated with the AllPrep 
DNA/RNA Mini Kit (Qiagen; cat. #80204). The gut microbiome was analysed using 
paired-end metagenomic shotgun sequencing (MGS) on a HiSeq2000, generating an 
average of 3.0 Gb of data (about 32.3 million reads) per sample. Samples with read 
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counts lower than 15 million were removed. Human contamination was further 
removed by mapping the reads against the human reference genome (build 37) using 
bowtie2 (version 2.1.0) (Langmead and Salzberg, 2012). 
 
Bioinformatics 
Microbial profiling of samples has been performed by mapping read sequences to 
approximately 1 million clade-specific marker genes using MetaPhlAn 2.2 (Segata et 
al., 2012), as described in (Zhernakova et al., 2016). 
 
Statistical analysis  
Diversity of microbial communities was calculated for every individual using the 
diversity function in the R package ‘vegan’ (version 2.5-3) at the genus level (Oksanen 
et al., 2018). To assess the difference in alpha-diversity between medication groups, 
one-way ANOVA test has been performed. To assess the heterogeneity of microbial 
communities between individuals, Bray-Curtis and Aitchison distances were 
calculated using the vegdist function from the same package and the ALDEx2 package 
(Fernandes et al., 2013), respectively. The approach of Aitchison distance calculation 
also recruited the absolute counts imputation from the relative abundance obtained 
with MetaPhLan2.2 and read depth information.  To check the homogeneity of the 
dispersions within medication groups the function betadisper with the ‘centroid’ 
option was applied to matrices of distance. The significance of differences of 
dispersions was estimated by permutest function using 1000 permutations. To test how 
much of the inter-individual microbial variation at species level could be explained by 
antipsychotic medications consumption, we then performed a PERMANOVA 
(permutational multivariate analysis of variance) corrected for sex, age, read depth, 
and depression using the adonis function from the same package. The p-value was 
determined by 1,000 and 10,000 permutations, and differences were considered 
significant at p<0.05. 
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To associate the available metadata with microbial relative abundances at species and 
genus level the function Maaslin relying on general linear models from the package 
‘MaAsLin2’ (version 0.2.3) was used (Mallick et al., 2019). Here we were considering 
only those species and genus that were present in at least 5% of the participants. 
Factors that have been shown to have influence on the gut microbiome composition 
earlier (age, sex, read depth) were considered in a multivariate model assessing the 
relation antipsychotic medications and relative microbial abundances. In each 
analysis, the default settings of Maaslin were applied (Total Sum Scaling (TSS) 
normalization, log transformation of microbial abundance, Benjamini-Hochberg (BH) 
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Results 
We examined the effect of psychotropics medications on alpha-diversity of the 
microbial community (Shannon index on genus level present in at least 5% of 
individuals). Psychotropic drugs did not show any significant effect on the alpha-
diversity of bacteria compared to non-users (Figure 5.1). 
 
 
Figure 5.1 Alpha-diversity plots in psychotropic users versus non-users. Abbreviations: 
BDZs benzodiazepines, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic 
antidepressants. 
 
Then we assessed whether psychotropic drugs affected the beta-diversity of the 
microbiome. Here, two different methods have been applied at the species level of 
bacteria: measurements of Bray-Curtis dissimilarity and Aitchison dissimilarity.  
Regarding Bray-Curtis dissimilarity, dispersions within medication groups were 
different (p<0.05). After correction of read depth, age and gender, SSRIs and TCAs 
were shown to influence microbiome composition (Adonis PERMANOVA p=0.0029 
and 0.005699 respectively on 10,000 permutations). Thus, usage of SSRIs explained 
0.2% of microbial variation as well as TCAs (Figure 5.2A).  Altogether, psychotropic 
drugs explained 0.66% of microbial variation (Adonis PERMANOVA p =0.0036; 
10,000 permutations). This suggests that a small effect is induced by psychotropic 
drugs on the microbiota, and some of the effect could be lost due to the small sample 
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size.  Associations remained significant also after correction for depression (SSRIs: 
R2=0.00212, p=0.004995; TCAs: R2=0.00197, p=0.011988; 1,000 permutations). 
Regarding Aitchison dissimilarity, no significant effects of medications on 
microbiome were detected (Figure 5.2B).   
 
 
Figure 5.2 Beta-diversity plots in psychotropic users versus non-users. (A) PCoA of 
Bray-Curtis dissimilarity matrix. (B) PCA of Atchison dissimilarity matrix. Abbreviations: 
BDZs benzodiazepines, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic 
antidepressants.  
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Our next aim was to investigate further the influence of single psychotropic 
pharmaceutical compounds on the microbiome diversity. For this analysis, we selected 
compounds that were present in at least more than 5 individuals (specifically: 
oxazepam [N05BA04, N=7], temazepam [N05CD07, N=7], diazepam [N05BA01, 
N=9], paroxetine [N06AB05, N=14], amitriptyline [N06AA09, N=9]). Due to the 
small sample size, no significant effects of individual compounds on beta-diversity 
was detected, after correction for read depth, age, gender and depression. 
A major advantage of shotgun sequencing compared to 16S sequencing is the 
opportunity to recover accurate species-level taxonomic and functional profiles of the 
microbiome (Ranjan et al., 2016). When analysing associations between species and 
drug consumed, due to the evident difference in sample size between drug users and 
non-users, we selected those species whose dispersion and SEM (standard error of the 
mean) where comparable in the user and non-user groups. Across several species, we 
found significant associations for SSRIs, TCAs, BDZs, paroxetine and diazepam. The 
specific associations are listed in Table 5.2.  
 
Table 5.2 Associations between psychotropic classes/drugs and bacterial species. Only 
species whose dispersion and SEM (standard error of the mean) where comparable in users 
and non-users were selected. Abbreviations: BDZs benzodiazepines, SSRIs selective 
serotonin reuptake inhibitors, TCAs tricyclic antidepressants. The cut-off for significance of 
q value is 0.05. 
Psychotropic 
class/drug 
Bacteria (species) Coefficient p value q value 




0.011485 1.286·10-6 9.277·10-5 
BDZs Anaerostipes hadrus 0.001369 7.479·10-6 4.623·10-4 
 Clostridium leptum 0.000371 2.170·10-3 5.050·10-2 
Paroxetine Roseburia intestinalis -0.00187 1.730·10-6 1.218·10-4 




-0.01058 8.602·10-6 5.172·10-4 
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Significant associations were also detected between type of drug consumed and 
bacterial genera (represented in the heatmap, Figure 5.3). The genera mostly 
associated to BDZ consumption were Corynebacterium, Alloscardovia and Gemella. 
The genera strongly associated to SSRIs were Roseburia and Eggerthella, while the 
ones strongly associated to TCAs were Bartonella and Methanobrevibacter.    
 
 
Figure 5.3 Associations between psychotropic classes/drugs and bacterial genera. Only 
significant associations are shown (q value<0.05, BH). Z-scores of associations are centred 
and normalized, colours represent the direction of an association. 
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When comparing the human data with our preclinical findings in rats, we found that 
the genus Roseburia was associated to psychotropic consumption in both studies. 
Specifically, Roseburia was positively correlated to SSRI consumption in the 
LifeLines-DEEP cohort (Table 5.2, Figure 5.3) and we found it to be increased by the 
psychotropics lithium (mood stabiliser) and aripiprazole (antipsychotic) in rats 
(Cussotto et al., 2019b). A possible reason for the detection of only one shared 
microbial genus might be the different sequencing methods used in the two studies: 
the analyses in rats were done via 16S sequencing which makes it challenging to 
compare them to data obtained through shotgun sequencing. Moreover, some species-
specific microorganism can occur only in rats or humans. Differences in DNA 
isolation methods could also explain the discrepancies in identification of bacteria, 
particularly rare ones.   
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Discussion  
In light of previous studies from our and other laboratories showing that psychotropic 
medications influence the gut microbiota in in vitro and in animal models, we wanted 
to investigate whether consumption of psychotropics would impact the microbiome in 
a human cohort. Our analysis shows that there are minor but significant effects of 
certain psychotropic classes and compounds on microbiome composition.  
Despite no differences were detected in alpha-diversity across groups, SSRIs and 
TCAs influenced significantly the microbiome composition according to the Bray-
Curtis dissimilarity measurements (Figure 5.2A).  
At the species level, the antidepressants SSRIs and TCAs were weakly but positively 
associated with Roseburia intestinalis and Methanobrevibacter smithii (Table 5.2). 
Although the functional relevance of such taxa has not been extensively characterised, 
changes these bacterial species have been reported in different physiological and 
pathological conditions. Roseburia intestinalis is a butyrate-producing bacterium 
(Duncan et al., 2002) and has been previously shown to protect the colonic mucosa 
against inflammation (Zhu et al., 2018). Methanobrevibacter smithii exerts xylanolytic 
activity of anaerobic ruminal fungi (Joblin et al., 1990) and was depleted in human 
obesity (Million et al., 2011). BDZ intake was positively correlated with Anaerostipes 
hadrus and Clostridium leptum. Anaerostipes hadrus is a butyrate-producing species; 
Clostridium leptum was shown to attenuate inflammation induced by airway allergy 
(Li et al., 2012) and was significantly altered in patients with ulcerative colitis (Zhang 
et al., 2007).  
More research is warranted to investigate the individual contribution of these bacterial 
species in drug efficacy or toxicity. Interestingly, bacterial species that were positively 
correlated to a certain drug class were sometimes negatively correlated to a compound 
belonging to the same class (or vice versa; i.e. Roseburia intestinalis is positively 
correlated with SSRIs but negatively correlated with paroxetine, an SSRI), 
highlighting the importance of investigating the individual contributions of each drug. 
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In our study, the investigation at compound-level was limited by the small sample size 
but future research should address this point.  
At the genus level, in our preclinical study we found that fluoxetine completely 
depleted the growth of Prevotella and Succinivibrio (Cussotto et al., 2019b) and we 
wanted to examine whether SSRIs induced similar changes in the LifeLines-DEEP 
cohort. We were not able to detect Succinivibrio in the human cohort, possibly due to 
the different method used for sequencing, while Prevotella was detected but did not 
show significant associations. Interestingly, the genus Roseburia was altered by 
psychotropics in our preclinical study and showed significant associations in the 
LifeLines-DEEP cohort. Roseburia, that we found increased by lithium (mood 
stabiliser) and aripiprazole (antipsychotic) in rats, was positively correlated with 
SSRIs in the LifeLines-DEEP cohort. It is important to note that Roseburia was 
positively associated with SSRIs both at genus and species level (Figure 5.3, Table 
5.2). Intriguingly Roseburia was previously shown to be increased in mice receiving 
fluoxetine, an SSRI (Lyte et al., 2019) and decreased in rats receiving a faecal 
transplantation from depressed individuals (Kelly et al., 2016). Our findings in the 
LifeLines-DEEP cohort support therefore an association between Roseburia and SSRI 
intake, although fluoxetine was not tested per se.   
In a recent study in mice, antidepressants administration reduced richness and 
increased beta-diversity of gut bacteria compared to controls (Lukić et al., 2019). 
Moreover, at the genus level, antidepressants reduced the abundance of Ruminococcus 
and Adlercreutzia. Strikingly, the antidepressive effect of duloxetine was attenuated 
by simultaneous administration of Ruminococcus flavefaciens. In the present human 
population, however, we could not find significant changes in Ruminococcus or 
Adlercreutzia.  
Intriguingly all three benzodiazepines investigated at compound level (oxazepam, 
diazepam and temazepam) showed a significant negative association with 
Corynebacterium (Figure 5.3) while a previous study has shown that psychotropics 
such as SSRIs and antipsychotics inhibited the growth of Corynebacterium 
urealyticum in vitro (Munoz-Bellido et al., 1996). These data suggest that more 
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research should investigate the role of the genus Corynebacterium and its species in 
psychotropic intake. 
This study does not lack limitations. Firstly, the difference in sample size between 
psychotropic users and non-users and the lower sample size among users would affect 
the power of the analysis. Although we corrected the analyses for read depth, age, 
gender and depression, we acknowledge that other factors including diet, GI 
symptomatology, smoke, alcohol consumption and comorbidities represent 
considerable confounder factors. Future studies with bigger sample sizes should take 
these cofounders into account and try to replicate the findings of the LifeLines-DEEP 
cohort. Finally, growing research in the field emphasises the effects of antipsychotic 
drugs on the gut microbiome (Flowers et al., 2017; Maier et al., 2018), with data 
showing that the metabolic side effects of olanzapine are mediated by microbial states 
(Davey et al., 2013; Kao et al., 2018; Morgan et al., 2014). Due to the low sample size, 
antipsychotics were not included in our analysis and a broader analysis including such 
drugs and others is warranted.  
In conclusion, our data show that minor but significant changes in microbiome 
composition are associated with the intake of psychotropic medications, especially 
antidepressants, in the Dutch LifeLines-DEEP cohort. The findings are in accordance 
with the increasing evidence suggesting a microbiota-targeted effect of psychotropic 
medications. 
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6.1 Overview and Summary 
In this thesis, I have explored the complex and bidirectional relationship between 
psychotropic medications (drugs commonly used to treat different psychiatric 
disorders) and the microbiota-gut-liver-brain axis. The findings here reported have the 
potential to be translated into clinical practice and represent a cornerstone piece of 
research for the development of microbiota-based personalised medicine.  
Our data show that chronic administration of psychotropic medications influences 
microbial and intestinal function in healthy adult rats (Chapter 2). Specifically, the 
SSRIs escitalopram and fluoxetine showed differential antimicrobial activity in vitro, 
with fluoxetine having stronger antimicrobial activity. Intriguingly fluoxetine was the 
only medication that impacted microbial activity both in vitro and in vivo. Lithium, 
valproate and aripiprazole administration induced a significant increase in the relative 
abundance of minor genera, while highly abundant genera were mostly not affected 
and were decreased in few instances (i.e. Lachnospiraceae NK4A136, Ruminococcus 
1, Bacteroides). Microbial diversity and richness were increased by lithium, valproate 
and aripiprazole. With marked alterations present at the microbiota level, it was 
perhaps not surprising that changes in SCFAs occurred. Valproate and aripiprazole 
influenced SCFA abundance in the caecum, with acetate and isovalerate being 
increased by aripiprazole treatment and propionate, butyrate and isovalerate being 
differentially altered by valproate. The alterations in SCFA levels seemed independent 
of changes in specific SCFA-producing taxa. The impact of psychotropic drugs on gut 
functionality is poorly understood and it is well known that the gut microbiota plays a 
role in shaping intestinal permeability (Karl et al., 2017; Ott et al., 2017; Ulluwishewa 
et al., 2011). Thus, we assessed epithelial permeability in the small and large intestine 
and found that the antidepressants escitalopram, venlafaxine and fluoxetine, together 
with the atypical antipsychotic aripiprazole, increased epithelial permeability in the 
ileum. Interestingly, the action of psychotropics on intestinal permeability was region-
specific, with the colon being largely unaffected. Together, these data highlight the 
importance of investigating the impact of drugs used for the treatment of psychiatric 
disorders on microbiota-gut-brain axis function. 
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In Chapter 3, we drilled deeper into the dataset to show that, across a range of 
psychotropic medications, the mood stabilisers lithium and valproate increase many 
BA species in circulation, in the colon content and the liver. Independent of BA class 
(primary, secondary or tertiary), and with the exception of tauro-conjugated BAs, all 
BAs were significantly increased by lithium and valproate administration. These 
changes were accompanied by an increase in some key intestinal bile acid-
metabolizing bacteria, mainly belonging to the Firmicutes phylum. Lithium and 
valproate also substantially altered the gene expression of enzymes and transporters 
involved in bile acid metabolism. For example, we observed a failure in the FXR-
Fgf19 pathway to appropriately feedback to the liver and stop the de novo synthesis of 
BAs, reflected as an increase in both CYP7A1 and CYP27A1 gene expression. With 
such high levels of circulating BAs, we hypothesised that the liver or distal ileum (site 
of BA reabsorption) might be damaged and we assessed the expression of genes 
involved in inflammation and fibrosis. According to gene expression levels, neither 
the liver nor the intestine showed signs of an inflammatory state. An alternate 
mechanism which might be responsible for BA dysregulation, a change in intestinal 
barrier function, did not play any overt role as assessed by Ussing chambers. 
Moreover, the decrease in bodyweight, epididymal fat and levels of circulating 
triglycerides observed in lithium- and valproate-treated rats might have been the result 
of massively increased levels of circulating BAs. With a particular focus on taurine, 
lithium and valproate decreased the levels of hepatic taurine-uptake transporter TauT, 
which was accompanied by a reduction in tauro-conjugated bile acids. The depletion 
in circulating taurine has the potential to impact distal sites in which this molecule is 
crucial, including the central nervous system. These data highlight the importance of 
examining the effects of psychotropic drugs on the microbiota-gut-liver axis, apart 
from the effects exerted in the central nervous system. 
Having shown that certain psychotropic drugs can influence the microbiome 
composition and intrigued by the potential clinical relevance of the drug-microbiota 
interactions, we decided to look at whether perturbations of the gut microbiota could 
alter the pharmacokinetics of psychotropic drugs, specifically the antipsychotics 
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olanzapine and risperidone (Chapter 4). Administration of antibiotics for two weeks 
to adult rats was accompanied by increased levels of olanzapine in circulation. This 
effect was drug-specific, as risperidone did not show the same trend. Antibiotics did 
not seem to induce barrier function dysregulation, maybe due to the short time-course. 
Interestingly, the pharmacokinetics of olanzapine correlated with the relative 
abundance of the bacteria Alistipes, a taxon previously associated with response to 
chemotherapy. These data give new insight into the potential role of the microbiome 
in drug absorption which, in turn, might have implications for drug efficacy and 
toxicity.  
The work presented in Chapter 5 is a collaborative project with the University of 
Groningen, where we examined the effects of psychotropic drugs intake on the human 
microbiome composition in the LifeLines-DEEP cohort. Here we show that minor but 
significant changes in the microbiome composition can occur as a result of 
psychotropic drugs’ intake. 
Taken together these data support the bidirectional interaction between psychotropic 
medications and the microbiota-gut-liver-brain axis (Figure 6.1). The potential 
clinical implications of these findings will be discussed in this chapter.  
 
 
Figure 6.1 Summary of the findings of this thesis.  
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6.2 Interplay between Psychotropic Drugs and the Gut 
Microbiota: Unravelling the Implications 
In this thesis, we show that the psychotropics fluoxetine (antidepressant), lithium 
(mood stabiliser), valproate (antiepileptic) and aripiprazole (antipsychotic) 
significantly alter the microbiome composition and richness. Moreover, the blood 
absorption of the antipsychotic olanzapine was increased following disturbance of the 
gut microbiome through administration of an antibiotic cocktail. The emerging drug-
microbiome network could guide future clinical practice and drug development. Some 
of the new avenues for translational applications include improving drug efficacy, 
mitigating drug side effects, repurposing of human-targeted drugs and more. The 
implications of our findings will be discussed in this section (Figure 6.2).  
 
6.2.1 Mechanism of action and efficacy of psychotropic drugs 
The antidiabetic drug metformin represents a clear example of a compound whose 
beneficial activity on the host depends on intestinal bacteria (Cabreiro et al., 2013; 
Forslund et al., 2015; Pryor and Cabreiro, 2015). Recent studies using faecal 
transplantation on germ-free mice and delayed-release formulations confirm that the 
microbiome is crucial for the mechanism of action of metformin (Buse et al., 2016; 
DeFronzo et al., 2016; Wu et al., 2017a). The absorption of the levodopa, a drug used 
in the treatment of Parkinson’s disease, is decreased by the presence of the bacterium 
Helicobacter pylori (Hamlet et al., 1999; Hashim et al., 2014; Miyaji et al., 1999). 
Recent studies have shown that levodopa conversion by bacterial tyrosine 
decarboxylase in the small intestine was a significant explanatory factor for the 
increased levodopa/carbidopa dosage regimen required in a subset of Parkinson’s 
patients (Clarke et al., 2019; Maini Rekdal et al., 2019; van Kessel et al., 2019). Our 
data suggest that microbiome modulation may contribute to the therapeutic effect of 
certain psychotropics, as we found that drugs with different chemical structures (i.e. 
lithium, valproate and aripiprazole) impacted the growth of a similar niche of gut 
microbes. Interestingly, a similar cluster of microbial effects was also reported by 
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Maier and colleagues regarding antipsychotic drugs (Maier et al., 2018). In that study, 
nearly all subclasses of the chemically diverse antipsychotics targeted a significantly 
more similar pattern of species than expected from their chemical similarity, raising 
the possibility that antimicrobial action may not only manifest as side effect of 
antipsychotics, but also be part of their mechanism of action. 
As discussed earlier, studies have shown that psychiatric populations (i.e. depressed 
or schizophrenic patients) can have altered microbiota composition and richness, 
therefore supporting the notion that psychotropics might work on intestinal microbes 
as part of their mechanism of action. Until now the effects of antipsychotics and other 
psychotropics on the microbiome have been mainly considered in the context of side 
effects (e.g. weight gain). Studying whether and how the microbiome might contribute 
to the mechanism of action of psychotropic drugs will substantially impact clinical 
practice and shed new light on the efficacy of existing drugs. Antidepressants, for 
example, bear considerable inter-individual variation in drug response and lack of 
efficacy, being only 20-30% more effective than placebo (Arroll et al., 2005), therefore 
continued metabolomic and metagenomic analyses of the microbiome have the 
potential to increase the individual response to antidepressants.  
Further studies are needed to evaluate whether the microbiome-targeting effects of 
psychotropic drugs play a role in the mechanism of action of such drugs, both in 
animals and humans. An example of a first attempt to clarify this point comes from 
Lukić and colleagues who have shown that the antidepressive effect of duloxetine was 
attenuated by simultaneous administration of Ruminococcus flavefaciens in mice 
(Lukić et al., 2019). Some of the approaches that can and should be employed to prove 
that microbiome modifications are causative and not epiphenomenological, are 
described in Section 6.4. 
 
6.2.2 Side effects and toxicity of psychotropic drugs 
The gut microbiome can also play a critical role in the side effects and toxicity of 
psychotropic drugs; an important point to remember especially in the context of 
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medications with narrow therapeutic window. Antibiotic treatment in rats attenuated 
both the microbial metabolism and the teratogenicity-associated adverse effects of the 
benzodiazepine nitrazepam (Elmer and Remmel, 1984). Antipsychotic-induced 
metabolic dysfunction has been linked to shifts in the gut microbiota composition. 
Olanzapine-induced weight gain is strictly dependent on intestinal microbes, as 
demonstrated by experiments on germ-free mice (Morgan et al., 2014). As a 
confirmation of this finding, antibiotic administration in olanzapine-treated rats 
attenuated the metabolic side effects of olanzapine (Davey et al., 2013). Treatment 
with the prebiotic B‐GOS significantly attenuated the olanzapine‐induced weight gain 
without altering the antagonism of central serotoninergic receptors necessary for drug 
efficacy (Kao et al., 2018). Strikingly, both olanzapine‐induced and risperidone‐
induced weight gain have been associated with an altered composition of the gut 
microbiota (Bahr et al., 2015b; Davey et al., 2012). Suppressed energy expenditure, 
induced by the gut microbiota, was found to cause the observed weight gain in 
risperidone‐treated mice. Furthermore, faecal microbiota transplantation (FMT) from 
risperidone‐treated mice to naive mice induced weight gain and suppressed energy 
expenditure in the FMT‐recipient mice (Bahr et al., 2015b). In addition to the 
microbiota-targeted effects of psychotropics in vivo, in this thesis we have shown that 
fluoxetine and escitalopram possess differential antimicrobial activity in vitro. The 
microbial effects reported in our work might be responsible for the side effects 
associated with antidepressants. Possible approaches to mitigating the collateral 
(anti)microbial effects and related side effects include optimizing drug choice, 
combining drugs with resistant probiotics or using selectively suppressive drug 
combinations (Brochado et al., 2018). In Chapter 3 we have shown that the mood 
stabilisers lithium and valproate can impair bile acid function and associated bile-
metabolising bacteria, thus suggesting that the microbiome might play a role in the 
hepato-toxicity often related with these medications. In Chapter 4 we have shown that 
a microbiome depletion induced a significant increase in plasmatic levels of the 
antipsychotic olanzapine, but not risperidone. The discrepancy between the two drugs 
might be due to the different chemical structure (despite belonging to the same 
therapeutic class). Increased levels of olanzapine might in turn translate into 
alterations in drug toxicity.  
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While most of the research to date has been focused on the metabolic side effects of 
olanzapine and risperidone, further studies are needed to prove the causal role of the 
microbiome in mediating the side effects of other psychotropic compounds.  
 
6.2.3 Repurposing new antibiotics  
When discussing the overlap between psychotropic drugs and antibiotics, iproniazid 
stands out as a striking example. Isoniazid (a structural analogue of iproniazid) was 
originally designed to treat tuberculosis and it was accidentally found to cause 
euphoria in tuberculosis patients. This led to the launch of iproniazid as the first 
antidepressant on the market (Butler et al., 2019). Moreover, in the context of 
microbes-mood interaction, exposure to antibiotics has been associated with an 
increased risk for depression and anxiety (Lurie et al., 2015). On the other hand, 
minocycline, a tetracycline antibiotic, has been shown to possess antidepressant 
properties (Pae et al., 2008; Reis et al., 2019; Rosenblat and McIntyre, 2018). 
Although this has largely been attributed to its ability to affect microglia function in 
the brain (Dai et al., 2019; Han et al., 2019), we cannot rule out an antimicrobial-
mediated effect on mood and depression. Interestingly, microglia function has been 
reported to be altered in several psychiatric disorders including depression (Mondelli 
et al., 2017; Perry, 2018; Yirmiya et al., 2015). In addition, microbiota alterations can 
lead to modifications in microglia function (Erny et al., 2015; Mosher and Wyss-
Coray, 2015; Thion et al., 2018), which in turn could impact brain function and 
behaviour. These examples remind us how sometimes antimicrobial and psychotropic 
effects can overlap. In this light, an intriguing implication of our results consists in the 
long-term opportunity for drug repurposing with the aim to develop new antibiotics. 
Psychotropic drugs with antimicrobial activity could provide a basis for the 
development of narrow-spectrum, species-specific antibiotics, urgently needed in the 
era of antibiotic resistance (Brown and Wright, 2016).   
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6.2.4 Antibiotic resistance: Could psychotropics be contributing?  
The use of psychotropic medications might play a role in the acquisition of antibiotic 
resistance. The antidepressant fluoxetine was recently shown to induce multi-
antibiotic resistance through a mechanism involving ROS-mediated mutagenesis (Jin 
et al., 2018). Specifically, exposure of Escherichia coli to fluoxetine at 5-100 mg/L 
for 30 days promoted its mutation frequency resulting in increased resistance against 
the antibiotics chloramphenicol, amoxicillin and tetracycline. Fluoxetine led to 
chromosomal mutations that up-regulated the expression of efflux pumps, further 
enhancing the antibiotic efflux (Jin et al., 2018). This is a very important aspect to 
consider, especially given the alarming rise of antibiotic resistance. Efficient control 
strategies are needed to minimise the emergence of antibiotic resistance due to human-
targeting drugs. Strikingly, the antidepressant fluoxetine is among the more prevalent 
categories of pharmaceuticals detected in the marine environment and therefore in fish 
(Brodin et al., 2014; Gaw et al., 2014; Kreke and Dietrich, 2008; Schultz et al., 2010; 
Vasskog et al., 2008), a factor that potentially contributes to the spread of antibiotic 
resistance. Further work is warranted to investigate the effects of fluoxetine and other 
psychotropic drugs on the dissemination of antibiotic resistance under 
environmentally relevant concentrations. 
 
6.2.5 Towards personalised medicine 
An interesting direction which will possibly influence future clinical practice is 
represented by manipulations of the individuals’ microbiome aimed at improving 
therapeutic outcome. Patient populations are not homogenous, and as previously 
discussed, in addition to the genetics and age of a patient, the host microbiome can 
influence the therapeutic outcomes. Not only genetic analysis but also the human 
microbiome could represent a challenge to optimal drug delivery and response (Grice 
and Segre, 2012). One option for precision medicine would be to alter the route of 
drug administration to avoid microbiota-drug interactions at the site of action, or 
tailoring a drug to act specifically within the colon, which could also provide a solution 
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to unwanted drug-related toxicities in other tissues (Kashyap et al., 2017). Excipients 
are pharmacologically inert substances that are added to formulations to stabilise the 
active substance or enhance the function of the dosage form. Recent research supports 
the possibility that excipients themselves might mediate microbiome changes. 
Polyethylene glycol (PEG), a polymer used in drug delivery, is linked to changes in 
the gut microbiota (Kashyap et al., 2013). Specifically, humanised mice fed a standard 
diet supplemented with 15% PEG 3350 for 10 days had significantly reduced 
abundance of the families Peptococcaceae and Eubacteriaceae. Further research into 
excipient-microbiota interactions is an aspect that needs to be considered for future 
drug formulation and delivery.  
A different precision medicine approach consists of altering the patient microbiome to 
enhance therapeutic efficacy, as an adjunctive therapy of drug response. Means to 
target the microbiome include faecal transplantation, administration of probiotics, 
prebiotics, postbiotics or antibiotics. Any of these approaches would require more 
randomised control trials in order to demonstrate the link between therapeutic efficacy 
and microbiome manipulations. It is important to remember that there is no such thing 
as a “normal microbiome” and that many factors can influence the stability of the 
microbiome including aging, hormones, diet and the external environment. In elderly 
hospitalised patients, dysbiosis of the microbiome was significantly associated with 
polypharmacy and mortality (Ticinesi et al., 2017). During the aging process, 
microbiome changes could impact the efficacy and toxicity of psychotropic 
medications. Therefore, a personalised approach to drug prescription and delivery, 
which takes into account the complex drug-microbiota interactions throughout the 
lifespan, is important if precision medicine is to achieve its potential. 




Figure 6.2 Possible implications for the interaction between drugs and the microbiome. The 
effect of the microbiome on drug efficacy/toxicity provides a rationale for improving 
personalised medicine approaches.  
 
6.3 Psychiatric Disorders, Psychotropic Drugs and the 
Microbiome: A Complex Trinity 
This thesis is focused on the interactions between psychotropic drugs and the 
microbiota-gut-liver-brain axis. Although our preclinical experiments are carried out 
in healthy rats, we have previously highlighted that the composition of the gut 
microbiome can be substantially altered in psychiatric populations (see Chapter 1, 
Table 1.1 in Appendix). Psychiatric disorders are heterogeneous and bear a complex 
pathophysiology. In addition to genetic predisposition, environmental factors and 
alterations of biological systems (such as the neuroendocrine and immune systems), 
the microbiome could also play a pivotal role in the onset/development of such 
disorders. An intriguing speculative hypothesis that emerges from our research is that 
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a decreased microbial richness observed in a specific psychiatric population (Kelly et 
al., 2016) might be counterbalanced through administration of psychotropics which 
increase the richness itself. We have shown in Chapter 2 that some psychotropic drugs 
indeed increase the microbial richness and diversity in healthy rats. Of course, this 
hypothesis should be tested and shown effective in human clinical cohorts. The 
microbiota is therefore at the interface between drugs and disease, the result of which 
will have implications for treatment outcome and efficacy (Figure 6.3). Moreover, 
psychotropic compounds other than those tested in this thesis should be screened for 
potential microbiota-targeting effects and their functional relevance. Successful 
translation of our work could lead to using the microbiome as a stratification tool 
which in turn could identify subgroups of patients that may be more likely to benefit 
from psychotropic medications.   
 
Figure 6.3 Complex interaction between disease state, drugs and the microbiome. In 
addition to the bidirectional link between psychotropic drugs and the microbiome, psychiatric 
disorders can also influence the microbiome composition. This three-compartmental model 
will, in turn, impact treatment outcome, drug efficacy and toxicity.  
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6.4 Drug-Bug Interactions: What Future Studies Are 
Needed?  
The investigation of the role of the gut microbiota in the pharmacodynamics and 
pharmacokinetics of psychotropic drugs is in its infancy and only a few cross-sectional 
clinical studies have been conducted thus far. While the field is expanding rapidly and 
provides encouraging evidence that the microbiome might be a target to improve the 
response to psychotropic medications, more mechanistic insights are required in order 
to move beyond associations and examine causal relationships between microbiome 
composition and drug response/toxicity. A fine example of an attempt to investigate 
specific bacteria involved in the response to antidepressants is represented by (Lukić 
et al., 2019). In the study, the authors have characterised the differences in microbiome 
induced by antidepressants and have subsequently supplemented chosen bacterial 
species with vehicle- and antidepressant-treated mice. Interestingly, supplementation 
with the bacteria Ruminococcus flavefaciens diminished duloxetine-induced 
antidepressant activity, while Adlercreutzia equolifaciens had no such effect (Lukić et 
al., 2019); suggesting a mechanism for microbial regulation of antidepressant 
treatment efficiency.  
Different types of experimental models can be used to investigate the microbiome and 
its interaction with the host, with the aim of gaining mechanistic insight. Here, some 
of the more common models will be discussed (Figure 6.4) 
 
6.4.1 Probiotics, prebiotics and synbiotics 
Probiotics refer to candidate species of live bacteria that, when ingested in adequate 
amounts, confer beneficial health effects upon the host (Butel, 2014). Through 
interacting with the host microbiota and intestinal epithelium, probiotics exert a wide 
range of effects on the host health, with various strains improving metabolism, 
immunity, endocrine function, and slowing aging in preclinical studies (El Aidy et al., 
2015; Patterson et al., 2016). Intriguingly, probiotics can exert beneficial effects on 
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brain physiology and behaviour. Faecalibacterium prausnitzii (ATCC 27766) may 
function as a promising psychobiotic, as it recently demonstrated an anxiolytic and 
antidepressant-like phenotype in rats, probably via increasing caecal short-chain fatty 
acids and plasma IL-10 while reducing corticosterone and IL-6 (Hao et al., 2019). 
Certain bacterial strains or cocktails of bacteria have demonstrated efficacy in 
improving behavioural symptoms of various disorders, including depression, anxiety 
and autism (Allen et al., 2016; Bravo et al., 2011; Buffington et al., 2016; Hsiao et al., 
2013; Kang et al., 2017; Savignac et al., 2014). These findings have led to the concept 
of psychobiotics for the treatment of various neurological and psychiatric disorders 
through targeting of the gut microbiota (Dinan et al., 2013). Psychobiotics are 
currently defined as microbiota-targeted interventions such as “beneficial bacteria 
(probiotics) or support for such bacteria (e.g. prebiotics) that influence bacteria-brain 
relationships” (Sarkar et al., 2016).  
Prebiotics are “substrates that are selectively utilized by host microorganisms 
conferring a health benefit” (Gibson et al., 2017). One of the main classes of prebiotics 
is dietary fibre, often defined as “carbohydrates with a degree of polymerization 
greater than 2, which fail to be hydrolysed or absorbed in the small intestine” (Stephen 
et al., 2017). These include inulin, fructooligosaccharides (FOS), 
galactooligosaccharides (GOS), resistant starch and other soluble dietary fibres, 
amongst others. Importantly, prebiotics do not always influence the composition and 
activity of the gut microbiota in a selective and predictable manner (Bindels et al., 
2015). Nonetheless, prebiotic supplementation has been demonstrated to reduce stress-
responsiveness, anxiety- and depressive-like behaviour, as well as facilitate changes 
in hippocampal synaptic efficacy, including increased hippocampal brain-derived 
neurotrophic factor (BDNF) expression, general hypothalamic neuronal activity, and 
enhanced cognition and learning. Most studies thus far have been descriptive and are 
limited to demonstrating prebiotic influence on brain physiology and behaviour 
(Azpiroz et al., 2017; Burokas et al., 2017; Grimaldi et al., 2018; Jia et al., 2016; 
Savignac et al., 2013; Vazquez et al., 2015) and studies should aim to understand the 
mechanisms involved. A growing body of work is also focused on combining 
prebiotics and probiotics to develop synbiotics (Ford et al., 2014).  
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The use of specific probiotics, prebiotics or cocktails of synbiotics as adjunctive 
therapy to improve the response to psychotropic medications (or reduce their side 
effects) represents a fascinating and powerful venue of direction for research. These 
investigations should ideally be carried out both in preclinical and clinical settings.  
 
6.4.2 Microbiota depletion: Germ-free models and antibiotics 
Germ-free (GF) animals (Williams, 2014) have been invaluable tools for 
understanding microbe-host relationships. Lacking exposure to microorganisms since 
birth, GF animals provide insights into how the microbiota is fundamental in shaping 
behaviour, physiology and neurobiology in the host (Weger et al., 2019). GF rodents 
are generated via aseptic caesarean section (C-section) and kept free of microbes 
throughout the lifespan. Animals lacking a microbiome have different development 
and physiology than animals with commensal bacteria, for example they are smaller 
in body weight and have impaired intestinal function (Aluwihare, 1971; Jeppsson et 
al., 1979; Savage et al., 1981), lower concentrations of most gastrointestinal luminal 
amino acids (Yamamoto et al., 2018), and live longer (Gordon et al., 1966; Luczynski 
et al., 2016; Tazume et al., 1991). Due to the lack of commensal microbes, GF animals 
have impaired immune systems, dysregulated hormone signalling, altered metabolism, 
and differences in neurotransmission from conventional counterparts (Kawase et al., 
2017; Neufeld et al., 2011; Pan et al., 2018; Sudo et al., 2004; Weger et al., 2019). 
Alternatively, colonization of GF mice with specific strains of bacteria has also shown 
to be a useful approach to interrogate microbiota-host interactions (Gordon and Pesti, 
1971). From these gnotobiotic animals, it is possible to investigate mechanisms of 
communication between specific members of the microbiota and host physiology.  
In addition to the GF model, antibiotics are also a useful tool for investigating the 
impact of microbiota perturbations on brain and behaviour. They offer much greater 
temporal flexibility and specificity compared to the GF model as they can be delivered 
acutely or chronically at any stage across an animal’s lifespan (Desbonnet et al., 2015; 
Leclercq et al., 2017; O’Mahony et al., 2014). Additionally, the ability to adjust the 
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dose of antibiotics allows to control the extent of microbiota depletion, from minor 
perturbations to substantial ablations of the entire microbiota. A crucial consideration 
in the use of antibiotics to investigate the microbiota-gut-brain axis is their absorption 
from the GI tract. Non-absorbable antibiotics (i.e. vancomycin, neomycin, and 
bacitracin) knockdown the microbiota without entering the circulation and avoiding 
potential central nervous system (CNS) effects. Other antibiotics such as 
metronidazole and minocycline can potentially enter the CNS and can have direct 
action on brain and behaviour (e.g., microglial inhibition with minocycline; (Riazi et 
al., 2015)); therefore, studies using such antibiotics should be interpreted with caution. 
Antibiotic administration to laboratory animals has been shown to influence 
behaviours such as sociability and anxiety (Bercik et al., 2011; Degroote et al., 2016; 
Desbonnet et al., 2015; Frohlich et al., 2016; Guida et al., 2018; Hoban et al., 2017).  
Microbiota-depleted animal models are useful tools for investigating the bidirectional 
relationship between the gut microbiota and administration of psychotropic drugs. In 
these models, single species of bacteria can also be administered, and their potential 
as an adjunctive therapy response can be studied.  
 
6.4.3 Faecal Microbiota Transplantation (FMT) 
FMT is a procedure that involves the transfer of intestinal microbiota from one 
individual to another and it is performed via oral administration of faecal material in 
rodents. This technique establishes a donor-like microbiome in the GI tract of the 
recipient, allowing stronger assumptions regarding the causal relationships between 
gut microbiota and host outcomes to be made. The FMT procedure has become best 
known for its remarkable success rate in the treatment of refractory C. difficile 
infection (Han et al., 2016; Sekirov et al., 2010; van Beurden et al., 2017; van Nood 
et al., 2013). FMT has opened up possibilities for more mechanistic investigations of 
the microbiota’s role in various clinical conditions via “humanisation” of the rodent 
microbiota (FMT from human to rodents) (Kelly et al., 2016; Staley et al., 2017). 
Intriguingly, various behavioural phenotypes can be transferred by FMT, including 
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anxiety-like behaviour and aspects of depressive symptomatology, suggesting that the 
microbiota is a key regulator of anxiety and depression (Bruce-Keller et al., 2015; 
Kelly et al., 2016; Zheng et al., 2016).  
From the drug-microbiota perspective, FMT could be employed to examine whether 
microbial changes induced by psychotropic medications causally mediate the efficacy 
of such drugs. One way to do this consists of transplanting faecal material from 
animals pre-treated with psychotropics into a microbiota-depleted recipient, followed 
by behavioural assessment. Clearly, a quantification of the drug (and its metabolites) 
levels that are potentially present in the donor faeces must be performed prior to the 
transplant itself, to confirm that there is no therapeutic dose of drug in the transplanted 
material.   
 
6.4.4 Metabolomic approaches: It’s not just what’s there but what 
they are doing  
In recent years, faecal metabolomics has increasingly gained attention and has shown 
promising results in characterising microbial metabolic functions (Matysik et al., 
2016). The major metabolites produced by gut bacteria include SCFAs, branched 
chain fatty acids (BCFAs), branched chain amino acids (BCAAs), bile acids, biogenic 
amines and gases (e.g. CO2, CH4) (Nicholson et al., 2012a). Intriguingly, 
metabolomics analyses have allowed a better understanding on the role of the 
microbiome in neurological and neurodevelopmental disorders. A recent study 
revealed that microbial metabolites impact susceptibility to epileptic seizure in mice, 
linking the anti-seizure effect of ketogenic diet to metabolic mechanisms (Olson et al., 
2018). Similar associations between metabolic neuroactive by-products of bacteria 
and behavioural outcomes have also been described in autism (Hsiao et al., 2013; 
Sharon et al., 2019). 
The shotgun sequencing and the bioinformatic software PICRUSt allow for inferring 
metabolic potential of the gut microbiota. A fine example of this approach is a recent 
study where the authors performed a functional analysis of the microbiota neuroactive 
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metabolic potential in the Belgian Flemish Gut Flora Project population cohort 
(n=1,054), which was validated further in the Dutch LifeLines DEEP cohort (Valles-
Colomer et al., 2019). In this study, specific microbial metabolites were found to be 
positively correlated to quality of life and depression scores (Valles-Colomer et al., 
2019).  
In conclusion, faecal metabolomics provides a functional readout of microbial 
metabolism as well as its interaction with host and environmental factors. Faecal 
metabolomics can be combined to brain metabolomics specifically to prove causality 
in the gut-to-brain communication. These types of metabolomics approaches are now 
warranted to gain a better mechanistic insight on the link between psychotropic drugs 
and the microbiome. 
 
6.4.5 Human observations and targeted interventions 
The relationship between consumption of psychotropic drugs and gut microbiome 
composition is currently unexplored in humans, therefore observations and 
interventions are warranted to translate preclinical findings into clinically relevant 
conditions. Metabolomic approaches, already mentioned in Section 6.4.4, should be 
employed not only in animal models but also in humans to gain a deeper insight on 
the role played by microbial metabolites. Translational limitations occur because of 
the clear discrepancy between the rodent and the human microbiota composition, in 
addition to a variety of cofounding factors (such as diet, comorbidities, smoke, etc.) 
that can be controlled in rodents but are more difficult to limit in human populations. 
Large-scale observations in humans should aim to compare the microbiome 
composition before and after a course of psychotropic drugs and to examine whether 
it associates with treatment outcome. Moreover, the field of drug-microbe interactions 
requires longitudinal studies in large-scale cohorts. A recent analysis based on daily 
sampling has revealed personalized diet-microbiome associations in humans (Johnson 
et al., 2019). A similar approach is warranted in the drug-microbiome field, with the 
aim to monitor changes in human gut microbiome composition in response to daily 
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drug intake. This will allow to test whether each subject’s daily drug-microbiome 
interaction is unique to that individual and will deepen the understanding of 




Figure 6.4 Approaches used to manipulate the microbiome for studying mechanisms and 
causality in the drug-microbiome field. The methods include probiotics, prebiotics, 
synbiotics, microbiota-depleted animal models and faecal microbiota transplantation. 
Metabolomics approaches and large-scale longitudinal human studies are also warranted.  
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6.5 Overall Conclusions 
This thesis presents data showing that brain-targeting (psychotropic) drugs modulate 
the gut microbiome composition and intestinal permeability in a preclinical model. 
Moreover, we demonstrate that the mood stabilisers lithium and valproate increase a 
population of bile-metabolising bacteria and alter bile signalling potentially through 
the gut-microbiota-liver route. In this thesis we also show that a disturbance of the 
microbiome through administration of an antibiotic cocktail significantly impacted the 
absorption of the antipsychotic olanzapine with a specific bacterium, Alistipes, being 
significantly correlated with the blood levels (AUC) of olanzapine. Minor but 
significant associations between psychotropic intake (especially antidepressants) and 
microbiome composition were also observed in the human LifeLines-DEEP cohort. 
This thesis, together with existing data, provides convincing evidence for the 
bidirectional link between the microbiome and psychotropic drugs. The findings 
presented here might inform future clinical psychiatric practice, suggesting that the 
microbiome should be taken into account when psychotropic medications are 
administered. Exploration of the role of the microbiome in the efficacy or toxicity of 
other psychotropic medications is now warranted. An open question that remains is 
whether subgroups of psychiatric patients would respond better or worse to specific 
medications or their side effects based on the microbiome composition. To answer 
this, more translational research is needed.  
This thesis represents an appropriate starting point for a deeper investigation of the 
relative contributions of psychotropic drugs on specific microbial taxa and more 
research on the implications for clinical practice is now warranted.  
 
 
“Every day we live and every meal we eat we influence the great microbial organ 
inside us - for better or for worse.”  
Giulia Enders, Gut: The Inside Story of Our Body’s Most Underrated Organ 
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Appendix 
Table 1.1 Correlations between psychotropic compounds and microbes, divided by experimental design. 




Details  Reference(s) 
Antipsychotics Aripiprazole In vivo 4-wks administration in rats increase the relative abundances of Clostridium, 
Ruminiclostridium, Intestinibacter and Eubacterium coprostanoligens  
Cussotto et al., 
2019b 
  In humans The microbiota communities of AAP-treated (including aripiprazole) and non-treated patients 
are significantly separated. The genera Lachnospiraceae, Akkermansia, and Sutterella are 
differentially abundant in the two groups 
Flowers et al., 
2017 
 Chlorpromazine In vitro  Antimycobacterial properties  Kristiansen and 
Vergmann, 1986; 
Molnar et al., 
1977 
   Synergistic effect in combination with certain antibiotics  Amaral et al., 
1992 
   Inhibits significantly the growth of S. aureus and E.coli 
 






 Fluphenazine In vitro Pronounced action against both Gram-positive and Gram-negative bacteria at concentrations 
of 20-100 μg/mL  
Dastidar et al., 
1995 
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   Against 293 strains from two Gram-positive and eight Gram-negative genera, 46 of 55 strains 
of S. aureus are inhibited by doses of 10-50 μg/mL. Shigella spp., Vibrio cholerae and V. 
parahaemolyticus are also inhibited at concentrations of 10–100 μg/mL  
Mazumder et al., 
2001 
 Olanzapine In vitro Completely inhibits the growth of E.coli NC101  Morgan et al., 
2014 
  In vivo 3-wks administration in rats alters the microbiota profile in both males and females  Davey et al., 
2012 
   4-wks administration in mice accelerates weight gain resulting from high-fat diet. The effect 
is absent under GF conditions but emerges quickly upon microbial colonization of the gut  
Morgan et al., 
2014 
   Coadministration with an antibiotic cocktail in female rats attenuates body weight gain, uterine 
fat deposition, macrophage infiltration of adipose tissue, plasma free fatty acid levels, all of 
which are increased by olanzapine alone  
Davey et al., 
2013 
   Coadministration with the prebiotic B-GOS in female rats attenuates olanzapine-induced 
weight gain  
Kao et al., 2018 
  In humans The microbiota communities of AAP-treated (including olanzapine) and non-treated patients 
are significantly separated. The genera Lachnospiraceae, Akkermansia, and Sutterella are 
differentially abundant in the two groups 
Flowers et al., 
2017 
   Cross-sectional study on psychiatric patients. No significant differences in microbiota 
composition at baseline between AAP users and nonusers. Non‐AAP users have increase in 
Alistipes. AAP‐treated females have decreased diversity compared with non‐treated females 
Flowers et al., 
2019 
 Prochlorperazine In vitro Strongly inhibits Bacillus spp. and Staphylococcus spp.  Rani Basu et al., 
2005 
 Risperidone In vivo 80μg/day in female mice induces weight gain which correlates with an altered gut microbiota. 
Faecal transplant from risperidone-treated mice causes a 16% reduction in total resting 
metabolic rate in naïve recipients, attributable to suppression of non-aerobic metabolism 
Bahr et al., 2015b 
  In humans The microbiota communities of AAP-treated (including risperidone) and non-treated patients 
are significantly separated. The genera Lachnospiraceae, Akkermansia, and Sutterella are 
differentially abundant in the two groups 
Flowers et al., 
2017 
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   Chronic treatment in psychiatrically ill children increases the BMI and reduces the ratio of 
Bacteroidetes:Firmicutes. There is a gradual decrease in the Bacteroidetes:Firmicutes ratio 
over the ensuing months of treatment 
Bahr et al., 2015a 
 Thioridazine In vitro Antimicrobial activity against methicillin-susceptible S. aureus, vancomycin-resistant 
pathogenic strains of Enterococcus species, Mycobacterium tuberculosis, Pseudomonas 
aeruginosa and Mycobacterium avium 
Hahn and 
Sohnle, 2014; 
Ordway et al., 
2002b; 
Wainwright et 
al., 1999; Amaral 
et al., 1996; 
Bettencourt et al., 




Viveiros et al., 
2005 
 Trifluoperazine  In vitro Antimicrobial activity against 46 of 55 strains of S. aureus at doses of 10-50 μg/mL. 
Antimicrobial against Shigella spp., Vibrio cholerae and V. parahaemolyticus at 
concentrations of 10–100 μg/mL 
Mazumder et al., 
2011 
Antidepressants Amitriptyline  In vitro Out of 254 bacterial strains, 185 are inhibited at different doses, with Staphylococcus spp., 
Bacillus spp. and Vibrio cholerae being the most affected bacteria. Amitriptyline also inhibits 
both Cryptococcus spp. and Candida albicans 
Mandal et al., 
2010 
  In vivo At doses of 25μg/g and 30μg/g significantly protects mice from Salmonella typhimurium  Mandal et al., 
2010 
 Clomipramine In vitro Cytotoxic effects against both human protozoan parasites Leishmania donovani and 
Leishmania major  
Zilberstein and 
Dwyer, 1984 
 Desipramine In vitro Effective against Plasmodium falciparum  Basco and Le 
Bras, 1990; 




 Escitalopram In vitro Antimicrobial effect on E.coli, but no effect on L. rhamnosus  Cussotto et al., 
2019b 
 Fluoxetine In vitro Strong dose-dependent antimicrobial activity against L. rhamnosus and E.coli  Cussotto et al., 
2019b 
  In vivo 4-wks administration in rats completely inhibits the growth of Succinivibrio and Prevotella 
caecal taxa  
Cussotto et al., 
2019b 




   Inhibits the growth of E. coli and Yersinia enterocolitica through interference with plasmid 





Weinbach et al., 
1992 
 Ketamine In vitro Antimicrobial activity against: S. aureus, S. epidermidis, E. faecalis, S. pyogenes, P. 
aeruginosa and E. coli; with S. aureus and S. pyogenes being the most sensitive strains  
Begec et al., 
2013; Gocmen et 
al., 2008 
   Sustained antimicrobial activity in a dose-dependent manner against micro-organisms in 
propofol, which is a strong growth-promoting factor  
Begec et al., 2013 





 Sertraline In vitro Potent antimicrobial against E.coli Bohnert et al., 
2011 
   Inhibits the growth of S. aureus, E.coli and P. aeruginosa, also shows synergy in combination 
with antibiotics  
Ayaz et al., 2015 
   Potent antifungal activity against Cryptococcus neoformans, Coccidioides immitis and 
Candida spp.  
Rossato et al., 
2016; Trevino-
Rangel Rde et al., 
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2016; Zhai et al., 
2012; Paul et al., 
2016, Lass-Florl 
et al., 2003 
   Kills 97.5% of the promastigotes of Leishmania donovani at a dose of 30mg/L. At the lowest 
concentration (3mg/L), it induces significant loss of viability in the promastigotes (61%)  
Palit and Ali, 
2008 
Antianxiety drugs Propranolol In vitro  Inhibits the growth of S. aureus and E.coli  Kruszewska et 
al., 2004; Hadera 
et al., 2018 




Lamotrigine In vitro Good antibacterial activity against Gram-positive bacteria B. subtilis, S. aureus and S. faecalis. 
Inhibition of bacterial ribosome biogenesis  
Qian et al., 2009; 
Stokes et al., 
2014 
 Lithium In vivo 4-wks administration in rats changes the caecal microbiome, with many genera being affected  Cussotto et al., 
2019b 
 Valproate In vitro  Inhibits Mycobacterium smegmatis  Esiobu and 
Hoosein, 2003 
  In vivo 4-wks administration in rats changes the caecal microbiome, with many genera being affected.  Cussotto et al., 
2019b 
Opioid analgesics Methadone In vitro Antimicrobial activity against S. aureus, P. aeruginosa and S. marcescens  Sheagren et al., 
1977 
  In humans Chronic opioid use (methadone N=1) in cirrhotic patients induces changes in microbiome 
composition, with lower relative abundance of Bacteroidaceae  
Acharya et al., 
2017 
 Morphine In vitro  Does not possess antimicrobial activity against any of the 10 microbial strains studied with the 
agar dilution method  
Rosenberg and 
Renkonen, 1985 
  In vivo  Induces dysbiosis in a morphine-dependent murine model. The dysbiosis is associated to an 
increase in pathogenic bacteria and a decrease in communities associated with stress  
Wang et al., 2018 
   Intermittent or sustained opioid regimen in mice influences the gut microbiome and this is 
causally related to behaviours associated with opioid dependence  
Lee et al., 2018 
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  In humans Chronic opioid use (morphine sulphate N=1) in cirrhotic patients induces changes in 
microbiome composition, with lower relative abundance of Bacteroidaceae 
Acharya et al., 
2017 
 Tramadol In vitro Strong bactericidal activity against E.coli and S. epidermidis. Weak antimicrobial activity 
against S. aureus and P. aeruginosa  
Tamanai-
Shacoori et al., 
2007 
  In vivo Subcutaneous injection in BALB/c-sensitive mice reduces the growth of S. aureus through 
enhancing phagocytes and tissue inflammation. It does not help eliminate P. aeruginosa  
Farzam et al., 
2018 
  In humans Chronic opioid use (tramadol N=23) in cirrhotic patients induces changes in microbiome 
composition, with lower relative abundance of Bacteroidaceae 
Acharya et al., 
2017 
Drugs of abuse  Cannabis In vitro Strong antimicrobial activity against a wide range of micro-organisms  
 
 
Appendino et al., 
2008; M M Ali et 
al., 2018; Nissen 
et al., 2010 
  In vivo Modifications in the gut microbiota consequential to diet-induced obesity are prevented in 
mice treated chronically with THC 
Cluny et al., 2015 
  In humans The microbiome of chronic marijuana users displays a Prevotella:Bacteroides ratio that is 13-
fold lower than non-users  
Panee et al., 2018 
   A combination of THC and CBD mitigates experimental autoimmune encephalomyelitis by 
altering the gut microbiome  
Al-Ghezi et al., 
2017 
 Cocaine In vivo Administration of antibiotics in mice induces an enhanced sensitivity to cocaine reward and 
an enhanced sensitivity to the locomotor-sensitizing effects of repeated cocaine administration  
Kiraly et al., 
2016 
  In humans Cocaine users display a higher relative abundance of Bacteroidetes than non-users  Volpe et al., 2014 
 Heroin In humans The composition and diversity of intestinal microbiota in a cohort of 50 patients with SUD (of 
which 52% on heroin) is significantly different from those of healthy controls. The relative 
abundance of Thauera, Paracoccus and Prevotella is significantly higher in SUDs compared 
to healthy participants 
Xu et al., 2017 
 Metamphetamine In vivo The gut microbiota of methamphetamine-treated rats differs from that of control rats. The fecal 
microbial diversity is higher in metamphetamine-treated rats. The genus 
Ning et al., 2017 
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Phascolarctobacterium is reduced and the family Ruminococcaceae is increased in 
metamphetamine-treated rats 
  In humans The composition and diversity of intestinal microbiota in a cohort of 50 patients with SUD (of 
which 30% on metamphetamine) is significantly different from those of healthy controls. The 
relative abundance of Thauera, Paracoccus and Prevotella is significantly higher in SUDs 
compared to healthy participants 
Xu et al., 2017 
Alcohol  NA In vivo 4-wks intermittent vaporised ethanol in mice alters the gut microbiota, increasing the levels of 
Alistipes and decreasing Clostridium IV, Dorea and Coprococcus  
Peterson et al., 
2017 
   In a mouse model of alcoholic liver disease, Bacteroidetes and Verrucomicrobia are increased 
in mice fed alcohol  
Yan et al., 2011 
  In humans Human alcoholics with dysbiosis have lower abundances of Bacteroidetes and higher ones of 
Proteobacteria 
Mutlu et al., 2012 
   Alcohol-dependent subjects have an increased intestinal permeability which is linked to 
significant microbiome alterations  




Leclercq et al., 
2014 
   In cirrhotic patients, the proportion of phylum Bacteroidetes is significantly reduced, whereas 
Proteobacteria and Fusobacteria are highly enriched compared to healthy controls. 
Enterobacteriaceae, Veillonellaceae and Streptococcaceae are prevalent in patients with 
cirrhosis at the family level 
Chen et al., 2011 
Nicotine NA In vitro Active against E.coli, P. aeruginosa and S. faecalis at a dose of 2µg/µl; and against Listeria 
monocytogenes and Viridans streptococci at a dose of 10µg/mL  
Idrees Zaidi et 
al., 2012; Pavia 
et al., 2000 
  In vivo Influences the gut microbiota composition in a sex-specific manner in mice  Chi et al., 2017 
  In humans Induces profound changes in the gut microbiome, with an increase of Firmicutes and 
Actinobacteria and a decrease of Bacteroidetes and Proteobacteria at the phylum level. 
Smoking cessation induces an increase in microbial diversity  
Biedermann et 
al., 2013 
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   Tobacco smokers display a higher relative abundance of Prevotella, lowered Bacteroides and 
lower Shannon diversity compared to controls  
Stewart et al., 
2018 
Xanthines Caffeine In vitro Inhibits the growth of E.coli and E. faecalis  Tatsuya and 
Kazunori, 2013; 
Daglia et al., 
2007 
  In vivo Consumption of 500μL/day of coffee for three consecutive days in specific-pathogen-free mice 
decreases the levels of E.coli and Clostridium spp.  
Tatsuya and 
Kazunori, 2013 
   Caffeine-rich Pu-erh tea remodels the intestinal dysbiosis in mice with metabolic syndrome. 
Akkermansia muciniphila and Faecalibacterium prausnitzii are the key gut bacterial links 
between the Pu-erh Tea treatment and metabolic syndrome  
Gao et al., 2018 
   Chronic coffee consumption in diet-induced obese rats decreases the abundance of Clostridium 
Cluster XI and increases Enterobacteriaceae. SCFAs are largely increased in the coffee-fed 
rats  
Cowan et al., 
2014 
   8 weeks of coffee consumption in rats does not alter the gut microbiota composition  Cowan et al., 
2013 
   Oral administration of 0.7 mg/kg/day caffeine for 21 days in mice decreases Lactobacillus  Kleber et al., 
2018 
  In humans Consumption of 3 cups of coffee daily for 3 wks in healthy volunteers increases the population 
of Bifidobacterium spp. In some subjects, there is a specific increase in the metabolic activity 
of Bifidobacterium spp. 
Jaquet et al., 
2009 
 Theobromine In vivo 2-wks administration of cocoa’s theobromine in rats induces marked changes in gut 
microbiota. Rats that received a 10% cocoa-containing diet have lower counts of E.coli. Rats 
that received a 0.25% theobromine-containing diet have lower counts of Bifidobacterium spp., 
Streptococcus spp. and Clostridium histolyticum - C. perfingens group 
Martín-Peláez et 
al., 2017 
 Theophylline In vivo Consumption of fermented green tea, containing theophylline, is able to restore the changes in 
gut microbiota composition associated to diet-induced obesity in mice 
Seo et al., 2015 
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Bioinformatics technique where highly conserved regions of the 16S 
rRNA gene (DNA) or transcript (cDNA) are used to identify present or 
metabolically active microbes in a sample, respectively 
Alpha diversity, 
beta diversity  
Statistical terms used in ecology to describe variability of a dataset. 
Alpha diversity describes within-sample variability, while beta-
diversity describes variability between samples. Many different 
formulas are available that define diversity differently, putting different 
weights on aspects like the number of species, how rare/abundant the 






Treatment where subjects are colonized with processed faecal matter 
(usually from a healthy donor in clinical cases or from a specific clinical 
population of interest in experimental studies). To ensure grafting of the 
donor microbiome, antibiotics (or germ-free animals) are generally used 
to deplete the recipient microbiome prior to FMT 
Germ-free (GF)  A host without a microbiome. Generally, refers to mice and rats that 
were born and reared in a sterile environment to keep them from 
developing a microbiome, for the purpose of experimentation 
GreenGenes, 
SILVA, RDP  
Sequence databases and tools used to identify which microbes are 
present in a sample and their taxonomic relationships 
Host  The organism (e.g., human, rodent etc.) that houses a given microbiome 
population 
Microbiome  A term often used synonymously with “microbiota” but more precisely 
used to refer to the collective genome of a given microbiota 
Microbiota  The collection of microorganisms found in/on a particular environment 






Parts of the bioBakery set, software tools developed by the Huttenhower 
lab, used to analyse microbiome data 
(https://bitbucket.org/biobakery/biobakery/wiki/Home)  
Prebiotics  Nondigestible foods (such as fibres) that have a beneficial effect on the 






analysis (PCA)  
Statistical methods used for datasets with many numerical values per 
sample, like microbiota data. The complex data are algorithmically 
converted to simpler set of values, called principal coordinates or 
components, with the aim of explaining variation in the data. Useful for 
visualizing differences between microbiome samples. If a principal 
coordinate or component is large, this is an indication it is determining 
a large proportion of the observed variance in the data 
Probiotics  Live microbes that have a positive effect on host health when ingested 
in adequate quantities 




Quantitative Insights Into Microbial Ecology: Software tools used to 
analyse microbiome data 
Short-chain 
fatty acids 
Metabolic products of dietary fibres produced by commensal gut 
bacteria (e.g. acetate, propionate, butyrate) 
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Synbiotics  Synergistic combination of prebiotics and probiotics. The aim is to 
optimize treatment effects by providing both the beneficial microbes 




Bioinformatics technique where all DNA in a sample is sequenced to 
identify which microbes are present in a sample and their functional 
(metagenomic) potential. More expensive than 16S rRNA sequencing, 
but gives more reliable functional predictions 
 
List of abbreviations 
 
5-ASA 5-aminosalicylic acid 
5-FU 5-fluorouracil  
5-HT 5-hydroxytryptamine 
AAP atypical antipsychotic 
ADME absorption, distribution, metabolism and excretion  
ALD alcoholic liver disease  
ALT alanine aminotransferase   
AMP antimicrobial peptides  
ANG1 angiogenin 
AST aspartate transaminase  
AUC area under the curve 
BA  bile acids 
BAC bile acid cholyl-CoA synthetase  
BAT bile acid-CoA:amino acid N-acyltransferase 
BBB blood-brain barrier 
BCAA branched chain amino acid 
BCFA branched chain fatty acid 
BDZ Benzodiazepine 
BHI Brain Heart Infusion  
BMI body mass index  
BSH Bile salt hydrolases  
CA cholic acid  
CDCA chenodeoxycholic acid  
CL clearance 
Cmax maximum serum concentration 
CNS central nervous system 
CRF corticotropin-releasing factor 
CYP  cytochrome P450 
DCA deoxycholic acid 
ENS enteric nervous system 
FGF fibroblast growth factor  
FMLP N-formylmethionyl-leucyl-phenylalanine  
FMT faecal microbiota transplantation  
FOS fructooligosaccharides 
FUDR 5-fluoro-2'-deoxyuridine 
FXR farnesoid X receptor  
GABA gamma-aminobutyric acid  
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GF Germ-free  
GI gastrointestinal 
GOS galactooligosaccharides 
HCA hyocholic acid 
HDCA hyodeoxycholic acid 
HPA hypothalamus-pituitary-adrenal 
IBD inflammatory bowel disease  
IL interleukin 
iNOS inducible nitric oxide synthase activity  
Isc short-circuit current  
JAM junctional adhesion molecules  
LCA lithocholic acid  
LCFA long-chain fatty acids  
LPS lipopolysaccharide 
MAMP microbial-associated molecular patterns  
MAOI monoamine oxidase inhibitor 
MCA muricholic acid 
MIC minimal inhibitory concentration 
NA noradrenaline 
NAFLD nonalcoholic fatty liver disease  
NO nitric oxide  
NSAID nonsteroidal anti-inflammatory drug 
OD optical density  
OF open field 
OLZ olanzapine 
PCoA principal coordinate analysis  
PD-1 anti-programmed cell death 1 protein  
PEG Polyethylene glycol  
PPI proton-pump inhibitor 
PRR pattern recognition receptor 
RISP risperidone 
RNASE4 RNase A family member 4  
ROS reactive oxygen species 
SCFA short-chain fatty acid 
SERT serotonin transporter 
SSRI selective serotonin-reuptake inhibitor 
SUD substance use disorder 
TCA tricyclic antidepressant 
TEER transepithelial electrical resistance 
TGR5 Takeda G-protein-coupled receptor 5 
THC tetrahydrocannabinol 
TLR Toll-like Receptor  
TMA trimethylamine 
TMAO trimethylamine N-oxide 
UDCA ursodeoxycholic acid  
UGT UDP-glucuronosyltransferase 
VLDL very-low density lipoproteins  
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